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Abstract 
 
 
 
Recent years have witnessed a rapid proliferation of gene editing in mammalian cells due to 
the increasing ease and reduced cost of targeted gene knockout. There has been much 
excitement about the prospect of engineering T-cells by gene editing in order to provide 
these cells with optimal attributes prior to adoptive cell therapy for cancer and autoimmune 
disease. I began by attempting to compare short hairpin RNA (shRNA) and zinc finger 
nuclease (ZFN) approaches using the CD8A gene as a target for proof of concept of gene 
editing in Molt3 cells. During the course of my studies the clustered regularly interspaced 
short palindromic repeats (CRISPR) mechanism for gene editing was discovered so I also 
included CRISPR/Cas9 in my studies. A direct comparison of the three gene editing tools 
indicated that the CRISPR/Cas9 system was superior in terms of ease, efficiency of knockout 
and cost.  
 
As the use of gene editing tools increases there are concerns about the inherent risks 
associated with the use of nuclease based gene editing tools prior to cellular therapy. 
Expression of nucleases can lead to off target mutagenesis and malignancy. To circumvent 
this problem I generated a non-nuclease based gene silencing system using the CD8A zinc 
finger (ZF) fused to a Krüppel associated box (KRAB) repressor domain. The ZF-KRAB fusion 
resulted in effective silencing of the CD8A gene in both the Molt3 cell line and in primary 
CD8+ T-cells. Importantly, unlike CRISPR/Cas9 based gene editing, the ZF-KRAB fusion was 
small enough to be transferred in a single lentiviral vector with a TCR allowing simultaneous 
redirection of patient T-cell specificity and alteration of T-cell function in a single construct. 
 
To improve the efficiency of gene editing with CRISPR/Cas9 I developed an ‘all in one’ 
CRISPR/Cas9 system which incorporated all elements of the CRISPR/Cas9 gene editing 
system in a single plasmid. The ‘all in one’ system was utilised to derive MHC-related protein 
1 (MR1) deficient clones from the A549 lung carcinoma and THP-1 monocytic cell lines in 
order to study MR1 biology. Mucosal-associated invariant T-cell (MAIT) clones were not 
activated by MR1 deficient A549 or THP-1 clones infected with bacteria.  
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1 Introduction    
 
1.1 The immune system 
The immune system is fundamental for the clearance of the many pathogens to which 
humans are exposed on a daily basis. The immune response can be divided into two phases 
- the innate and adaptive immune response. Some pathogens are cleared by the innate 
immune system alone, as the innate immune system provides the initial rapid defence 
against a broad range of pathogens. In contrast, the adaptive immune system mounts a 
response which is specific to the pathogen. The adaptive immune system can take a few 
days to initiate a response. After a particular infectious agent has been encountered by the 
adaptive immune system a small portion of the pathogen-specific cells persist in secondary 
lymphoid organs as memory cells and are able to rapidly proliferate and respond to 
subsequent infections from the same pathogen. This process is known as immunological 
memory (Panum, 1847). This study is focused on the T-cell component of the adaptive 
immune system and therefore the innate immune system and the other arms of the 
adaptive immune system will not be discussed any further here. 
 
1.1.1 T-cells  
T-cells are derived from haematopoietic stem cells in the bone marrow which differentiate 
and mature in the thymus. During T-cell development, thymocytes rearrange germline gene 
segments termed variable (V), diversity (D) and joining (J) which are fused to a constant (C) 
domain by alternative splicing to form an antigen receptor molecule known as a T-cell 
receptor (TCR). The process of gene rearrangement is called VDJ recombination. Prior to T-
cells entering the circulation they must survive the process of negative and positive 
selection in the thymus which eliminates self and non-reactive T-cells. A diverse T-cell 
receptor repertoire is fundamental for the successful clearance of pathogen and abnormal 
cells (Messaoudi et al. 2002). Deficiencies in these T-cell subsets lead to severe combined 
immunodeficiency (SCID). Broadly speaking, T-cells can be subdivided into conventional T-
cells and unconventional T-cells and each of these subtypes will be described in turn. 
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1.1.1.1 Conventional T-cells 
Conventional T-cells recognise peptides presented by classical major histocompatibility 
complex (MHC) molecules (Doherty & Zinkernagel 1975). Typically, conventional T-cells 
express a heterodimeric TCR consisting of an α and a β chain although some unconventional 
T-cells also express an αβ TCR. The TCR chain usage in conventional T-cells is broad and 
results in a diverse TCR repertoire (Reviewed in Nikolich-Žugich et al. 2004; Laydon et al. 
2015). Conventional T-cells are located in peripheral blood, tissues and lymph nodes 
(Gaspari & Tyring 2008). Conventional T-cells can be divided into two subsets which are 
identifiable by the surface expression of either CD4 or CD8.  
 
CD4+ T-cells 
CD4+ T-cells recognise peptides 12-20 aa in length presented by MHC class II molecules 
(MHCII) (Murphy 2012). The CD4+ subset can further divided into two main subtypes - 
helper cells (Murphy 2012; Kara et al. 2014) and regulatory cells subsets (Reviewed by 
Sakaguchi et al. 2010). In addition, cytotoxic CD4+ T-cells have been identified (Marshall & 
Swain 2011). The helper subset can be further divided into several subsets, TH1, TH2, TH17 
and follicular helper cell (TFH) (Kara et al. 2014). The main role of helper T-cells is to aid B 
cells in antibody production, affinity maturation and class switching and activate a wide 
range of cell types including CD8+ T-cells, neutrophils, macrophages, basophils and 
eosinophils to aid in pathogen clearance (Zhu & Paul 2010). Treg cells are essential for 
inducing self-tolerance and preventing autoimmunity by suppressing the function of other 
immune cells (Sakaguchi et al. 2010). The exact mechanism of suppression is currently 
unknown in humans, however, in vitro experiments have shown that human Treg cells may 
kill effector T-cells through granzyme secretion (Grossman et al. 2004), secretion of 
immunosuppressive cytokines such as TGF-β (Powrie et al. 1996) and IL-10 (Asseman et al. 
1999), through consumption of IL-2 (Höfer et al. 2012), through interaction of Fas : FasL 
(Strauss et al. 2009) and by interaction of immune checkpoint receptors (Tai et al. 2012). 
 
CD8+ T-cells 
CD8+ T-cells express the CD8 co-receptor formed by a heterodimer of α and β CD8 chains. 
CD8+ T-cells recognise MHC class I (MHCI) molecules presenting peptides 8-13 amino acids 
(aa) in length (Wooldridge et al. 2010). Recognition of cognate antigen leads to activation of 
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naive CD8+ T-cells and differentiation into cytotoxic T-cells. CD8+ cytotoxic T-cells can be 
divided into two subsets – type 1 (Tc1) and type (Tc2) dependent on the cytokines produced 
and secreted by the cells. Both Tc1 and Tc2 subsets have high cytotoxic activity (Kemp et al. 
2005). Tc1 produce and secrete IFN-γ and IL-2 (Kelso & Groves 1997). Tc2  produce and 
secrete  IL-4, IL-5, IL-6, IL-10 (Kelso & Groves 1997) and moderate levels of IFNγ (Kemp et al. 
2005). Cytotoxic T-cells are so called as they synthesise cytotoxic granules such as perforin 
and granzyme leading to lysis of target cells (de Saint Basile et al., 2010). The release of 
cytotoxic granules is highly regulated as they are secreted at the immunological synapse to 
ensure precise killing of the target cell (Griffiths et al., 2010). Perforin released by cytotoxic 
T-cells leads to the formation of pores on the cell surface of the target cell allowing the 
entry of other cytolytic granules into the cell cytosol (Pipkin & Lieberman, 2007) such as 
granzyme (Elemans et al. 2012). Cytotoxic T-cells also utilise the FAS : FASL pathway to 
eradicate cells (Elemans et al., 2012). Activated cytotoxic cells express the FAS ligand which 
induces apoptosis when it binds to FAS (CD95) on target cells leading to initiation of the 
caspase cascade (Magnusson & Vaux 1999; Waring & Mullbacher 1999; Murphy 2012).  
 
1.1.1.2 Unconventional T-cells 
Unconventional T-cells are so named because they are not MHC restricted. Some 
unconventional T-cells may not express TCRs formed from the conventional α and β chains, 
and alternatively these T-cells may express a TCR formed by γ and δ chains. Unconventional 
T-cells do not recognise peptides presented by MHCI or II but instead can recognise lipids, 
phosphoantigens, metabolites, MHC like stress ligands and altered peptides presented by 
MHC-like molecules (Reviewed by Godfrey et al. 2015). In contrast to conventional T-cells 
which express a diverse TCR repertoire due to a diverse range of gene segment usage, 
unconventional T-cells typically express TCRs with a limited diversity (either germline 
encoded, invariant or semi invariant) (Reviewed by Liuzzi et al., 2015) however, there are 
exceptions such as γδ T-cells which are extremely diverse. MHC-like molecules are largely 
invariant in the population and thus unconventional T-cells are not restricted to an 
individual donor whereas conventional T-cells are restricted to specific allelic variants of 
MHC molecules. Some unconventional T-cells are described as innate-like as they do not 
require antigen stimulation to develop effector functions (Ribot et al. 2009; Gold et al. 
2013). Several unconventional T-cell subsets have been described in the literature, these 
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include γδ T-cells, germline encoded mycolyl reactive (GEM) T-cells, invariant NKT (iNKT) 
cells and mucosal-associated invariant T-cells (MAITS) (Reviewed by Godfrey et al. 2015). 
Table 1.1 describes the main unconventional T-cell subsets. The MAIT subset of 
unconventional T-cells will be discussed in greater detail in chapter 5.  
 
Table 1.1. Types of unconventional T-cells  
Cell type Reactive against Presentation molecule Chain usage 
GEMs Glucose monomycolate CD1b TRAV 1-2 
TRAJ9 
MAITs Riboflavin derivatives MR1 TRAV 1-2 
TRAJ12, 33 or 20 
TRBV 6 or 20 
γδ T-cells 
 
 
 
 
 
 
 
 
 
IPP and HMBPP 
 
EPCR, ULBP and MICA 
 
Undefined self lipids 
 
α-GalCer, sulfatide and other 
lipids 
 
Phosphatidylethanolamine 
from pollen 
Butyrophilin  
 
MHC like stress ligands 
 
CD1c 
 
CD1d 
 
 
CD1a 
TRDV2 and TRGV9 
 
TRDV1 and 5 
 
TRDV1 
 
TRDV1 and 3 
 
 
TRDV1 
HLA-E restricted T-
cells 
MHCI leader and CMV derived 
peptides 
HLA-E  
 
NK T-cells 
Type I 
 
Type II 
Α-GalCer and other lipids 
 
Lysophosphatidylcholine and 
other lipids 
CD1d  
 
CD1d 
 
TRBV25, TRAV10 and 
TRAJ18 
Other CD1 restricted 
T-cells 
Lysophosphatidylcholine,  
Dideoxymycobactin and other 
lipids 
 
Glucose monomycolate, 
Sulfoglycolipid and other lipids 
 
Phosphomycoketides, 
Methyl-lysophosphatidic acid 
and other lipids 
CD1a 
 
 
 
CD1b 
 
 
CD1c 
 
 
 
Table adapted from Godfrey et al. 2015. 
 
 
1.2 TCR ligands 
1.2.1 Classical MHC molecules  
Conventional T-cells recognise antigens in the form of peptides presented by classical MHC 
molecules known as human leukocyte antigens (HLA) in humans. The human HLA locus is 
found on chromosome 6 at position 6p21.3 and encompasses several genes including the 
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classical MHCI molecules (HLA-A, B and C) and MHCII (HLA-DR, -DP and –DQ) (Traherne 
2008; Shiina et al. 2009; Murphy 2012). 
 
MHCI 
MHCI is a heterodimeric protein formed from a 44 kDa heavy α chain and a 12 kDa β2-
microglobulin (β2m) chain. The heavy α chain is polymorphic with many allelic variants 
across the population (Neefjes et al. 2011). Folding of the heavy α chain forms three distinct 
domains α1, α2 and α3. The α1 and α2 domains form the peptide binding groove and the α3 
domain covalently bonds to the β2m (Bjorkman et al. 1987). MHCI molecules are expressed 
by almost all nucleated cells, they present short peptide fragments of 8-13aa derived from 
antigen present in the cytosol and nucleus (Wooldridge et al. 2010; Neefjes et al. 2011; Rist 
et al. 2013). 
 
MHCII 
The MHCII molecule is formed from a polymorphic α and β chain. Folding of the α and β 
chain leads to the formation of 2 distinct domains in each chain. The α1 and β1 domains 
form the peptide binding groove (Murphy 2012) which houses peptides 12 to 20aa in length 
(Godkin et al. 2001). MHCII molecules have a more limited cellular expression pattern than 
MHCI molecules and are only expressed on professional APCs (Neefjes et al. 2011) such as 
dendritic cells (Shin et al. 2006), macrophages and B-cells (Reviewed by Reith et al. 2005). 
MHCII present antigens derived from exogenous peptides (Roche & Furuta 2015). As MHCII 
does not form an essential part of thesis it will not be discussed further. 
 
1.2.2 Non-classical MHC molecules 
In contrast to the conventional T-cells, unconventional T-cells do not recognise peptide-
MHC molecules. Instead, unconventional T-cells often recognise antigens presented by non-
classical MHC like molecules or MHC like stress ligands. For completeness, two of the main 
non-classical MHC like molecules (HLA-E and CD1) will be discussed next in turn. The non-
classical MHC class I-related molecule (MR1) will be discussed in greater detail in chapter 5. 
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HLA-E 
The HLA-E molecule was identified in 1988 and shown to have a sequence with 63-65% 
homology to that of HLA-A, B and C (Koller et al. 1988). Like the classical MHCI molecules, 
HLA-E is formed form a heavy chain which consists of three distinct domains upon folding, 
covalent bonded to a β2m molecule (Kaiser et al. 2008). Unlike the classical MHCI 
molecules, HLA-E is invariant as only two alleles have been identified in the human 
population HLA-E HLA-E0101 (HLA-E107R) and HLA-E0103 (HLA-E107G) (Grimsley et al. 2002; 
Pietra et al. 2010). Low expression of HLA-E has been observed on a variety of cells (Pietra et 
al. 2010). HLA-E has been shown to present signal sequences from classical MHCI molecules 
(Lemberg et al. 2001), peptides from the leader sequence from CMV and glycoprotein UL40 
(Tomasec et al. 2000) which are identical in sequence to sequences from various HLA-A and 
–Cw alleles, peptides derived from HIV (Nattermann et al. 2005) and Salmonella enterica 
(Salerno-Gonçalves et al. 2004) which bear a high homology to leader sequences from 
classical MHCI molecules. Presentation of the MHCI leader sequences is important for 
natural killer cells immunosurveillance through NKG2A/CD94 interaction with HLA-E (Kaiser 
et al. 2008). 
  
CD1 molecules 
The CD1 molecules are unlike the classical MHC molecules as they do not present peptides, 
instead they present lipids. The structure of the CD1 molecules is similar to that of the 
classical MHCI molecules as they are composed of a heavy chain with three distinct 
extracellular domains covalently bonded to a β2m. In humans, the CD1 molecules can be 
divided into either group 1 (CD1a, CD1b and CD1c) and group 2 (CD1d) (Reviewed by Barral 
& Brenner 2007). CD1a is expressed on skin resident dendritic cells (DCs) (Wollenberg et al. 
1996), CD1b is expressed on migrating DCs (Olivier et al. 2013). CD1c is expressed on 
Langerhans cells, monocyte derived DCs (Sugita et al. 2000; Milne et al. 2015). CD1d is 
expressed by intestinal epithelial cells (Landau et al. 1991), B-cells (Lang et al. 2008), dermal 
and monocyte derived dendritic cells (Gerlini et al. 2001). CD1 group 1 restricted T-cells 
were first identified in the CD4-CD8- T-cell subset (Porcelli et al. 1989) and then more 
recently have been identified in the CD8+ (Rosat et al. 1999) and CD4+ (Sieling et al. 2000) T-
cell populations. It is thought that these cells are clonally diverse that is they express a 
broad TCR chain usage (Reviewed by Barral & Brenner 2007). There appear to be two 
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subsets of cells that that recognise CD1d - CD1d-restricted iNKT-cells and CD1d-restricted 
diverse NKT-cells. The CD1d restricted iNKT-cells have a invariant TCR chain usage and the 
CD1d restricted diverse NKT-cells are less characterised but are thought to express a diverse 
TCR repertoire (Reviewed by Barral & Brenner 2007). 
 
1.3 Developing gene editing tools  
The interest in developing and utilising gene editing tools has vastly increased in recent 
years following the ease of creating genetically modified cells for experimental purposes 
and the success of genetic modified cells for therapy in recent publications. The discovery of 
zinc finger nucleases (ZFN), transcription activator like effectors nucleases (TALENs) and 
more recently the clustered regularly interspaced short palindromic repeats (CRISPR) fused 
to CRISPR associated proteins (Cas) system have been major developments in the field of 
genetic engineering; these methods have extended the capabilities of gene editing on from 
RNAi. 
 
1.3.1 RNAi 
RNAi is the term used to describe the inhibition of gene expression using RNA molecules. 
Typically, this process induces gene silencing by inducing the degradation of specific 
messenger (m)RNA sequences. Initial studies involving RNAi suggested that the gene 
silencing observed was due to co-suppression (Napoli et al. 1990), quelling (Romano & 
Macino 1992) and sense mRNA (Guo & Kemphues 1995). An explanation for the gene 
silencing was published in 1998 which elicited that the silencing observed in the previous 
studies was due to degradation of mRNA (Fire et al. 1998). Andrew Fire and Craig Mello 
received a Noble prize in Physiology or Medicine for their work on RNAi in Caenorhabditis 
elegans in 2006. Of particular interest in this thesis is short hairpin RNA (shRNA). shRNA will 
be discussed further in chapter 3. 
 
1.3.2 Nuclease gene editing 
The alternative to RNAi interference is nuclease gene editing. The three nuclease gene 
editing tools which will be discussed in this thesis can be characterised as either monomeric 
or dimeric nucleases. The two examples of dimeric nuclease gene editing tools are ZFN and 
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TALEN which consist of two binding domains and two corresponding copies of the Fok1 
nuclease which require dimerisation to be activated and functional. More recently a 
monomeric nuclease system has been identified known as the CRISPR/Cas9 system. The 
CRISPR/Cas9 nuclease consists of a single Cas9 protein. The ZFN, TALEN and CRISPRCas9 
system will be discussed in greater detail in chapter 3. 
 
1.3.3 Features and principles of nuclease gene editing 
The priniciple of gene editing is the same for ZFN, TALEN and CRISPR/Cas9.  In each case a 
protein or RNA binds to the specific DNA sequence at the target site. Once bound the DNA is 
cleaved by the nuclease protein leading to a double strand break (DSB). The DSBs in DNA are 
repaired by two mechanisms either by homogous recombination (HR) or non-homologous 
end joining (NHEJ) (Sanjana et al. 2012). HR can correctly repair the DSBs in DNA by utilising 
the sister chromatid as a template. In contrast, NHEJ is error prone and can result in 
insertions or deletions at the DNA cleavage site (Mao et al. 2008; Kim et al. 2013). The 
principle of the nuclease gene editing tools is shown in Figure 1.1. The medical importance 
of genome editing with engineered nucleases was highlighted by Nature Methods in 2011 
when it won method of the year (Nature methods, 2012).  
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DNA binding domain Nuclease 
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Figure 1.1. The main principles of nuclease gene editing. The DNA binding domain targets the DNA sequence of interest and the nuclease 
domain induces a double strand break. The DNA can be repaired by NHEJ which is error prone and commonly introduces small indels into  
the DNA sequence. Alternatively, DNA can be repaired by HR with or without introducing new template DNA which can lead to complete 
repair of the DSB. 
 
1.3.4 Uses of gene editing tools 
Several types of genetic modifications have been reported - gene disruption, gene insertion, 
point mutations, gene correction and structural chromosomal rearrangements. Gene 
disruption/ knockout rely on the introduction of small insertions and deletions (indels) by 
the NHEJ DNA repair pathway which can lead to frameshifts in the open reading frame of 
the protein. Frameshifts can lead to truncation or inactivation of the protein, which can 
result in a complete loss of gene expression if it occurs on both alleles. Gene insertion – A 
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gene editing nuclease can be co-transfected with a DNA sequence flanked with arms which 
are identical to the DNA near the target sequence this allows for this new sequence to be 
inserted into targeted areas of the genome (Li et al. 2011). Point mutations and gene 
correction – In a similar manner to gene insertion, gene editing tools can be co-transfected 
alongside targeting vectors or single stranded oligodeoxynucleotides to lead to the 
introduction of point mutations to repair mutated/ faulty genes (Soldner et al. 2011; Bialk et 
al. 2015). Finally, gene editing tools can be used to induce structural chromosomal 
rearrangements, such as duplications, deletions, inversions and translocations by 
introducing two DSBs at particular chromosomal locations (Brunet et al. 2009; Lee et al. 
2010; Söllü et al. 2010; Lee et al. 2012). 
 
1.3.5 Delivery of gene editing tools into target cells 
The frequency of biallelic knockout of genes is affected by the transduction and transfection 
efficiency. Inefficient delivery decreases the frequency of biallelic inactivation. There are 
several methods used by researchers to induce expression of an exogenous protein into the 
cells such as mRNA (Kuhn et al. 2012), plasmid DNA (Luo & Saltzman 2000) or viral delivery 
(Bouard et al. 2009). In humans, lentiviral delivery has been utilised for the transfer of genes 
into T-cells such as TCR (Yang et al. 2008; Circosta et al. 2009) and ZFNs (Lombardo et al. 
2007; Provasi et al. 2012). An integrase deficient lentiviral system has been developed which 
has a mutant integrase enzyme preventing uncontrolled DNA integration and thereby 
limiting cellular toxicity (Yanez-Munoz et al. 2006; Wanisch & Yáñez-Muñoz 2009). However, 
the efficiency of transduction is typically lower with transient methods therefore the 
integrating lentivirus system was used to deliver endogenous DNA into target cells for this 
project. In previous studies, genetically modified cells became immunogenic (Riddell et al. 
1996), however, a more recent clinical trial with ZFNs targeting the CCR5 gene concluded 
that the treatment was considered safe and the genetically modified cells persisted in the 
patients suggesting that editing the cells in this manner did not lead to them becoming 
immunogenic (Tebas et al. 2014). 
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1.4  Aims 
The work in this thesis aimed to expand the existing knowledge of gene editing tools and 
develop new tools that were safer and effective for gene silencing in primary T-cells. I set 
out to compare shRNA, ZFN, TALEN and CRISPR/Cas9 reagents that target CD8A as proof of 
principle. As there are currently concerns about the safety of nuclease based gene editing 
tools I also aimed to generate a non-nuclease based gene silencing system. Prior to my 
studies, the CRISPR/Cas9 system had relied upon several plasmids for the delivery of the 
CRISPR/Cas9 elements into the target cell for gene knockout. To improve the effectiveness 
of the CRISPR/Cas9 system, I also aimed to generate an ‘all in one’ CRISPR/Cas9 system that 
incorporated all of the CRISPR/Cas9 elements into a single plasmid, allowing for more 
efficient gene editing. As proof of principle this system was used to generate MR1 deficient 
APCs, in order to study MAIT / MR1 restricted T-cell biology in greater detail and to gain 
insight into antigen processing and presentation though MR1. 
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2 Materials and Methods  
 
2.1 Bacterial cell culture   
 
2.1.1 Culture medium and agars 
All bacterial mediums and agars were supplemented with either 50 mg/ L carbenicillin 
(Carbenicillin Direct), 50 mg/ L Streptomycin (Sigma Aldrich) or 5 mg/ L Tetracycline HCl 
(Sigma Aldrich) for the selection of transformants. 
 
Luria Bertani (LB) medium 
10 g/ L NaCl (Fisher Scientific), 10 g/ L tryptone (Fisher Scientific) and 5 g/ L yeast extract 
(Fisher Scientific).  
 
TYP medium 
16 g/ L tryptone, 16 g/ L yeast extract and 5 g/ L potassium phosphate dibasic (Acros 
organics). 
 
PSI broth 
5 g/ L yeast extract, 20 g/ L tryptone and 5 g/ L Magnesium sulphate, (pH to 7.6 with 
potassium hydroxide). 
 
Lemco culture media 
5 g/ L Lemco powder (Oxoid), 10 g/ L tryptone, 5 g/ L NaCl and 0.5 mL/ L Tween 80 (Sigma-
Aldrich).  
 
LB agar  
10 g/ L NaCl, 10g/ L tryptone, 5 g/ L yeast extract, 15 g/ L agar bacteriological (Oxoid).  
 
TYP agar 
16 g/ L tryptone, 16 g/ L yeast extract, 5 g/ L potassium phosphate dibasic and 15 g/ L agar 
bacteriological. 
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Lemco agar 
5 g/ L Lemco powder, 10 g/ L tryptone, 5 g/ L NaCl and 15 g/ L agar bacteriological  
 
Freezing buffer 
75% LB medium and 25% glycerol. 
 
2.1.2 Chemically competent cells  
Esherichia coli XL10-Gold (Agilent) competent cells were used as host for large plasmid 
vectors and cultured in LB medium or on LB medium agar. BL21 Star (DE3) pLysS® (Thermo 
Fisher) competent cells were used for protein expression and cultured in TYP medium or on 
TYP agar.  
 
2.1.2.1 Buffers 
TfbI 
30 mM CH3COOK (Sigma Aldrich), 100 mM RbCl (Acros organics), 10 mM CaCl2 (Sigma 
Aldrich), 50 mM MnCl2 · 4H2O (Fisher scientific) and 15% w/v glycerol (Fisher Scientific). pH 
was adjusted to 5.8 with dilute acetic acid (Fisher Scientific). 
  
TfbII 
10 mM MOPS (Sigma Aldrich), 75 mM CaCl2, 10 mM RbCl and 15% w/v glycerol. pH was 
adjusted to 6.5 with dilute sodium hydroxide (Fisher Scientific). 
 
2.1.2.2 Production of chemically competent cells 
E. coli XL10-Gold and BL21 Star (DE3) pLysS were produced in house by inoculating 1 mL of a 
30 mL PSI broth starter culture in 100 mL of PSI broth and monitoring the optical density 
(OD) until it reached 0.45 at 600 nm (OD600). At this stage the cells were placed on ice for 15 
minutes (min), before being pelleted by centrifuging at 5465 x g for 10 min. The cells were 
resuspended in 40 mL of TfbI buffer and incubated on ice for a further 15 min. The cells 
were pelleted once more by centrifuging at 5465 x g for 10 min and finally suspended in 4 
mL of TfbII, incubated on ice for 15 min and then snap frozen in 100 µL aliquots. 
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2.1.3 Transforming chemically competent cells  
Transformation was carried out in accordance with the manufacturer’s guidelines, briefly, 
20 µL of chemically competent cells were thawed on ice, up to 100 ng (<5 µL) of DNA was 
added to the cells, after a 5 min incubation on ice the cells were heat shocked at 42 °C for 
90 seconds (sec), then rested on ice for a further 5 min. Dependent on the initial 
concentration of DNA added and the antibiotic resistance the cells were immediately 
streaked onto agar plates or incubated in an orbital shaker for one hour (h) at 37 °C with 
100 µL of SOC medium (Invitrogen) before streaking onto agar plates.  
 
2.1.4 Bacterial cultures 
Bacterial cultures of either 5 mL, 30 mL or 250 mL were produced by incubating a single 
colony from an agar plate into LB medium, TYP or PSI medium (with appropriate antibiotic) 
and incubating the culture in an orbital shaker at 37 °C and 220 rpm for 16 h. 
 
2.1.5 Mycobacterium smegmatis (M. smegmatis) strain 
The mc2155 strain of M. smegmatis, which grows quickly in synthetic media, was used in 
this thesis; it was kindly donated by Dr Matthias Eberl. 
 
2.1.5.1 Culture of M. smegmatis 
To culture M. smegmatis, a loop of the frozen glycerol stock was streaked onto a Lemco 
agar plate and placed in an incubator at 37 °C for 48 h. Following this, a single colony was 
inoculated into 20 mL of Lemco media. The bacteria culture was incubated in an orbital 
shaker at 37 ᵒC and 150 rpm for a minimum of 48 h. A growth curve was used to determine 
the concentration and phase of growth of bacteria at a given time point. 
 
2.1.5.2 Frozen stocks of M. smegmatis 
M. smegmatis was cultured as described in section 2.1.5.1. After a minimum of 48 h the OD 
was determined and the relative number of CFU/ mL was calculated. M. smegmatis was 
then frozen in glycerol at a concentration of 10,000 CFU per vial.  
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2.2 Protein chemistry   
 
2.2.1 Generation of expression plasmids 
To produce the HLA-A*0201 protein (referred to as HLA A2 from now on) bound to peptide 
for tetramerisation and dextramerisation, the cDNA sequences encoding for the HLA A2 α 
chain (α1, α2 and α3 chain domains) and the β2m were inserted into separate pGMT7 
plasmids (Banham & Smith 1993) as described by Boulter et al. 2003. The HLA A2 α chain 
(α1, α2 and α3 chain domains) and β2m were cloned into the pGMT7 plasmid downstream 
of an isopropyl β-D-1- thiogalactopyranoside (IPTG) inducible T7 promoter enabling maximal 
protein production by the introduction of IPTG during the log phase of E.coli growth. The 
HLA A2 a chain was tagged with a 15 amino acid (aa) biotinylation sequence 
(GLNDIFEAQKIEWHE) which allowed for the peptide-MHC (pMHC) monomer to be bound to 
a tetramer streptavidin or dextran streptavidin backbone for use as tetramers or 
dextramers. The full HLA A2 and β2m sequence is listed in Appendix Figure 1. 
 
2.2.2 Peptides 
Peptides with purity above 90% were used to produce monomers for tetramer and 
dextramer production. For protein refolding and T-cell activation assays crude peptides with 
a purity of between 50-60% were used. All peptides were synthesised by GL Biochem Ltd. 
(Shanghai, China) and Peptide Protein Research Ltd. (Hampshire, UK) respectively. Peptides 
were reconstituted in DMSO (Sigma Aldrich) at a concentration of 20 mg/ mL. For T-cell 
activation assays, working concentrations of peptide were prepared on the day of an 
experiment using R0 medium. The peptides used in this thesis were: The HLA-A2 restricted 
ELAGIGILTV peptide (designated as ELA) derived from Melan-A26-35 and recognised by the 
MEL5 TCR. The HLA-A2 restricted RQFGPDFPTI peptide (designated as RQF) which is a high 
affinity version of the ALWGPDPAAA preproinsulin15-24 epitope recognised by the T-cells 
bearing the PPI TCR. The HLA- B*1801 restricted peptide SELEIKRY derived from EBV 
BZLF1173-180  
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2.2.3 Protein expression as inclusion bodies  
   
2.2.3.1 Buffers 
 
Lysis buffer  
10 mM TRIS (pH 8.1), 10 mM MgCl2, 150 mM NaCl, 10% Glycerol.  
 
Triton wash buffer 
0.5% Triton X (Sigma Aldrich), 50 mM TRIS (pH 8.1), 100 mM NaCl and 10 mM EDTA.  
 
Resuspension buffer  
50 mM TRIS (pH 8.1), 100 mM NaCl and 10 mM EDTA.  
 
Guanidine buffer  
6 M guanidine, 50 mM TRIS (pH 8.1), 100 mM NaCl and 10 mM EDTA.  
 
2.2.3.2 Production of inclusion bodies (IB) 
The pGMT7 plasmid vectors containing the β2m and HLA-A2 α chain were transformed in 
BL21 Star (DE3) pLysS bacteria and cultured overnight at 37 °C on a TYP agar plate. A single 
colony starter culture was set up for the β2m and HLA-A*0201 α chain constructs and grown 
at 37 °C at 220 rpm in 30 mL of TYP medium overnight. All of the overnight starter culture 
was transferred into 1 L of TYP and incubated at 37 °C at 220 rpm and the OD was 
monitored until an OD of 0.5 at 600 nm (OD600) was observed. The expression of the protein 
was induced by the addition of 0.5 mM IPTG (Fisher Scientific) and incubating the culture for 
three h in an orbital shaker at 37 °C at 220 rpm. The cells were harvested by centrifugation 
for 20 min at 3452 x g in a Legend RT centrifuge (Sorvall) with a Heraeus 6445 rotor, the cell 
pellet was resuspended in 40 mL of lysis buffer and sonicated using a MS73 probe (Bandelin) 
for 20 min using a 2 sec on 2 sec off programme at 60% power. The sample was kept on ice 
during sonication. The sample was treated with 200 μL of 20 mg/ mL DNAase (Sigma) and 
incubated for 60 min at room temperature (RT). The pellet was resuspended in 100 mL of 
Triton wash buffer and ultracentrifugation at 15,180 x g for 20 min at 4 °C in an Evolution RC 
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centrifuge with a SLA-1500 rotor (Sorvall). The pellet was resuspended in 100 mL of 
resuspension buffer and ultracentrifuged at 15,180 x g for 20 min at 4 °C in an Evolution RC 
centrifuge with a SLA-1500 rotor (Sorvall).  The supernatant was discarded and the pellet 
was resuspended in 5 mL of guanidine buffer. The concentration of protein was determined 
using a NanoDrop ND1000 (Thermo Scientific) and calculated taking into account the 
reading at 280 nm wavelength and the extinction co-efficient. A 20 µL fraction of the 
suspension was taken at several time points (before IPTG treatment and 3 h after IPTG 
induction). These fractions were run on a Sodium dodecyl sulphate-polyacrylamide (SDS-
PAGE) gel (section 2.2.6.) to assess the quality of the IB production. 
 
2.2.4 Refolding of pMHCI    
 
2.2.4.1 Buffers 
 
MHC redox buffer 
50 mM Tris (pH 8.1) (Fisher Scientific), 400 mM L-arginine (Sigma Aldrich), 2 mM EDTA 
(Fisher Scientific), 6 mM L-cysteamine (Sigma Aldrich) and 4 mM L-cystamine (Sigma Aldrich) 
in dH2O. 
 
Dialysis Buffer 
10 mM Tris in dH2O (pH 8.1). 
 
2.2.4.2 Refolding of pMHCI procedure 
30 mg of HLA-A2 α chain with a biotin tag inclusion bodies, 30 mg of β2m inclusion bodies 
and 4 mg of synthetic peptide were made up to 6.4 mL with guanidine buffer supplemented 
with dithiothreitol (DTT) (final concentration 10 mM) (Sigma Aldrich) and denatured at 37 °C 
for 15 min. The solution was then added to 1 L pre-chilled MHC redox buffer and incubated 
for 3 h at 4 °C on a magnetic stirrer. After which the refold solution was transferred to a 12 
KD cut-off dialysis tube (Sigma Aldrich). The tube was placed in 20 L of dialysis buffer for 24 
h and then placed into 20 L of dialysis buffer for a further 24 h until the conductivity of the 
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refold was below 2 mS/ cm. All buffers were filtered refolded protein samples were filtered 
through a 0.45 µm and 0.22 µm filter (Sartorius) before downstream purification steps. 
 
2.2.5 Fast Protein Liquid Chromatography (FPLC) purification   
 
2.2.5.1 Buffers 
 
Buffer A 
10 mM Tris in dH2O (pH 8.1). 
 
Buffer B 
10 mM Tris (pH 8.1) and 1 M NaCl in dH2O. 
 
Monomer buffer 
1x PBS in dH2O. 
 
2.2.5.2 Fast Protein Liquid Chromatography (FPLC) purification procedure  
The refolded protein sample was purified using an anion exchange column (POROS® 50HQ, 
Life Technologies). Briefly, the column was equilibrated with buffer A and the refolded 
protein sample was loaded onto the column at a flow rate of 20 mL/ min with the alarm 
pressure set to 5 MPa. The sample was then eluted from the column by increasing the salt 
gradient and collecting the fractions in FPLC tubes (Greiner Bio-one). The fractions 
corresponding to the peak were collected and run on an SDS-PAGE gel (section 2.2.6) to 
assess the purity. The fractions of the refolded protein sample which were shown to contain 
MHC from the SDS-PAGE gel (section 2.2.6) were pooled and concentrated to a volume of 
100 µL by centrifuging the sample at 1900 x g in a Vivaspin centrifugal concentrator (10 kDa 
molecular weight cut-off, Sartorius). The sample was made up to 700 µL with buffer A and 
the monomers were biotinylated by the addition of 100 µL Biomix A (Avadin), 100 µL Biomix 
B (Avadin), 100 µL d-Biotin 500 µM (Avadin) and 2 µL BirA enzyme (Avadin) and incubating 
the sample at RT overnight. To remove aggregates and biotin gel filtration was carried out 
using the Superdex HR 200 column (Amersham Pharmacia). The column was equilibrated in 
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monomer buffer by loading 40 mL of monomer buffer at a flow rate of 0.5 mL/ min with the 
alarm pressure set to 2 MPa. Once equilibrated the concentrated refold sample was loaded 
into the 2 mL loop and the purified sample was eluted into FPLC tubes. The fractions 
corresponding to the peak were run on a SDS-PAGE gel (section 2.2.6.) to assess purity and 
determine whether they contained a refold pMHCI protein. The monomers were stored as 5 
µg aliquots at -80 °C until required. 
 
2.2.6 SDS-PAGE electrophoresis 
 
2.2.6.1 Buffers 
5x non reducing loading buffer  
125 mM Tris (pH 6.8), 4% SDS, 20% glycerol and 20 μg/ mL bromophenol blue. 
 
5x reducing loading buffer 
125 mM Tris (pH 6.8), 4% SDS, 20% glycerol, 20 μg/ mL bromophenol blue and 10% DTT. 
 
2.2.6.2 Running of an SDS-PAGE gel 
The quality and quantity of protein was determined by running a diluted sample of the 
protein on a SDS-PAGE gel. Each sample was prepared to be run on the SDS-PAGE gel by 
diluting in 5x non reducing loading buffer and 5x reducing loading buffer. The samples were 
incubated at 90 °C for 5 min and run on a 10% Bis/Tris gel in 1X NuPAGE running buffer 
(Invitrogen). A BLUeye, 10-245 kDa protein ladder (Geneflow) was run alongside the 
samples to allow for the size of the proteins to be determined. 10% Bis/Tris gels were run at 
200 V for 25 min. The gel was removed from the plastic cast and stained with Quick 
Coomassie stain (Generon) heated in the microwave for 30 sec and then destained in dH2O 
overnight. 
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2.3 Mammalian cell culture  
 
2.3.1 Mammalian cell culture medium   
All Mammalian cell culture medias were filtered through a 0.2 µm Stericup and Steritop 
Vacuum Driven Sterile Filter (Merck Millipore) using a Divac 1.2 L pump. Cells were cultured 
in 6, 24, 48, 96 multi well plates (Greiner Bio-One) or T25, T75 and T175 flasks (Greiner Bio-
One). To ensure that cell lines were not contaminated with Mycoplasma, regular screening 
was carried out using the Mycoplasma kit (Lonza) manufacturer’s guidelines.  
 
R0 
Roswell Park Memorial Institute medium 1640 (RPMI-1640) (Invitrogen) supplemented with 
2 mM L-glutamine (Invitrogen), 100 units/ mL penicillin (Invitrogen) and 100 µg/ mL 
streptomycin (Invitrogen). 
 
R5 
RPMI-1640 medium supplemented with 5% FBS (fetal bovine serum) (Invitrogen), 2 mM L-
glutamine, 100 units/ mL penicillin and 100 µg/ mL streptomycin. 
 
R10 
RPMI-1640 medium supplemented with 10% FBS, 2 mM L-glutamine, 100 units/ mL 
penicillin and 100 µg/ mL streptomycin. 
 
Antibiotic-free R10 
RPMI-1640 medium supplemented with 10% FBS and 2 mM L-glutamine.  
 
D10 
Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% FBS, 2 mM L-
glutamine, 100 units/ mL penicillin and 100 µg/ mL streptomycin. 
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200 IU IL-2 T-cell medium  
RPMI-1640 medium with 10% FBS, 2mM L-glutamine, 100 units/ mL penicillin and 100 µg/ 
mL streptomycin, IL-15 (25 ng/ mL) (Peprotech Inc), IL-2 (200 IU/ mL) (Proleukin), non-
essential amino acids (1x) (Life Technologies), Sodium pyruvate (1 mM) (Life Technologies) 
and HEPES buffer (1 mM) (Life Technologies). 
 
200 IU IL-2 R20 T-cell media  
RPMI-1640 medium with 20% FBS, 2 mM L-glutamine, 100 units/ mL penicillin and 100 µg/ 
mL streptomycin, IL-15 (25 ng/ mL), IL-2 (200 IU/ mL), non-essential amino acids (1x), 
Sodium pyruvate (1 mM) and HEPES buffer (1 mM). 
 
20 IU IL-2 T-cell medium  
RPMI-1640 medium with 10% FBS, 2 mM L-glutamine, 100 units/ mL penicillin and 100 µg/ 
mL streptomycin, IL-15 (25 ng/ mL), IL-2 (20 IU/ mL), non-essential amino acids (1x), Sodium 
pyruvate (1 mM) and HEPES buffer (1 mM). 
 
20 IU IL-2 Priming T-cell medium  
RPMI-1640 medium with 10% FBS, 2 mM L-glutamine, 100 units/ mL penicillin and 100 µg/ 
mL streptomycin, IL-2 (20 IU/ mL), non-essential amino acids (1x), Sodium pyruvate (1 mM) 
and HEPES buffer (1 mM). 
 
2.3.2 Mammalian cell culture buffers 
All mammalian cell culture buffers were sterilised using a 0.22 μm nitrocellulose filter 
(Millipore) before use. 
 
Freezing medium 
90% FBS and 10% DMSO (dimethyl sulfoxide).  
 
Red cell lysis buffer 
155 mM NH4Cl (Fisher Scientific), 10 mM KHCO3 (BDH), 0.1 mM Ethylenediaminetetraacetic 
acid (EDTA) (Sigma Aldrich) in dH2O (pH adjusted to 7.2 to 7.4 with HCl (Fisher Scientific)).  
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Dissociation buffer  
2 mM EDTA in PBS.  
 
MACS buffer 
DPBS pH 7.2 CaCl2
- and MgCl2
- (life technologies), 0.5% bovine serum albumin (BSA) (Sigma 
Aldrich) and 2 mM EDTA. The buffer was sterilised using a 0.2 µm Stericup before use. 
 
2.3.3 Cell lines and culture conditions   
Cells were split regularly before reaching a cell density of <90% or before the medium 
became yellow in colour. Suspension cell lines were split by suspending cells in fresh R10 
medium at the optimal density. Adherent cell lines were split by removing the old medium 
and replacing the medium with either Hank’s Cell Dissociation Buffer (Life Technologies) or 
dissociation buffer and incubating at 37 °C for 5 min. After which the cells were transferred 
to a 50 mL falcon tube and centrifuged at 558 x g, the cell pellet was resuspended in either 
R10 or D10 cell culture medium and seeded into fresh flasks at the optimal seeding density. 
 
HEK 293T clone 17 cell line (ATCC product code CRL- 11268)  
The 293T cell line is an adherent and highly transfectable cell line. 293Ts are derived from 
the 293 embryonic kidney cells which were transduced to stably express the SV40 large T 
antigen. This cell line was cultured in D10 media and maintained at 37 °C with 5% CO2.  
 
Molt3 (ATCC product code CRL- 1152)  
The Molt3 cell line is a highly transfectable suspension hypertetraploid T lymphoblast cell 
line derived from a patient with relapsing acute lymphoblastic leukaemia. This cell line is 
cultured in R10 media and maintained at 37 °C with 5% CO2 
 
THP-1 (ATCC TIB 202) 
The THP-1 cell line  is  a transfectable suspension cell line derived from a patient with acute 
monocytic leukaemia. This cell line is cultured in R10 media and maintained at 37 °C with 5% 
CO2 
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A549 (ATCC CCL 185) 
The A549 cell line is a transfectable adherent cell line derived from lung carcinoma. This cell 
line is cultured in R10 media and maintained at 37 °C with 5% CO2. The A549 cell line has 
been HLA typed: A*2501/3001, B*18/4403 and C*1203/ 1601 
 
HeLa (ATCC CCL-2) 
The HeLa cell line is a transfectable adherent cell line derived from a patient with 
adenocarcinoma of the cervix. This cell line is cultured in R10 media and maintained at 37 °C 
with 5% CO2. 
 
MM909.24  
The MM909.24 cell line is a tumour cell line derived from a tumour excised from a patient 
with metastatic melanoma which was kindly donated by I.M. Svane (Copenhagen University 
Hospital). This cell line is cultured in R10 media and maintained at 37 ˚C with 5% CO2. 
 
2.3.4 Culture of primary CD8+ T-cells 
2.3.4.1 Processing the peripheral blood mononuclear cells (PBMCs) from blood  
Buffy coats were ordered from the Welsh blood service in accordance with the human 
tissue act and appropriate ethical approval. The Welsh blood service tested and confirmed 
that each of the bags of buffy coats were seronegative for HIV-1, HBV and HCV before 
delivery. The buffy coats were separated by density gradient centrifugation by layering 25 
mL the buffy coats onto 25 mL of Ficoll Hypaque (Lymphoprep) in sterile 50 mL falcon tubes 
and centrifugation for 20 min at 872 x g without brakes. The PBMC layer was aspirated from 
the density gradient using a pasteur pipette and the PBMC layer was transferred into a 
sterile 50 mL falcon tube. The volume was made up to 50 mL with R0 and the cells were 
centrifuged at 706 x g for 10 mins with the brake on. The supernatant was poured off and 
the cells were resuspended in 25 mL of red blood cell lysis buffer (section 2.3.2) and 
incubated in the water bath at 37 ˚C for 10 min. 25 mL of R10 was added to each tube to 
make the volume up to 50 mL and the cells were centrifuged at 314 x g for 6 min and the 
supernatant was poured off. The cells were resuspended in R10 media and counted. 
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Isolated PBMCs were either used as feeders to expand T-cells or to isolate CD8+ T-cells for 
lentiviral transduction.  
 
2.3.4.2 Irradiation of PBMCs  
An equal amount of PBMC from three donors were irradiated with Cesium-137 for 3100 
centigrays (cGy) after irradiation the cells were recounted and then an equal number of cells 
from each donor were pooled together. 
  
2.3.4.3 T-cell expansion   
On day 0, 0.5 - 1 x 106  T-cells were transferred to a T25 flask in 15 mL of 20 IU IL-2 T-cell 
media containing 15 µg phytohaemagglutinin (PHA) (Alere) (1 µg/ mL final) and 1.5 x 107 
irradiated PBMCs (section 2.3.4.2), 5 days post stimulation 7.5 mL of the medium was 
removed and replaced with 7.5 mL of fresh 20 IU T-cell media and incubated for a further 48 
h, after which the cells were counted and plated in 24 well plates at a cell density of 3 - 4 x 
106 cells per well in 2 mL of 200 IU IL-2 T-cell media. 
 
2.3.4.4 MACs separation of CD8+ T-cells from PBMCs 
PBMCs were isolated as described in section 2.3.4.1. CD8+ T-cells were purified from the 
PBMCs using anti-CD8 microbeads (Miltenyi Biotec) following the manufacturer’s guidelines. 
Briefly, the cells were counted and centrifuged at 300 x g for 10 min, the supernatant was 
aspirated the pellet was resuspended in 80 μL of cold MACS buffer (section 2.3.2) per 1 x 107 
cells. 20 μL of anti-CD8 microbeads (Miltenyi Biotec) was added per 1 x 107 cells and the cell 
suspension was incubated for 15 min in the refrigerator after which the cells were washed 
and resuspended in 500 μL of cold MACs buffer. Up to 2 x 108 cells were applied to a pre-
rinsed MS column and allowed to drain by gravity, the column was washed in 500 μL of cold 
MACs buffer 3 times and finally the cells were eluted in 1 mL of cold MACs buffer. The cells 
were centrifuged at 300 x g for 10 mins and resuspended in 200 IU IL-2 T-cell medium and 
plated into 48 well plates at a density of 1 - 2 x 106 cells per well. 
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2.3.5 Cell counting by Trypan exclusion  
Cells were diluted to an appropriate density in R0 medium. An equal volume of diluted cells 
and trypan blue (STEMCELL Technologies) were combined and mixed. The cells were loaded 
onto a haemocytometer (Weber Scientific International Ltd) and viable cells counted using a 
microscope to visualise the cells and a cell counter to record the number. The number of 
viable cells per mL was calculated as follows: 
(Number of viable cells * Dilution factor) *10,000 = number of viable cells per mL 
 
2.3.6 Cryopreservation of cell lines  
2.3.6.1 Cryopreservation of cell lines procedure 
Cells were centrifuged at 558 x g for 5 min, the supernatant was removed and the cell pellet 
was resuspended in 1 mL of freezing medium described in section 2.3.2. Cells were 
transferred to cryovials (Greiner bio-one) which were stored in Mr Frosty freezing pots 
(Thermo Scientific) at -80 ˚C for 48 h, for long term storage the cryovials were transferred to 
liquid nitrogen storage.  Cell lines were typically frozen at a cell concentration of 1 - 2 x 106 
cells/ mL and primary T-cells and T-cell clones were frozen at 2 - 6 x 106 cells/ mL. 
 
2.3.6.2 Thawing of cryopreserved cell lines   
Cryovials containing the frozen cells were thawed briefly in a water bath at 37 ˚C, once 
thawed the cells were transferred into a falcon tube containing 1 mL of R10 medium, the 
cells were pelleted by centrifugation (558 x g for 5 min), the supernatant was removed and 
the cell pellet was resuspended in appropriate medium before being transferred to a flask 
or plate for culture. 
 
2.3.7 Generation of transduced and transfected cells  
Cells were transduced by integrase proficient lentivirus or transfected transiently by CaCl2 
precipitation or lipofectamine. 
 
2.3.7.1 Buffers 
All of the buffers used were sterilised through a 0.22 μm nitrocellulose filter before use. 
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Buffered water 
2.5 mM HEPES (Fisher Scientific) in dH2O. Final pH 7.3. 
 
CaCl2 
2.5 M CaCl22H2O (Fluka Biochemika) in dH2O.  
 
HEPES-buffered saline 2×  
0.28 M NaCl, 0.05 M HEPES and 1.5 mM anhydrous Na2HPO4 (BDH) in dH2O. The pH was 
adjusted to 7 with 1 M NaOH (Fisher Scientific).  
 
TE buffer 
10 mM Tris (pH 8.1) (Fisher Scientific) and 1 mM EDTA with dH2O. Final pH 8.0 with HCl.  
 
2.3.7.2 Lentivirus production  
2nd and 3rd generation lentivirus were used within this thesis, for the production of 2nd 
generation lentiviruses a three plasmid system (pMD2.G, pCMV-dR8.74 and a 
pRRLSIN.cPPT.PGK-GFP.WPRE transfer vector containing hPGK internal promoter and target 
genes with or without a GFP reporter) was used. For the production of 3rd generation 
lentiviruses a four plasmid system (pMD2.G, pMDLg/pRRE, pRSV-Rev and pELNSxv transfer 
vector containing EF-1 alpha promoter and target genes with or without a rCD2 reporter) 
was used. Prior to commencing lentiviral production 293T cells were seeded in a T175 flask, 
at a cell density of 2 × 106 cells in 20 mL D10 medium, the cells were at 60-80% confluency 
on the day of transfection. 4 h prior to transfection cell confluency was assessed; the 
medium was carefully removed and replaced with 20 mL of fresh D10 medium. Lentiviruses 
were produced as described previously (Mikkola et al. 2000). Briefly 1.1 mL TE, 550 µL 
buffered water, were combined with either 13 µg pMD2.G and 24 µg pCMV-dR8.74 or 15 µg 
pMD2.G, 15 µg pMDLg/pRRE and 15 µg pRSV-Rev per sample dependent on the generation 
of lentivirus being produced. The solutions were vortexed briefly to mixed, before the 
addition of 18.75 µg of the transfer vector containing the DNA of interest and 190 µL CaCl2 
mix. 1.9 mL of HEPES buffered saline was added in dropwise fashion whilst vortexing the 
solution. The solution was left at RT for 15 - 25 min to allow precipitates to form. After 
which the solution was slowly added to the media of the 293Ts in a dropwise fashion whilst 
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the flask was gently agitated to mix the solution into the medium. The cells were incubated 
overnight at 37 °C and 5% CO2. 16 h after the transfection the medium was carefully 
removed and replaced with 17 mL of D10 medium, the cells were incubated for a further 48 
h at 37 °C and 5% CO2, the supernatant was collected at 24 h intervals (24 and 48 h), the 
supernatants were filtered through a 0.45 μm nitrocellulose filter (Millipore) and the 24 hr 
and 48 h supernatants were pooled and concentrated by ultracentrifugation at 150,146 x g 
for 2 h at 4 °C in sterilised ultra-clear ultracentrifuge tubes (Beckman Coulter). After 
centrifugation, the medium was discarded and the lentivirus pellet was resuspended in 
either 300 µL T-cell media for infecting T-cells or 1 mL R10 or D10 if infecting a cell line. The 
lentivirus preparations were aliquoted into cryovials and snap frozen on dry ice before 
transferring to -80 °C where they were stored until required. 
 
2.3.7.3 Transduction of cell lines  
Cells were plated at a concentration of 1 - 5 x 106 cells per well in a 24 well plate in 900 μL of 
appropriate medium and the cells were transduced with 100 µL of concentrated lentivirus. 
The cells were incubated overnight at 37 ˚C 5% CO2, 16 h post transduction the media was 
removed from the cells and the cells were resuspended in cell appropriate cell culture 
medium. 
 
2.3.7.4 Transduction of CD8+ T-cells 
CD8+ T-cells were isolated from PBMCs as described in section 2.3.4.4, the CD8+ T-cells were 
activated with anti CD3 anti CD28 Dynabeads (Life technologies) at a ratio of 1 : 1 for 24 h 
and cultured at a concentration of 2 x 106 cells/ well in a 48 well plate (2 mL final volume). 
The following day 1.1 mL of medium was removed and 100 µL of concentrated lentivirus 
added to the cells in addition to Polybrene (Santa Cruz Biotechnology, CA) at a 
concentration of 500 μg/ mL. The cells were incubated overnight at 37 ˚C 5% CO2, the 
following day 1 mL of 200 IU IL-2 R20 T-cell media was added to the cells. The beads were 
removed using a MACS magnet (Miltenyi Biotec) 4 days post CD8+ T-cell isolation. 
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2.3.8 Calcium chloride transfection of 293T cells 
293T cells were plated in 6 well plates 24 h prior to CaCl2 transfection, on the day of 
transfection the cells were 60 - 80% confluent.  5 µg of the plasmid of interest was made up 
to a volume of 250 µL with TE buffer, then 180 µL of HEPES buffered H2O and 75 µL CaCl2 
was added to the solution. 500 µL of HEPES buffer saline was added in dropwise fashion 
whilst vortexing. The solution was left for 15 - 25 min for precipitates to form and then 
slowly added to the cells. The cells were incubated overnight at 37 °C and 5% CO2. 16 h after 
the transfection the medium was carefully removed and replaced with fresh D10 medium. 
 
2.3.9 Lipofectamine transfection  
Cells were transfected using the lipofectamine 2000 reagent kits (Invitrogen). Briefly, the 
cells of interest were plated in 96 well plates 24 h prior to lipofectamine transfection, on the 
day of transfection the cells were 70 - 90% confluent. 2.5 μL of lipofectamine 2000 reagent 
was made up to 25 μL with opti-MEM medium (Thermo Fisher). In a separate tube 2.5 μg of 
plasmid DNA was made up to a volume of 125 μL with opti-MEM medium. The reagent mix 
and DNA mix were vortex briefly to mix and then combined at a 1 : 1 ratio. The solution was 
incubated at room temperature for 5 min and then 10 μL of the solution was added to the 
appropriate wells containing the cells of interest.  
 
2.3.10 Flow cytometry analysis  
The expression of cell surface markers and the antigen specificity of the TCR were 
monitored by antibody and pMHC tetramer/ dextramer staining. Flow cytometry data was 
collected on the FACSCalibur (BD Bioscience) or the FACSCanto II (BD Bioscience) flow 
cytometry machines. Cell sorting was carried out on the FACSAria (BD Bioscience) flow 
cytometry machine. All FACS data was analysed using FlowJo software (Treestar Inc). 
 
2.3.10.1 Buffers 
All buffers were filtered through a 0.22 µm nitrocellulose filter to sterilize. 
 
FACS buffer  
2% FBS and PBS (Life technologies). 
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Wash buffer  
0.4% EDTA and PBS.  
 
Cell fixing buffer 
2% paraformaldehyde (PFA) and PBS.  
 
2.3.10.2 Surface marker antibodies 
For analysis by flow cytometry cells were stained with a combination of the antibodies listed 
in Table 2.1 and live dead markers in Table 2.2. To compensate for spectral overlap anti-
mouse Igκ antibody capture beads (BD Biosciences) were used to prepare individual 
compensation tubes for each fluorochrome used in an experiment. 
 
2.3.10.3 Staining protocol 
Prior to commencing staining the cells were counted and an appropriate number of cells 
were washed with wash buffer in FACS tubes (Elkay) by centrifugation at 706 x g for 3 min at 
RT. The supernatant was discarded and the cells were stained with a dead stain dye (Vivid) 
diluted 1 : 40 in PBS for 5 min in the dark at RT. A cocktail of the cell surface markers with or 
without 7AAD was added to the cells and the samples were incubated for 20 min on ice in 
the dark. The cells were washed in 3 mL FACS buffer by centrifugation at 706 x g for 3 min at 
RT. The supernatant was discarded and the cells were resuspended in 200 μL of FACS buffer. 
Cells which were transduced with lentivirus and cells which were stained more than 1 hr 
prior to flow cytometry analyse required fixing (section 2.3.10.4). 
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Table 2.1.1. Cell surface marker antibodies 
Marker Colour Brand Clone Isotype 
CD8 
APCY Miltenyi Biotec BW 135/80 IgG2a 
PE Vio770 Miltenyi Biotec BW 135/80 IgG2a 
CD3 PerCp Miltenyi Biotec BW 264/56 IgG2a 
CD19 PB Biolegend HIB19 IgG1κ 
CD14 PB Biolegend M5E2 IgG2a 
Pan αβ TCR 
 
APCY Biolegend IP26 IgG1κ 
PE eBioscience IP26 IgG1K 
rat CD2 PE Biolegend OX-34 IgG2a 
MR1 PE Biolegend 26.5 IgG2a 
Mouse IgG2a  
isotype control 
PE eBioscience eBM2a  
HLA-A, B and C APCY Biolegend W6/32 IgG2a 
 
Table 2.2. Live / dead stain antibodies 
Live dead stain Colour Brand 
7AAD  eBioscience 
Live dead vivid Violet Life Technologies 
 
2.3.10.4 Fixing cells 
After cell surface staining the cells were resuspended in cell fixing buffer (section 2.3.10.1) 
and incubated for 30 min on ice in the dark. The cells were washed in FACS buffer and 
resuspended in 200 µL of FACS buffer. The samples were stored in the dark at 4 °C for up to 
48 h before being analysed on the flow cytometer. 
 
2.3.11 Tetramer and dextramer staining  
The cells of interest were counted and 5 x 105 – 1 x 106 cells were washed in wash buffer by 
centrifugation at 706 x g for 5 min at RT in a FACS tube.  
 
2.3.11.1 Treatment with Protein kinase inhibitor (PKI) 
Prior to tetramer or dextramer staining cells were treated with PKI. Briefly, a working 
concentration of 100 nM of PKI (Dasatinib, Axon Medchem) was prepared. The cells were 
resuspended in a volume of 50 µL wash buffer after washing and 50 µL of 100 mM PKI was 
added so that cells were treated with a final concentration of 50 nM PKI. The cells were 
incubated at 37 °C for 30 min before continuing to tetramer/ dextramer staining. 
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2.3.11.2  Tetramer preparation  
Tetramer with a streptavidin (strept) APCY backbone was prepared by adding 3 µL of strept 
APCY backbone (Life Technologies) to 5 µg of biotinylated monomer (section 2.2.5) in 5 
equal amounts of 0.6 µL at 20 min intervals whilst incubating on ice. Finally, 1 µL of protease 
inhibitor was added to the tetramer and the concentration was adjusted to a final 
concentration of 0.1 µg/ µL with PBS. 
 
2.3.11.3 Dextramer preparation 
Dextramers with a APCY backbone were prepared by adding 12.12 µL APCY dextran 
backbone (Immundex) per 1 µg of biotinylated monomer (section 2.2.5) and incubating the 
sample at RT in the dark for 30 min. 1 µL of protease inhibitor was added to the dextramer 
and the concentration was adjusted to a final concentration of 0.1 μg/ µL with dextramer 
buffer (Immundex). 
 
2.3.11.4 Tetramer/ dextramer staining protocol 
Prior to tetramer/ dextramer staining the cells were counted, washed in wash buffer and 
treated with PKI (optional) (section 2.3.11.1). Without a further wash step the cells were 
stained with 3 µL tetramer or 3 µL dextramer, the tubes were vortexed briefly and 
incubated in the dark on ice for 30 min. The cells were washed with 3 mL of wash buffer and 
centrifuged at 706 x g for 3 min at RT after which the supernatant was discarded. The cells 
were stained with live/dead and cells surface marker antibodies as described in section 
2.3.10.4. 
 
2.3.12 CD8+ T-cell effector function assays  
 
2.3.12.1 Peptide titration assay   
T cells were washed by the addition of excess R0 medium and centrifugation at 654 x g for 5 
min. The supernatant was discarded and the cells were resuspended in R5 medium and 
incubated for a minimum of 18 h at 37 °C with 5% CO2. The APC cell line was pulsed with the 
appropriate concentration of peptide for 2 h incubated at 37 °C with 5% CO2 after which the 
APCs and T-cells were washed in R5 medium 3 times and resuspended in R5. T- cells and 
APCs were counted and plated at a ratio of 2 : 1 T-cells : APCs in a U bottomed 96 well plate 
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and incubated overnight at 37 °C with 5% CO2. Cell supernatants were collected after 18 h 
and the production of cytokines was analysed by Enzyme-linked immunosorbent assay 
(ELISA) (section 2.3.13). 
 
2.3.13 ELISA  
 
2.3.13.1 Buffers  
 
Wash buffer 
0.05% Tween 20 (Sigma Aldrich), PBS tablets (1x) (Oxoid TM) to dH2O. 
Reagent diluent 
10% BSA and PBS tablets (Oxoid) (10x) in dH2O. A working 1x solution was made by diluting 
the 10x stock in the appropriate volume of dH2O.  
 
2.3.13.2 ELISA procedure 
ELISAs were used for the detection of IFN-γ, TNFα and MIP-1β cytokine production using the 
IFN-γ, TNFα and CCL4 Duoset ELISA kits (R&D Systems). The kit was used in combination 
with the accessory reagents - wash buffer, reagent diluent (section 2.3.13.1) and 
strepavidin-HRP, reagent A (tetramethylbenzidine) (R&D Systems), reagent B (hydrogen 
peroxide) (R&D Systems) and stop solution (sulphuric acid) (R&D Systems) according to the 
manufacturer’s guidelines. The plates were washed 3 times with 190 µL/ well of wash buffer 
using a plate washer III (tricontinent) plate washer between every step of the protocol, after 
washing the plates were carefully blotted to remove excess liquid before commencing with 
the next step of the protocol. Briefly, 96-well half well flat bottom ELISA microplates 
(Corning Costar) were coated with 50 µL of mouse anti-human IFN-γ, TNFα or MIP-1β 
capture antibody diluted in PBS (1.5 μg/ mL) and incubated overnight at RT. The plates were 
blocked with 150 µL of reagent diluent for a minimum of 1 h. The plate was washed 3 times 
and 50 μL of supernatant collected from an activation assay was added to the appropriate 
wells. Alongside the supernatant, 50 μL of reagent diluent or standard solution titrated from 
1000 pg/ mL to 15.6 pg/ mL in reagent diluent were aliquoted into each well (in duplicate) in 
order to produce a standard curve allowing for the concentration of cytokine to be 
determined. The plate was incubated at RT for a further 75 min. The plate was washed 3 
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times and 50 μL of biotinylated goat anti-human IFN-γ, TNFα and MIP-1β detection antibody 
diluted in reagent diluent to a concentration of 50 ng/ mL was aliquoted into each well. The 
plates were incubated at room temperature for a further 75 mins. The plate was washed 3 
times and 50 µL of strepavidin-horseradish peroxidase pre-diluted in reagent diluent 
according to manufacturer guidelines was aliquoted into each well. The plates were 
incubated for a further 20 min. Following 3 washes 50 μL of a 1 : 1 solution of reagent A and 
reagent B was added per well. The plates were incubated in the dark for up to 20 min, until 
there was an observable colour change, at which point 25 µL of stop solution (2 N sulphuric 
acid) was added per well. OD readings of plates were taken at 450 nm (Bio-rad iMark 
microplate reader) with correction set to 570 nm.  The results were analysed with Excel 
(Microsoft) and GraphPad Prism 5 (GraphPad) software. 
 
2.3.14 Enrichment of MR1 deficient THP-1 cells  
To generate MR1 deficient THP-1 cells, THP-1 cells were first transduced with CRISPR/Cas9 
MR1 crRNA A lentivirus. The bulk population was incubated with the D481A9 MAIT clone at 
an E : T ratio of 1 : 2 (T-cell : APCs) using 50,000 THP-1 cells to 25,000 D481A9 MAIT cells. 
The cells were incubated for 1 week in priming media (section 2.3.1) after which the media 
was replaced with R10 which allowed for the D481 A9 MAIT clone to die off whilst the THP-1 
cell number expanded.  
 
2.3.15 Enrichment of MR1 deficient MM909.24 cells  
MR1 deficient MM909.24 tumour cells were generated by transducing the cells with 
CRISPR/Cas9 MR1 crRNA A lentivirus and incubating the bulk MM909.24 tumour cells with 
the MC.7.G5 MAIT clone which was identified and characterised by Michael Crowther 
(unpublished data). The MM909.24 deficient cells were enriched from the bulk population 
by incubation with the MC.7.G5 clone at an E : T ratio of 1 : 2 (T-cell : APCs) using 50,000 
MM909.24 cells to 25,000 MC.7.G5 cells. The cells were incubated for 1 week in priming 
media after which the media was replace with R10 which allowed for the MM909.24 cell 
number to expand and the MC.7.G5 clone numbers to decline.  
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2.3.16 Assessing the function of MR1 deficient A549 and THP-1 cells by 
infection with M. smegmatis 
The MAIT cell clones (D426B1 and D481A9) were washed with R0 medium and then rested 
in R5 medium overnight. The A549 and THP-1 cells (WT and MR1 knockouts) were washed 
with R0 and cultured in antibiotic-free R10 overnight. On the day of the experiment, 
bacteria density of the M. smegmatis culture was determined and the A549 and THP-1 cells 
were exposed to M. smegmatis at a multiplicity of infection (MOI) of 100 : 1 (bacteria to 
cells) in antibiotic-free R10 and incubated for 2 h in an incubator at 37 °C. The A549s and 
THP-1s were washed in R10 and the supernatant was removed and the cells were 
resuspended in R10. The cells were incubated for a further 2 h. To ensure all bacteria were 
killed the A549s and THP-1 cells were washed in R10 medium three times and finally 
resuspended in R5 medium. Control cells were mock-treated with R10 instead of M. 
smegmatis. The A549 and THP-1 cells were plated into U bottom 96 well plates at a density 
of 6 x 104 cells per well. The MAIT cells were plated into the appropriate wells at a density of 
3 x 104 cells per well. The cells were cultured overnight and the supernatant was harvested 
after 16 h and assayed for MIP-1β, TNFα and IFN-γ ELISA (section 2.3.13). 
 
2.3.17 Assessing the function of MR1 deficient MM909.24 cells with the 
MC.7.G5 clone 
The MC.7.G5 T-cell clone was washed with R0 medium and then rested in R5 medium for 16 
h. The WT and MR1-/- MM909.24 tumour cells were washed in R0, resuspended in R5 
media and plated into U bottom 96 well plates at a density of 6 x 104 cells per well. The 
MC.7.G5 MAIT cells were washed in R0 media, resuspended in R5 media and plated into the 
appropriate wells at a density of 3 x 104 cells per well. The cells were cultured overnight and 
the supernatant was harvested after 16 h and assayed for MIP-1β and TNFα ELISA (section 
2.3.13). 
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2.4 Molecular biology  
 
2.4.1 Cloning by enzymatic digestion   
During the course of these projects a variety of DNA constructs were generated. The 
constructs were generated by the digestion and ligation of inserts and vectors by restriction 
enzymes (Fast digest AgeI, BamHI, BsmBI, EcoRI, NdeI, NheI, NsiI, SalI, SpeI, XbaI and XhoI 
(Thermo Scientific)) (section 2.4.5). The restriction sites were introduced at DNA synthesis 
or by polymerase chain reaction (PCR). Plasmid maps for each of the constructs used in this 
thesis is shown in Figure 2.1. The cloning process for each of the constructs is described in 
Appendix Table 1. The inserts and vectors were ligated using T4 ligase (Thermo Scientific) 
(section 2.4.6). DNA was transformed into XL10-Gold E. coli bacteria (section 2.1.3). To 
confirm that the colonies contained plasmids with the correct DNA sequence, colony PCR 
was performed to check whether the inserts were the correct size before confirming the 
nucleotide sequence by Sanger sequencing and analysing data using APE software (A 
plasmid Editor, M. Wayne Davis). 
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XhoI BamHI AgeI XbaI SalI 
hPGK Zinc finger (R) KRAB 2A WPRE Rev RRE GFP 
XhoI BamHI AgeI XbaI SalI 
hPGK Zinc finger (R) KRAB 2A WPRE Rev RRE GFP KRAB 5G 
XbaI 
XhoI BamHI AgeI XbaI SalI 
hPGK Zinc finger (R) KRAB 2A WPRE Rev RRE GFP SID 5G 
XbaI 
XhoI NdeI XbaI SalI 
hPGK KRAB 2A WPRE Rev RRE GFP 
Rev RRE eGFP U6 shRNA  
EcoRI BamHI NdeI 
hPGK 
Rev RRE eGFP hPGK Zinc finger  
BamHI SalI 
Fok1 2A WPRE 
NsiI XbaI XhoI 
NheI XhoI 
WPRE rCD2 Rev RRE EF-1a 2A TCRα TCRβ 2A 
XbaI 
CMV 
BamHI SpeI AgeI 
Repressor domain Zinc finger (L or R) 
Rev RRE U6 
BamHI KpnI NheI 
Cas9 WPRE Puro EFS P2A crRNA  
A 
B 
C 
D 
E 
F 
G 
H 
I 
J 
K 
XhoI XhoI 
Rev RRE eGFP hPGK WPRE ZF Binding site (1x/3x) 
WPRE 
BamHI SaII 
Rev RRE Zinc finger (R) KRAB 2A TCRα 2A TCRβ 
NheI XhoI 
EF-1a PRE 
 
 
 
 
 
 
 
 
Figure 2.1. Plasmid maps of all plasmids used in this thesis.  A) pLKO.1 shRNA GFP B) pRRL ZF Fok1 GFP C) crRNA CRISPRlentiV2 puro D) 
pRRL 1x/3x reporter system E) pV2 ZF repressor domain F) pRRL RZF-KRAB G) pRRL  KRABx H) pRRL RZF-KRAB 5G KRAB I) pRRL RZF-KRAB 
5G SID J) pELNSxv TCR RZF-KRAB K) pELNSxv TCR  rCD2 
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2.4.2 Agarose gel production 
 
2.4.2.1 Buffers 
 
Electrophoresis loading buffer 
A 6x loading buffer was made by combining 30% glycerol and 20 μg/ mL bromophenol blue 
in dH2O. 
 
50x Tris acetate EDTA (TAE) buffer  
40 mM Tris (pH 8.1), 20 mM acetic acid and 1 mM EDTA in dH2O. 
 
5x Tris borate EDTA (TBE) buffer 
90 mM Tris (pH 8.1), 90 mM boric acid and 2 mM EDTA in dH2O. 
 
2.4.3 Agarose gel electrophoresis 
DNA was run on 1 - 2% agarose gel dependent on fragment size. 1 µL of 6x electrophoresis 
loading buffer was added to every 5 µL of DNA. Agarose (0.5 g for 1% gel or 1 g for a 2% gel) 
(Invitrogen) was dissolved in 50 mL Tris acetate EDTA buffer (or tris borate EDTA buffer for 
the Surveyor assay) by heating the solution in a microwave. Once the solution had cooled to 
40 °C 2 µL of Midori green nucleic acid stain (Nippon genetics) was added and the gel was 
poured into a gel mold with the appropriate size combs. Agarose gels were run at 80 V for 
20 - 40 min dependent on the fragment size. 5 µL of hyperladder 25 bp or hyperladder 1 kb 
(Bioline) was loaded alongside the DNA to determine fragment size. Agarose gels were 
visualised in a transilluminator (Modern Biology Inc). 
 
2.4.4 DNA purification from agarose gel  
Agarose gels were run as described in section 2.4.3, inserts and vectors were excised from 
the agarose gel and the DNA extracted using the Wizard SV Gel and PCR Clean-Up System 
(Promega) according to manufacturer’s guidelines. Briefly, the excised gel was dissolved in 
10 µL membrane binding solution per 10 mg of gel slice and incubated at 65 °C until the gel 
was dissolved. The solution was transferred to the mini column and incubated at RT for 1 
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min. The column was centrifuged at 16,000 x g for 1 min and the flow through was 
discarded. The column was washed with wash buffer twice (700 µL for 1 min at 16,000 x g, 
followed by a second wash 500 µL for 5 min at 16,000 x g). The flow through was discarded 
and the column was spun for a further 1 min at 16,000 x g to remove excess ethanol. The 
DNA was eluted from the column in 50 µL of dH2O. The concentration of DNA was 
determined using a NanoDrop ND100 (Thermo Scientific). 
 
2.4.5 Digestion with restriction enzymes 
Restriction enzyme digestion was carried out by combining 2 µL of green fast digest buffer 
(Thermo Scientific), 0.5 µL of each restriction enzyme and up to 5 µg of DNA, the solution 
was made up to a final volume of 20 µL with nuclease free water. The reaction was briefly 
vortexed and centrifuged then incubated at 37 °C for 30 min and heat deactivated at 70 °C 
for 15 min before running the samples on an agarose gel (section 2.4.3). The appropriate 
DNA band was excised and the DNA extracted (section 2.4.4).  
 
2.4.6 Ligation    
Inserts were cloned into vectors by ligation with T4 ligase (New England Biolabs) following 
manufacturer’s guidelines. Briefly, the concentration of DNA of the vector and inserts was 
determined using a NanoDrop ND1000. Inserts were cloned at a ratio of either  1 : 1 or 5 : 1, 
using 1 µL of T4 ligase, 2 µL of 10x T4 ligase buffer (New England Biolabs) and made up to a 
final volume of 20 µL with nuclease free water. The solution was incubated at room 
temperature for a minimum of 30 min before bacterial transformation (section 2.1.3). 
 
2.4.7 Plasmid DNA extraction 
Plasmid DNA was extracted from bacterial cultures with the use of miniprep kit (Sigma 
Aldrich) for 5 mL cultures or the PureLink HiPure plasmid filter purification kit (Invitrogen) 
for 250 mL cultures. DNA extractions were carried out following manufacturer’s guidelines. 
 
2.4.7.1 Miniprep DNA extraction 
Briefly, the 5 mL culture was centrifuged at 12,000 x g for 1 min to pellet the E.coli cells, 
which were resuspended in 200 µL of resuspension buffer. The cells were lysed by the 
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addition of 200 µL of lysis buffer and incubated at RT for a maximum of 5 min, after which 
the solution was neutralised with 350 µL of precipitation buffer. The solution was 
centrifuged at 12,000 x g for 10 min to pellet the cell debris. The supernatant was 
transferred to a DNA column which had been treated with column preparation solution, the 
solution was loaded and centrifuged at 12,000 x g for 1 min. The flow through was discarded 
before washing the column 750 µL wash buffer and centrifugation at 12,000 x g for 1 min. 
The flow through was discarded and the column was centrifuged at 12,000 x g for 2 min to 
remove excess ethanol. The DNA was eluted in 100 µL of dH2O. The concentration of DNA 
was determined using a NanoDrop ND1000. 
 
2.4.7.2 Maxiprep DNA extraction 
Briefly, the maxiprep column was prepared by the addition of 30 mL of equilibration buffer 
and allowing the solution to drain by gravity flow.  The 250 mL E.coli culture was centrifuged 
at 4,000 x g to pellet the E.coli. The pellet was resuspended in 10 mL of resuspension buffer, 
the E.coli were lysed by the addition of 10 mL of lysis buffer,  the falcon tube was inverted to 
ensure homogeneous lysis and incubated at RT for a maximum of 5 min.  The solution was 
neutralised with 10 mL of precipitation buffer and loaded onto the maxiprep column and 
allowed to drain by gravity flow. The column was washed with 50 mL of wash buffer and the 
flow through drained by gravity flow. The DNA was eluted into a fresh 50 mL falcon tube 
containing 10.5 mL of isopropanol with 15 mL of elution buffer. The tube was centrifuged at 
12,000 × g for 30 min at 4 °C and the supernatant was carefully removed. The pellet was 
resuspended in 5 mL of 70% ethanol and centrifuged at 12,000 × g for 5 min at 4 °C. The 
supernatant was poured off and the pellet allowed to air dry before being resuspended in 
an appropriate volume of dH2O. The concentration of DNA was determined using a 
NanoDrop ND1000. 
 
2.4.8  QPCR   
2.4.8.1 RNA extraction  
Up to 10 million cells were resuspended in 1 mL Trizol. 200 μL of chloroform was added and 
the sample was shaken vigorously for 15 seconds. The sample was incubated at RT for 3 min 
then centrifuged for 5 min at 12,000 x g at 4 ˚C. The aqueous phase was transferred to a 
new Eppendorf tube and 500 μL of 100% propanol-2-ol was added. The sample was 
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incubated at RT for 10 min. The sample was centrifuged for 10 min at 12,000 x g at 4 ˚C. The 
supernatant was discarded and 1 mL of 70% ethanol was added onto the pellet. The sample 
was vortexed briefly then centrifuged for 5 min at 7,500 x g at 4 ˚C. The supernatant was 
discarded and the pellet was allowed to air dry for 10 min before resuspension in RNAse 
free water and incubation at 55 ˚C for 15 min to dissolve the pellet. The concentration of 
RNA was determined on a NanoDrop ND1000 and the quality and integrity of RNA was 
determined on a bioanalyser by CBS staff. 
 
2.4.8.2 cDNA synthesis  
cDNA was produced utilising the Superscript 20 VILO cDNA synthesis kit following 
manufacturer’s guidelines, briefly 4 μL of 5X VILO™ Reaction Mix was combined with 2 μL of 
10X SuperScript® Enzyme Mix and up to 2.5 μg of RNA. The mixture was then made up to 20 
μL using DEPC-treated water. The tube was gently mixed before being placed in a 
thermocycler for the following reaction programme: 
 
Temperature Time 
25 ˚C  
42 ˚C  
85 ˚C  
10 min 
120 min 
5 min 
 
2.4.8.3 SYBR green QPCR set up 
A master mix was prepared for each set of primers which consisted of 10 μL Power SYBR 
Green PCR Master Mix (Thermo Scientific ), 0.3 μL forward primer (100 μM stock), 0.3 μL 
reverse primer (100 μM stock) and 4.4 μL H2O per well. cDNA was synthesised as described 
in section 2.4.8.2, the cDNA was diluted into a final volume of 20 ng per 1 μL with dH2O. 5 μL 
of diluted cDNA (100 ng) was aliquoted into each of the appropriate wells. Eppendorfs 
containing the master mixes and cDNA mixes were vortexed and centrifuged briefly. 15 μL 
of master mix was aliquoted into each of the appropriate wells. All QPCRs were set up in 
triplicate and run on a ViiA7 real time PCR system for the following PCR programme: 
 
Stage Temperature  Time 
Activation  
Denaturing  
Annealing/ Extension  
95 ᵒC 
95 ᵒC 
60 ᵒC 
10 min 
15 sec              x40 cycles 
1min 
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2.4.8.4 TaqMan QPCR set up 
A master mix was prepared for each set of primers which consisted of 5 μL TaqMan Fast 
advance master mix (Thermo Scientific ), 0.5 μL TaqMan gene expression assay and 2.5 μL 
dH2O per well. cDNA was synthesised as described in section 2.4.8.2, the cDNA was diluted 
into a final volume of 25 ng per 1 μL with dH2O. 2 μL of diluted cDNA (50 ng) was aliquoted 
into each of the appropriate wells. 8 μL of master mix was aliquoted into each of the 
appropriate wells. All QPCRs were set up in triplicate and then placed in a ViiA7 real time 
PCR system for the following PCR programme: 
 
Stage Temperature  Time 
Incubation 50 ᵒC 120 sec 
Activation  
Denaturing  
Annealing/ Extension  
90 ᵒC 
95 ᵒC 
60 ᵒC 
20 sec 
1 sec              x40 cycles 
20 sec 
 
All QPCR data was analysed using Excel and GraphPad Prism 5 (GraphPad) software. 
 
2.4.9 High fidelity PCR amplification  
For PCR amplification of genomic DNA and plasmid cloning a high fidelity (HF) Phusion taq 
DNA polymerase (Thermo Scientific) was used to minimise PCR errors. The following 
reagents were combined in either 200 μL PCR tubes (Star labs) or 96 well PCR plates 
(Thermo Scientific). A master mix of all the reagents was used for large numbers of samples. 
 
Component  Volume 
DNA (5-100 ng) variable 
Phusion taq HF DNA polymerase 0.3 μL 
Forward primer (100 μM) 0.1 μL 
Reverse primer (100 μM) 0.1 μL 
dNTPs (10 mM) 0.5 μL 
HF Buffer 10 μL 
H2O up to 50 μL 
Final volume 50 μL 
 
The PCR tubes/ plates were briefly centrifuged after set up and then placed in a 
thermocycler for the following PCR programme: 
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Stage Temperature  Time 
Denaturation 98 ᵒC 30 sec 
Denaturation  
Annealing  
Extension  
Final extension  
98 ᵒC 
XX ᵒC 
72 ᵒC 
72 ᵒC 
10 sec 
30 sec                                    x 30 cycles 
30 sec per 1kb 
10 min 
 
2.4.10 Colony PCR 
To check the size and orientation of inserts into plasmid vector was correct colony PCR was 
performed using a master mix of Green Dream Taq PCR master mix (Thermo Scientific) and 
primers, in the volumes listed below: 
 
Component  Volume 
Green Dream Taq PCR master mix 7.5 μL 
Forward primer (100 μM) 0.05 μL 
Reverse primer (100 μM) 0.05 μL 
H2O up to 15 μL 
Final volume 15 μL 
 
The PCR tubes/ plates were briefly centrifuged after set up and then placed in a 
thermocycler for the following PCR programme: 
 
Stage Temperature  Time 
Denaturation 98 ᵒC 1 min 
Denaturation  
Annealing  
Extension  
Final extension  
98 ᵒC 
XX ᵒC 
72 ᵒC 
72 ᵒC 
30 sec 
30 sec                         x 30 cycles 
1 min per 1kb 
5 min 
 
2.4.11 Genomic DNA PCR clean up  
Genomic DNA was PCR amplified as described in section 2.4.9 and the size of the PCR 
amplification was confirmed by running 5 μL of the PCR product by gel electrophoresis 
(section 2.4.3). The PCR product was purified using PCR clean up beads (Axygen) following 
manufacturer’s guidelines. Briefly, the PCR product was mixed with PCR clean up beads at a 
5 : 9 ratio, the sample was mixed and incubated for 5 min at RT. The beads were placed on a 
magnet until a pellet was formed and the supernatant was discarded. Following this the 
sample was washed twice with 200 μL of 70% ethanol and the supernatant was discarded. 
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Finally the pellet was allowed to air dry for 10 - 15 min and the DNA was eluted from the 
pellet by suspending the beads in 40 μL of dH2O. 
 
2.4.12 Mammalian DNA extraction 
Mammalian DNA was extracted from cells using a mammalian DNA extraction kit (Sigma 
Aldrich), briefly, cells were washed in PBS and lysed in 200 µL of Lysis Solution C. The 
samples were vortexed for 15 sec and then incubated at 55 °C for 10 min. To prepare the 
GenElute Miniprep Binding Column 500 µL of the Column Preparation Solution was added to 
the column which was centrifuged for 1 min at 12,000 x g. 200 µL of 100% ethanol was 
added to the cell lysate. The cell lysate was vortexed to mix and transferred onto the DNA 
binding column which was centrifuged for 1 min at 6500 x g. The flow through was 
discarded and 500 μL of wash Solution was added to the column, the column was 
centrifuged for 1 min at 6500 x g and the flow through was discarded. 500 µL of Wash 
Solution was added to the column which was centrifuged for a further 3 min at 16,000 x g, 
the through flow was discarded and the column was centrifuged for a further min at 16,000 
x g to remove any existing ethanol from the column. To elute the DNA from the column 200 
µL of the Elution Solution was added to the centre of the column. The column was 
centrifuged for 1 min at 26500 x g. The concentration was determined on the NanoDrop 
ND1000. 
 
2.4.13 Surveyor assay 
The Surveyor assay was carried out using the Surveyor Mutation Detection Kit (Integrated 
DNA Technologies) following the manufacturer’s guidelines. The Surveyor assay is based on 
a nuclease which cleaves DNA at mismatch specific sites.  Briefly, genomic DNA was 
extracted (section 2.4.12) from wild type (WT) cells and transfected or transduced cells. The 
DNA was amplified using primers which spanned the region thought to contain mutations 
induced by the gene editing tools. PCR amplicons derived from WT cells and transduced 
cells were hybridised using the thermocycler programme below.  
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Once hybridised the samples were digested by combining the following reagents into 200 μL 
PCR tubes: 
 
 
Reagent Volume 
Hybridised DNA (200 - 400 ng) Variable 
Surveyor enhancer S  1 μL 
Surveyor nuclease S  1 μL 
0.15 M MgCl2  2 μL 
dH2O  Up to 20 μL  
Final Volume 20 μL 
 
The samples were incubated for 1 hr at 42 °C in a thermocycler. The reaction was stopped 
by the addition of 2.2 μL stop solution and the DNA was run on a 2% agarose TBE gel.  
 
2.4.14 DNA extraction trizol method 
For genomic DNA extraction from high cell numbers (>5 x 106) DNA was extracted using the 
trizol method. Briefly, up to 1 x 107 cells were resuspended in 1 mL Trizol and 960 μL of 
chloroform and 40 μL of isopropanol were added to each tube. The samples were vortexed 
for 60 sec and centrifuged for 5 min at 12,000 x g at 4 ˚C. The aqueous layer was transferred 
to a clean Eppendorf tube and sodium acetate was added (final concentration 300 mM). 2 - 
Temperature Time Temperature ramp 
95 °C 10 min  
95 °C to 85 °C      (–2.0 °C/ sec) 
85 °C  1 min     
85 °C to 75 °C   (–0.3 °C/ sec) 
75 °C  1 min     
75 °C to 65 °C      (–0.3 °C/ sec) 
65 °C  1 min  
65 °C to 55 °C     (–0.3 °C/ sec) 
55 °C  1 min     
55 °C to 45 °C   (–0.3 °C/ sec) 
45 °C  1 min     
45 °C to 35 °C      (–0.3 °C/ sec) 
35 °C  1 min  
35 °C to 25 °C  (–0.3 °C/ sec) 
25 °C 1 min     
4 °C Hold  ∞   
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2.5x volume of ice cold 100% ethanol was added and the samples were placed on dry ice for 
an h or in the freezer overnight. After which the samples were centrifuged for 5 min at 
12,000 x g at 4 ˚C and the supernatant was discarded. 1 mL of RT 70% ethanol was added 
and the samples were centrifuged for 5 min at 12,000 x g at 4 ˚C, the supernatant was 
discarded and the pellet was air dry for 10 - 15 min. The pellet was resuspended in 100 μL 
H2O and the concentration was determined by NanoDrop ND1000. 
 
2.4.15 RNAseq 
2.4.15.1 RNAseq library preparations  
Prior to preparation of RNA libraries RNA was extracted and quality control was performed 
(section 2.4.8.1). Library preparation and RNAseq was performed at the University of UTAH, 
briefly, the RNA was purified with the Ribo-Zero Gold kit (Illumina) and RNA libraries were 
prepared using the TruSeq Stranded Total RNA Sample Prep kit (Illumina) following 
manufacturer’s guidelines. The protocol is summarised in Figure 2.2. The samples were 
sequenced on an Illumina HiSeq using a HiSeq 125 Cycle Paired-End Sequencing v4 kit 
(Illumina). 
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RiboZero Deplete and fragment RNA 
First strand cDNA synthesis 
Second strand cDNA synthesis 
  
Adenylate 3’ ends 
  
Ligate adapters 
PCR amplification 
Library validation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2. A schematic representation of the main steps in the library preparation protocol prepared prior to RNAseq 
 
2.4.15.2 Analysis of the RNAseq data 
The analysis of the RNAseq data was performed by Dr Colin Farrell (University of UTAH). 
Raw reads which did not meet quality control conditions were excluded from the analysis. 
The raw reads were aligned to the reference genome using Cufflinks software (Roberts et al. 
2011). The differential expression of genes was determined using the Cufflinks pipeline 
(Roberts et al. 2011; Trapnell et al. 2012) and DeSeq2 package (Love et al. 2014) to perform 
pairwise comparisons between the samples. 
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NEBNext End Prep 
Adaptor ligation 
Size selection and clean-up of adaptor ligated DNA 
PCR Amplification 
Clean up of PCR amplified DNA 
2.4.16 Whole genome sequencing 
 
2.4.16.1 Next generation sequencing library preparations  
Prior to the preparation of DNA libraries DNA was extracted from cells (section 2.4.14) and 
the quality of DNA was determined using a bioanalyser (run by CSB staff). 1 μg of DNA was 
fragmented to an average size of 300 bp by a Covaris M220 focused ultrasonicator, which 
was confirmed by running the samples on a bioanalyser (run by CSB staff). Libraries were 
prepared using NEBNext Ultra library preparation kits (New England Biolabs), following 
manufacturer’s guidelines, the protocol is summarised in Figure 2.3. A sample of the library 
preparations were run on a bioanalyser once more to check the fragment size of the 
adaptor ligated DNA fragments. To assess quality the whole genome library preps were 
initially run on the MiSeq (Illumina) using 250 bp paired end kit (Illumina). After the QC step 
the whole genome sequencing library preparations were run on a NextSeq 500, using High 
Output 150 bp paired end kit (Illumina) to a depth of >20x coverage for each genome. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3. A schematic representation of the main steps in the library preparation protocol prepared prior to DNA sequencing. 
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2.4.16.2 Analysis of the whole genome sequencing data 
The analysis of the whole genome sequencing data was performed by Dr Thomas Connor. 
Briefly, the reads were mapped against the DNA sequences using the Burrows Wheeler 
Alignment tool (Li & Durbin 2009) and Artemis software was used to visualise the aligned 
reads (Rutherford et al. 2000). The sequencing analysis for the data collected for the whole 
genome sequencing was completed in two phases: 
1) The most likely off target sites in genes were identified using the CRISPRdesign tool (an 
algorithm developed at MIT) were screened. 
2) Any reads containing a sequence with 15/20 bp or more matching the CRISPR RNA 
(crRNA) sequence were screened.  
 
Approach 1 
The most likely off target sites were identified were identified using the CRISPRdesign tool 
(MIT) and eCRISP software (German cancer research centre), using these algorithms 37 
potential off target sites and one unintentional on target site were identified for the crRNA 
A. Of the 38 sites identified, 1/38 of these predicted sites was within the RP11-46A10.6 
gene, which encodes an unprocessed pseudogene, which was found to share 20/20bp 
homology within the crRNA.  5/38 of these predicted off target sites were within genes, the 
crRNA was found to share 17/20bp with the cAMP responsive element binding protein 3-like 
1 (CREB3L1) gene, 16/20bp with the uncharacterized LOC728730 (LOC728730) long non-
coding RNA gene, 16/20bp with tectonin beta-propeller repeat containing 1 (TECPR1) gene, 
16/20bp with chromosome 16 open reading frame 59 (C16orf59) gene and 16/20bp with 
NLR family pyrin domain containing 1 (NLRP1) gene. Lastly, 32/38 of these predicted off 
target sites were not located within gene encoding DNA. The likely off target sites are shown 
in Table 2.3. The reads produced from the whole genome sequencing were aligned to the 
reference sequence GRCh38 and the 38 predicted off target sites were manually examined.  
  
Approach 2 
To analyse any off target mutations in the genome which were not identified by the 
CRISPRdesign tool (MIT) and eCRISP software (German cancer research centre) algorithms, 
all of the sequence reads which contained a sequence matching, or complimentary to the 
guide RNA at 15/20 bases were extracted as a set of fastq files. The fastq files were 
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assembled to the reference sequence using Velvet. This analysis identified 7,574 locations in 
sample clone 9 and 7516 locations in clone 11 at which there were discrepancies between 
the reference sequence and the sequenced reads. Each query was examined manually by 
comparing the WT sequence to the sequenced reads.  
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Table 2.3. The most likely off target sites of MR1 crRNA A. The most likely off target sites of MR1 crRNA A were predicted using the 
CRISPRdesign tool (MIT) and eCRISP software (German cancer research centre).Variations between the MR1 crRNA and other likely sites 
are highlighted in turquoise. PAM sequences are underlined. 
 Sequence Score Mismatches UCSC gene 
MR1 GGATGGGATCCGAAACGCCCAGG 100.0 0MMs [] NM001195000 
RP11-46A10.6 GGATGGGATCCGAAACGCCCAGG 100.0 0MMs []  
 CGAGGGGTTCAGAAACGCCCTGG 0.8 4MMs [1:4:8:11]  
 GGTGGGGATGCGAAACACCCTAG 0.5 4MMs [3:4:10:17]  
LOC728730 GCTTGGGACCCGAAACGCCTCGG 0.4 4MMs [2:3:9:20] NR037875 
 CTATGGGATCAGAAACGCTCAGG 0.3 4MMs [1:2:11:19]  
 AGATGGGATCCTAAAGGCCCAGG 0.3 3MMs [1:12:16]  
 GGATGGGATCAAAAACTCCCTGG 0.3 3MMs [11:12:17]  
 GGATGGGGGCGAAAACGCCCGGG 0.2 4MMs [8:9:11:12]  
 AGATGGGACCTGAAACACCCCAG 0.2 4MMs [1:9:11:17]  
 GAATGTGATCTGAAACTCCCCAG 0.2 4MMs [2:6:11:17]  
 GGAGAGGATCCTAAGCGCCCTGG 0.2 4MMs [4:5:12:15]  
 GGCTGGGATGTGAAACGGCCAAG 0.2 4MMs [3:10:11:18]  
 GGATGGGATTAAAAACTCCCAAG 0.1 4MMs [10:11:12:17]  
TECPR1 GGTTGAGCTCCGACACGCCCAGG 0.1 4MMs [3:6:8:14] NM015395 
 GGGTGGCATCAGAAACGGCCAGG 0.1 4MMs [3:7:11:18]  
 GCATGGGTTCCAATACGCCCAGG 0.1 4MMs [2:8:12:14]  
 TGATGGGAGCAGAAATGCCCTGG 0.1 4MMs [1:9:11:16]  
 AGATGGGACCTGAAAGGCCCAAG 0.1 4MMs [1:9:11:16]  
 GGAAGGGAGCTGAAAGGCCCCAG 0.1 4MMs [4:9:11:16]  
 GGAAGGGATCTGCACCGCCCTGG 0.1 4MMs [4:11:13:15]  
 GGATGGGGCCTGAAAAGCCCAGG 0.1 4MMs [8:9:11:16]  
 GGATGGGTCCTGACACGCCCAAG 0.1 4MMs [8:9:11:14]  
 GGATGTGTTCCGAAACAGCCCGG 0.1 4MMs [6:8:17:18]  
 AGATGGGATCAGAAAAGCCATAG 0.1 4MMs [1:11:16:20]  
C16orf59 GGATGGGAGCCCGAACCCCCAGG 0.1 4MMs [9:12:13:17] NM025108 
 GGATGGGATGACAAAGGCCCTGG 0.1 4MMs [10:11:12:16]  
 GGAAGGGATCCTAAACATCCGGG 0.1 4MMs [4:12:17:18]  
 GGAAGGGATCAGCAAGGCCCGAG 0.1 4MMs [4:11:13:16]  
 GGATGGGATGAGAAAGGCCAGGG 0.1 4MMs [10:11:16:20]  
 GGATTGGATCCCAAAACCCCAAG 0.0 4MMs [5:12:16:17]  
 TGATGGGATCCCAAAGGGCCCAG 0.0 4MMs [1:12:16:18]  
 GGCTGGGATCCGAAGGCCCCAGG 0.0 4MMs [3:15:16:17]  
 GGAGGGGATCAGAGAGGCCCTGG 0.0 4MMs [4:11:14:16]  
 GGATGGGAGCCGACACCCACAAG 0.0 4MMs [9:14:17:19]  
 GGATGGGATCCAAACCCTCCCAG 0.0 4MMs [12:15:17:18]  
 GGATGAGATCCCAGAAGCCCAAG 0.0 4MMs [6:12:14:16]  
NLRP1 GGATGGGATCCGGAGGGCTCTAG 0.0 4MMs [13:15:16:19] NM033004 
CREB3L1 GGATGGGATCAAAAACTCCCTGG - 3MMs [11:12:17] NM052854 
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2.4.17 Design of CRISPR/Cas9 systems for gene editing 
Two CRISPR/Cas9 lentiviral vector plasmids were used in this thesis an ‘all in one’ system 
which was developed in house and the lentiCRISPRv2 vector which was developed by the 
Zhang lab. Each is described in turn: 
 
2.4.17.1  Development of an “all-in-one” CRISPR/Cas9 lentivector targeting the MR1 gene 
An ‘all in one’ CRISPR/Cas9 lentiviral vector was produced based upon the two plasmid 
system developed by Mali et al. 2013,  which consisted of gRNA cloning vector (Addgene 
#41824) and hCas9 (Addgene #41815). As it was thought that a single plasmid system would 
improve infectivity and therefore efficiency of CRISPR/Cas9 induced gene editing. To 
generate the single plasmid system, the DNA sequence of the U6 RNApolIII promoter and a 
crRNA sequence which encompassed the MR1 specific crRNA and the trans-activating 
CRISPR RNA (tracrRNA) sequence were ordered and synthesised by (Eurofins MWG Operon, 
Ebersberg, Germany). The U6 RNApolIII promoter and a crRNA sequence were flanked by 
SpeI restriction sites which were used to clone the sequence into the pCDNA.3-TOPO_WT-
Cas9 plasmid (a gift from George Church (Addgene#41815)) by non-directional cloning at 
the Spe1 restriction site upstream of CMV promoter. To produce a lentiviral vector the 
portion of the vector containing the U6 promoter, gRNA sequence, CMV promoter and WT 
Cas9 were amplified by PCR using the pCDNA.3_Fwd and pCDNA.3_Rev primers to introduce 
an AgeI restriction site upstream of the U6 promoter and an NsiI restriction site downstream 
of the Cas9 sequence. The U6 promoter, gRNA sequence, CMV promoter and WT Cas9 
sequence was cloned into the 2nd generation pRRL.sin.cppt.pgk-gfp.wpre lentivector 
backbone  (a gift from Didier Trono’s laboratory (Addgene#12252)) which had been PCR 
amplified using the pRRL.0_Fwd and pRRL.0_Rev primers to introduce AgeI and NsiI 
restriction sites and remove the human PGK promoter and GFP sequence. All of the primer 
sequences used in this thesis are listed in Appendix Table 2.  
 
2.4.17.2  Design and introduction of novel crRNA target sequences into “all-in-one” 
CRISPR/Cas9 lentivector 
The ‘all in one’ system was designed so that the 20bp crRNA sequence could be modified to 
target new DNA sequences. The novel crRNA target sequences were designed by identifying 
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potential sites with the either a 5’ 20bp NGG or 5’ CCN 20bp sequences, the sequences were 
run on the blastn aligorithm NCBI (Altschul et al. 1990). Novel crRNA sequences were 
introduced into the ‘all in one’ system by PCR cloning. The primers designed contained the 
new crRNA sequence flanked by a sequence complementary to the plasmid sequence. The 
primers were phosphate modified at the 5’ end. The primers used were in the format below 
(where N represents nucleotides of the target sequence). The lentivirus vector was PCR 
amplified (section 2.4.9) with the appropriate primers and an annealing step at 53 °C.  
 
5’GTTTTAGAGCTAGAAATAGCAAGTTAANNNNNNNNNN 3’  
3’                                                                  NNNNNNNNNNGGAAAGGACGAAACACC ’5 
 
2.4.17.3 Production of novel crRNA target sequences into lentiCRISPRv2 vector (Zhang lab)  
The lentiCRISPRv2 vector (Addgene plasmid #52961) was provided courtesy of the Zhang lab 
(Sanjana et al. 2014; Shalem et al. 2014). Novel crRNA sequences targeting genes of interest 
were designed with the use of the CRISPRdesign tool which ranked all of the potential crRNA 
sequences according to the likelihood of off target binding. Once the crRNAs were designed 
primers were ordered in the format (where N is crRNA sequence): 
 
5’     CACCGNNNNNNNNNNNNNNNNNNNN             3’ 
3’               CNNNNNNNNNNNNNNNNNNNNCAAA   5’  
 
Production of the lentiviral vector was carried out following the guidelines found on the 
Zhang Lab GeCKO website: http://www.genome-engineering.org/gecko/. The three steps 
are described in sections 2.4.17.4, 2.4.17.5 and 2.4.17.6. 
 
2.4.17.4 Dephosphorylation of the lentiviral vector 
The lentiCRISPRv2 vector was digested and dephosphorylated by combining the reagents 
below in 200 μL PCR tubes: 
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 Reagent Volume 
LentiCRISPRv2  5 μg 
FastDigest BsmBI (Fermentas) 3 μL 
FastAP (Fermentas)    3 μL 
10X FastDigest Buffer    6 μL 
100 mM DTT  0.6 μL 
ddH2O       X μL 
Final volume  60 μL 
 
The tubes were incubated at 37 °C for 30 min and run on an agarose gel (section 2.4.3) the 
backbone was excised from the gel and the DNA extracted as described in section 2.4.4. 
 
2.4.17.5 Phosphorylation of oligos 
Oligos were phosphorylated for downstream applications by combining the reagents below 
in 200 μL PCR tubes: 
 
Reagent Volume 
Oligo 1 (100 µM)    1 µL  
Oligo 2 (100 µM)    1 µL 
10X T4 Ligation Buffer (New England Biolabs)    1 µL  
ddH2O 6.5 µL 
T4 PNK (New England Biolabs)    0.5 µL 
Final volume   10 µL 
 
The samples were vortexed and centrifuged briefly and then placed in a thermocycler for 
the following programme: 
 
Temperature Time 
37 °C 30 min 
95 °C 5 min 
95 °C to 25 °C 5 °C/ min 
 
 
2.4.17.6 Ligation of dephosphorylated backbone and phosphorylated annealed oligos 
The dephosphorylated backbone and phosphorylated annealed oligos were ligated by 
combining the following reagents: 
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Reagent Volume 
Dephosphorylated backbone (50 ng)   X μL 
oligo duplex (100 nM) 1 μL 
2X Quick Ligase Buffer (New England Biolabs)   5 μL 
ddH2O      X μL 
Quick Ligase (New England Biolabs)     1 μL 
Final volume 11 μL 
 
A control with dH2O replacing the oligo duplexes was also prepared. The samples were 
incubated at RT for 30 min and then transformed into XL10-gold bugs (section 2.1.3). 
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3.1 Introduction 
The basic principles of gene silencing with RNAi and nuclease gene editing are described in 
the section 1.3. The shRNA, ZFNs, TALENs and the CRISPR/Cas9 systems will each be 
discussed in more depth in the following sections. 
 
3.1.1 Small hairpin RNA (shRNA) 
To induce stable silencing of the target gene shRNA is typically expressed in a viral vector. 
The viral vector contains a DNA sequence which consists of a sense and antisense copy of 
the target sequence separated by a loop sequence. After transcription the shRNA is 
exported from the nucleus and the loop is removed from the shRNA by a dicer, resulting in a 
small interfering RNA (siRNA). The double stranded siRNA is converted into a single stranded 
siRNA and the resulting single stranded siRNA binds to an RNA inducing silencing complex 
(RISC). mRNA with an identical sequence to that of the single stranded siRNA is degraded 
(Reviewed by Sen & Blau 2006; Moore et al. 2010). A schematic representing the process is 
shown in Figure 3.1. 
 
 
Figure 3.1. A schematic representation of shRNA processing and mRNA degradation. Pre shRNA is processed into shRNA which is 
subsequently converted to double stranded siRNA and then single stranded siRNA. The single stranded siRNA forms an RNA-induced 
silencing complex leading to denaturing of corresponding mRNA. 
 
3.1.1.1 Design considerations 
There are several design considerations when designing potential shRNA sequences. One 
issue is the GC content of shRNA sequence as the GC content affects the thermodynamic 
stability (Elbashir et al. 2002; Holen et al. 2002). A low internal stability at the 5’ antisense 
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strand was shown to be important both for effective unwinding and entry into the RISC 
complex (Reynolds et al. 2004). Finally, shRNA are designed with minimal palindromic 
repeats within the sequence to avoid the formation of additional folds within the secondary 
structure (Reynolds et al. 2004). shRNA design algorithms are publically available to aid in 
the design of shRNA sequences (Olson et al. 2006).  
 
3.1.1.2 shRNA uses 
Silencing of genes with shRNAs has been a popular method since the technique was first 
characterised (Fire et al. 1998). Table 3.1 summarises some of the genes which have been 
silenced in humans with shRNA technology in recent publications.  
 
Table 3.1. A table summarizing examples of genes in human cells which have been silenced with shRNA. 
iRNA induced 
silencing 
Genes  Reference 
Gene silencing DNMT1, DNMT3B, E-cadherin, HER2  Kawasaki & Taira 2004 
PRMT5  Zhao et al. 2009 
β-catenin  Assimakopulos 2007  
CCR5-GFP, RASSF1A  Kim et al. 2006 
EZH2  Kondo et al. 2008  
α-1-antitrypsin  Giering et al. 2008  
APK14, KIF11, IGF1R and KIF14  Siolas et al. 2005 
TF, PSKH1  Holen et al. 2002  
p53  Schomber et al. 2004 
SHP2, STAT5 and Gab2  Scherr et al. 2006  
MTA1  Jiang et al. 2011 
10839 gene library  Silva et al. 2005 
 
3.1.2 Fok1 nuclease based technologies  
Zinc finger proteins (ZFPs) (section 3.1.3) were first fused to the Fok1 restriction enzyme by  
Kim et al., 1996, to form ZFN. This approach was later applied to Transcription activator like 
effectors (TALEs) to produce TALENs. For gene editing purposes, Fok1 nucleases have been 
designed to be inactive in their monomeric form and only become functional once 
dimerised. This approach adds to the specificity of targeting and minimises potential off 
target effects associated with shorter DNA binding motifs (Hockemeyer et al. 2009). In order 
to increase specificity, all ZFNs and TALENs are designed in pairs to promote dimerisation at 
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the required genomic location (Hockemeyer et al. 2009). The wildtype form of the Fok1 
restriction enzyme cleaves DNA when in a homodimer formation which was shown to lead 
to off target effects. Thus the Fok1 nuclease used in modern ZFN and TALEN design has 
been modified to only become activated in the heterodimeric form but retaining the 
cleavage efficiency shown by the wildtype form (Szczepek et al. 2007; Miller et al. 2007; 
Doyon et al. 2011). 
 
3.1.3 ZFPs 
A ZFP is usually comprised of several Cys2-His2 motifs (Wolfe et al. 2000; Messina et al. 
2004) assembled in an array with each Cys2-His2 motif targeting three nucleotides of DNA in 
sequence (Pavletich & Pabo 1991). The motif also forms a hydrogen bond with one 
nucleotide of DNA on the opposing strand (Isalan et al. 1997). A Cys2-His2 ZF motif is 
composed of 2 histidine and 2 cysteine amino acid residues which interact with a central 
zinc ion, and a number of conserved amino acids  (Phe16, Leu22 and His25) aid in the 
formation of a hydrophobic core (Pavletich & Pabo 1991). The first crystal structure of a ZFP 
bound to a DNA oligonucleotide revealed that the ZF binds in the major groove of the DNA  
with amino acids at residues 1, 3 and 6 determining the nucleotide specificity (Pavletich & 
Pabo 1991). Artificial ZFP domains can be constructed by modular assembly of individual 
fingers in order to target specific genomic DNA sequences, typically 9 to 18 nucleotide long 
(Urnov et al. 2010). This major advance allowed protein targeting of explicit sequences 
within the genome for the first time and was quickly utilised by fusing ZFPs to the Fok1 
nuclease domain to form  ZFNs. To limit the likelihood of off target effects ZFNs are 
designed in pairs with a  spacer of between 5 - 7 nucleotides between the left and right ZFPs 
(Christian et al. 2010) to allow Fok1 to function (Figure 3.2).  
 
 
 
 
 
 
Figure 3.2. Schematic diagram of ZFN. The ZFNs are formed from two domains – the ZF arrays and the Fok1 nuclease domain. The ZF is 
fused to the Fok1 domain by a peptide linker.  
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 
Zinc finger Fok1 
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3.1.3.1 ZFN design considerations 
ZFPs targeting specific DNA stretches can be produced by assembly of individual ZF modules 
(Mandell & Barbas 2006), by oligomerized Pool Engineering (Maeder et al. 2008; Maeder et 
al. 2009) or through DNA synthesis using the published ZF module sequences published for 
56/64 of the potential 3bp DNA stretches (Segal et al. 1999; Dreier et al. 2001; Dreier et al. 
2005; Mandell & Barbas 2006). ZFPs have not been identified for all of the potential 3bp 
stretches, which limits the DNA sequences that can be targeted by ZFNs. There are several 
resources and algorithm tools available online to design gene specific ZFNs (such as 
toolgen/ZFNfinder and umassmed/ZFPsearch).  
 
3.1.3.2 ZFN uses 
ZFNs have been utilised for gene editing purposes in many organisms including virus 
(Cradick et al. 2010; Wayengera 2011), plants (Zhang et al. 2010) and many animals such as 
Zebrafish (Meng et al. 2008), Nematode (Caenorhabditis elegans) (Wood et al. 2011), mice 
and rats (Cui et al. 2011). Table 3.2 summarises some of the human genes which have been 
targeted by ZFNs.   
 
Table 3.2. A table summarizing examples of genes in human cells which have been modified with ZFNs. 
ZFN induced 
gene editing 
Gene(s)  Reference 
Gene disruption CCR5  Perez et al. 2008; Kim et al. 2009 
CXCR4  Yuan et al. 2012; Didigu et al. 2014 
TP73, MAP3K14, 
EP300, BTK, CARM1, 
GNAI2 RIPK1 and KDR  
Doyon et al. 2010 
 
 
TSC2  Doyon et al. 2010; Lu et al. 2013 
NR3C1  Doyon et al. 2011 
TCR Provasi et al. 2012; Torikai et al. 2012 
VEGF, HOXB13 and 
CFTR  
Maeder et al. 2008 
 
Gene correction IL2RG  Urnov et al. 2005 
A1AT  Yusa et al. 2011 
HBB  Zou et al. 2011 
SNCA  Soldner et al. 2011 
LRRK2  Sanders et al. 2014  
β globin  Sebastiano et al. 2011; Zou et al. 2011 
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3.1.4 TALENs 
TALEs are bacterial DNA binding proteins found naturally in Xanthomonas proteobacteria 
(Joung & Sander 2013) which can be customized to target specific sequences within the 
genome. TALEs are formed from tandem repeat modules, which are typically 34 amino acid 
in length. The 12th and 13th amino acids in the module determine the binding specificity of 
the module (Cermak et al. 2011; Cong et al. 2012). Thus using TALE modules with alternative 
residues at the 12th and 13th amino acid position changes the nucleotide to which the TALE 
module will bind. The residues used in the literature are - NG (T), NI (A), HD (C) and NK/ NN 
(G) (Cermak et al. 2011; Christian et al. 2012; Schmid-Burgk et al. 2013). TALEs are most 
commonly fused to the Fok1 nuclease domain forming TALENs. A schematic diagram of a 
TALEN is shown in Figure 3.3. 
 
 
 
 
 
Figure 3.3. Schematic diagram of TALEN. TALENs consist of two domains – a TALE domain which is typically made up of 20 modules linked 
to a Fok1 domain by a peptide linker.  
 
3.1.4.1 TALE design considerations 
TALE proteins require a thymine nucleotide one bp upstream of the 5’ of the TALE DNA 
binding sequence (Boch et al. 2009). There are several different TALEN backbones each with 
optimal spacer lengths (14 - 33 nucleotides) (Christian et al. 2012). TALENs can be 
synthesised or produced by modular assembly using several commercially available kits 
using golden gate cloning (Cermak et al. 2011; Sanjana et al. 2012).  
 
3.1.4.2 Applications of TALEN technology 
TALENs have been used for gene editing in many organisms including yeast (Li et al. 2011), 
plants (Wang et al. 2014) and many animals such as zebrafish (Solin et al. 2015), nematode 
(Caenorhabditis elegans) (Cheng et al. 2013), mice (Sung et al. 2013). Table 3.3 summarises 
some of the human genes which have been targeted by TALENs. 
 
 
TALE Fok1 
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 
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Table 3.3. A table summarizing examples of genes in human cells which have been modified with TALENs. 
TALEN induced 
gene editing 
Genes  Reference 
Gene disruption CCR5  Mussolino et al. 2011 
TCR  Berdien et al. 2014 
PSIP1  Fadel et al. 2014 
RAP1  Kabir et al. 2014 
NDUFA9 Stroud et al. 2013 
TERF1IP  Kabir et al. 2014 
AKT2, ANGPTL3, APOB, 
ATGL, C6orf106, CIITA, 
CELSR2, CFTR, GLUT4, 
LINC00116, NLRC5, 
PLIN1, SORT1, TRIB1, 
TTN  
Ding, et al. 2013 
Library of TALENs 
targeting 17,120/18,742 
(91% of protein coding 
genes). 
Kim et al. 2013 
Gene correction HBB  Ma et al. 2013 
 
 
3.1.4.3 RNA guided endonucleases/ CRISPR/Cas system 
The most recently discovered gene editing tools are RNA guided engineered nucleases 
(RGEN) which are based on CRISPR prokaryotic immune system. The observation of clusters 
of short fragments of DNA separated by repeating DNA sequences were first identified in E. 
Coli (Ishino et al. 1987) and have been identified in a variety of bacteria and archaea since 
(Mojica et al. 1993; Mojica et al. 2000). The function of these DNA sequences remained 
uncharacterised until it was revealed that they were derived from invading bacteriophage 
and plasmid DNA (Bolotin et al. 2005; Mojica et al. 2005). Incorporating the DNA from 
invading pathogenic DNA into its own genome in CRISPR arrays allowed the host bacteria to 
destroy pathogenic DNA upon reinfection. The ability of CRISPR/Cas to target and cleave 
specific DNA sequences has been put to use for gene editing. The CRISPR/Cas II system is of 
particular relevance to my own work. The CRISPR/Cas II system allows for the targeting of 
specific DNA sequences by crRNA and the introduction of DSBs by the Cas proteins. There 
are several Cas proteins but typically it is the Cas9 variant which is used as a nuclease in 
combination with CRISPR for gene editing (van der Oost 2013). Several groups have 
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successfully optimised the CRISPR system to induce DSBs in DNA by co-expressing human 
codon optimised Cas9 with a crRNA and trans-acting crRNA (tracrRNA)  in mammalian cells 
(Cong et al. 2013; Mali et al. 2013). A tracrRNA is needed to initiate the processing of the 
crRNA by ribonuclease III (Deltcheva et al. 2011) and activating the cleavage of the DNA by 
Cas9 (Jinek et al. 2012). The target site of the CRISPR/Cas9 protein is determined by the 
crRNA sequence, thus altering the crRNA sequence allows for novel genes to be targeted. A 
schematic diagram of a CRISPR/Cas9 is shown in Figure 3.4. 
 
 
 
 
 
 
 
 
 
 
Figure 3.4. Schematic diagram of type II CRISPR/Cas9 system. The structure of Streptococcus pyogenes Cas9 bound to target DNA 
sequence. The crRNA and tracrRNA are shown.  
 
3.1.4.3.1 CRISPR/Cas9 design considerations 
The Cas9 proteins used for gene editing can be derived from several bacterial species. The 
protospacer adjacent motif (PAM) sequence utilised for targeted binding differs somewhat 
between bacterial species (Karvelis et al. 2015). The most commonly used bacterial species 
and the species used in this thesis is Streptococcus pyogenes. S. pyogenes Cas9 protein 
requires a PAM sequence of NGG where N is any nucleotide (Cong et al. 2013; Mali et al. 
2013). Typically crRNAs are designed between 17-20bp in length (Mali et al. 2013; Fu et al. 
2014). The NGG motif occurs regularly in the human genome (of all the possible 
combinations of NNN sequences 1/8 will be suitable PAMs). 
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3.1.4.3.2 Gene editing applications 
The CRISPR/Cas9 system has been used for gene editing  in many organisms including fungi 
(Liu et al. 2015), viruses (Yuan et al. 2015; van Diemen et al. 2016), plants (Jiang et al. 2013) 
and many animals such as Zebrafish (Jao et al. 2013), Nematode (Caenorhabditis elegans) 
(Tzur et al. 2013) and mice (Wang et al. 2013). Table 3.4 summarises some of the human 
genes targeted by the CRISPR/Cas9 system. 
 
Table 3.4. A table summarizing examples of genes in human cells which have been modified with CRISPR/Cas9. 
CRISPR/Cas9 
induced gene 
editing 
Genes  Reference 
Gene disruption Β-globin  Cradick et al. 2013; Liang et al. 
2015 
CCR5  Cho et al. 2013; Cradick et al. 2013 
AKT2, CELSR2, CIITA ,  
GLUT4, LINC00116 and 
SORT1 
Ding, et al. 2013  
 
EMX1,FANCF, RUNX1, 
and ZSCAN2 
Kleinstiver et al. 2016 
EMX1  Cong et al. 2013; Hsu et al. 2013 
PKMYT1 and WEE1 Toledo et al. 2016 
MUC18  Chu et al. 2015 
non-coding RNAs  Ho et al. 2014 
MR1 Laugel et al. 2016 
TCR  Osborn et al. 2015 
PD1 Rupp et al. 2016 
PVALB Cong et al. 2013 
18,080 genes (GeCKO 
library)  
Shalem et al. 2014 
Gene correction CFTR Schwank et al. 2013 
DMD  Li et al. 2015 
FANCC  Osborn et al. 2015 
HBB Xie et al. 2014 
Dystrophin Ousterout et al. 2015 
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3.2 Aims  
My research group is interested using T-cells in therapeutic applications for a wide variety of 
diseases. Many studies have introduced specific T-cell receptors (TCRs) into T-cells so as to 
alter their antigen specificity (Morris et al. 2005; Morgan et al. 2006) and TCR transduced 
peripheral blood lymphocytes have been used to treat cancer in mice (Dossett et al. 2009) 
and humans (Morgan et al. 2006; Parkhurst et al. 2011; Morgan et al. 2014). As an extension 
of this approach, there is currently wide interest in gene-modifying T-cells in order to 
enhance treatment efficiency. Systemic blocking of T-cell checkpoint inhibitors such as 
CTLA-4  (Ribas et al. 2005; Callahan et al. 2010; Wolchok et al. 2010) and PD1 (Brahmer et al. 
2010; Topalian et al. 2012; Hamid et al. 2013) using antibodies has shown great success in 
the clinic for some cancers but is associated with many autoimmune side effects. A more 
targeted approach would be to use gene editing to knockout checkpoint inhibitors in only 
the T-cells of interest. In order to examine and compare gene editing in T-cells during proof-
of-concept studies, we wanted to choose a target that was easy to monitor. The CD8A gene 
fitted these criteria as it is highly expressed at the T-cell surface and there are a wide range 
of CD8 specific fluorochrome-conjugated antibodies available. This enables easy monitoring 
of CD8 protein expression in T-cells by flow cytometry. At the outset of my thesis, I set out 
to compare gene silencing of the CD8A gene by shRNA, ZFNs and TALENs. During the course 
of my work CRISPR/Cas9 systems became available so I also attempted to add this system to 
the comparison. I struggled to get good results with my TALENs so finally aimed to compare 
gene silencing by shRNA, ZFNs and CRISPR/Cas9. 
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3.3 Results 
3.3.1 Design and construction of shRNA targeting the CD8A gene 
A shRNA sequence targeting the CD8A gene published on the Broad Institute website (clone 
ID TRCN0000057583) was synthesised (Eurofins) and cloned into the PLKO.1 lentiviral 
backbone between NdeI and EcoRI restriction sites. The CD8A shRNA targets a 21bp stretch 
of exon 2 of the CD8A gene as shown in Figure 3.5. 
 
 
Figure 3.5. Generation of the shRNA targeting CD8A gene. A) The shRNA targets a 21bp stretch (purple lettering) of DNA located within 
exon 2 of the CD8A gene. B) The DNA encoding the shRNA sequence was cloned into the pLKO.1 lentiviral backbone between NdeI and 
EcoRI restriction sites upstream of a U6 promoter. The pLKO.1 backbone contains a GFP reporter gene. 
 
3.3.2 Design and construction of ZFNs targeting the CD8A gene 
Zinc finger nucleases targeting exon 2 of the CD8A gene were designed and validated by 
Sigma Aldrich. These ZFNs were cloned into the pRRL.sin.cppt.pgk-gfp.wpre lentivector 
backbone. The left zinc finger (LZF) protein consists of 4 modules targeting a 16 bp stretch of 
DNA. The right zinc finger (RZF) protein consists of 5 modules targeting a 19 bp DNA 
sequence as shown in Figure 3.6. The two ZF binding sites were separated by a 4 bp spacer 
sequence which was necessary for Fok1 function. 
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Figure 3.6. Generation of ZFN gene editing tools targeting the CD8A gene. A) The ZFNs bind within exon 2 of the CD8A gene. The target 
sequences of the ZFN binding sites are shown in red (left ZFN (LZFN)) and blue (right (RZFN)) with the spacer sequence shown in black. B) 
The lentiviral vector generated express the ZFN in the target cells. 
 
 
3.3.3 Design and construction of CRISPR/Cas9 targeting the CD8A gene 
5 non-overlapping crRNA sequences targeting the CD8A gene were selected from a list of 
potential crRNA target sequences identified by the CRISPR design tool MIT. The risk of off 
target mutagenesis was low as the crRNA sequences selected had a minimum of 4 
mismatches from other sites in the human genome. The crRNA sequences were cloned into 
the lentiCRISPRv2 vector (section 2.4.17.3). crRNA 1 recognised a sequence in exon 1 of the 
CD8A gene, crRNAs 2, 3, 4 and 5 bound to sequences within exon 2 as shown in Figure 3.7. 
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1 GAGCAAGGCGGTCACTGGTA AGG  1 + 
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3 TCCGATCCAGCGGCGACACC CGG  2 + 
4 AACAAGCCCAAGGCGGCCGA  GGG 2 - 
5 CTCTCGGCGGAAGTCGCTCA  GGG  2 + 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7. Generation of CRISPR/Cas9 gene editing tools targeting the CD8A gene. A) Positioning of the 5 crRNA target sequences with 
respect to the intron/exon structure of the CD8A gene. crRNA 1 (green) binds within exon 1, crRNA 2 (purple), 3 (blue), 4 (orange) and 5 
(red) bind within exon 2. B) A table listing the target sequences, PAM sequence and strand orientation for each of the crRNAs. C) The DNA 
encoding the crRNA sequence was cloned into the lentiCRISPRv2 backbone upstream of a U6 promoter. The lentiCRISPRv2 backbone 
contains a puromycin (puro) resistance gene which allowed for selection of transduced cells.  
 
3.3.4 Validation of shRNA targeting the CD8A gene in Molt3  
To assess whether the shRNA construct was functional the shRNA was expressed in Molt3 
cells by lentiviral transduction. Two weeks post transduction, the cells were analysed by 
flow cytometry. Transduced cells were identified by expression of GFP. The MFI of CD8 was 
reduced by 84% in the GFP+ population compared to the WT. The MFI of the GFP+ 
population within the shRNA control was reduced by 6% compared to the WT (Figure 3.8). 
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Figure 3.8. Validation of the CD8A shRNA in the Molt3 cell line. Molt3 cells were transduced with the CD8A shRNA or the MR1 shRNA as a 
control by lentiviral transduction. The cells were cultured for two weeks and then analysed by flow cytometry. A) Dot plots of WT and 
transduced Molt3 cells. Of the cells transduced with the CD8A shRNA approximately 80% were GFP, of these 60% were CD8 negative. B) 
Histogram plots were produced by gating on the GFP+ of transduced cells and GFP- population of untransduced cells. The percentage of 
CD8 expressed by each of the samples was determined relative to the WT and FMO controls. An 84% reduction in the geometric mean of 
CD8A shRNA was observed in the GFP+ population of transduced cells relative to WT cells. Data shown is representative of 3 experiments 
 
3.3.5 Validation of ZFNs targeting the CD8A gene in Molt3 
To assess the functionality of the ZFNs, Molt3 cells were transduced with the LZFN, RZFN or 
both the LZFN and RZFN by lentiviral transduction. The cells were monitored for CD8 surface 
expression two weeks post transduction. In order to induce knockout of CD8, the cells must 
have been transduced with both the LZFN and RZFN construct, as both constructs had a GFP 
reporter it was not possible to accurately determine the frequency of cells that were 
transduced with both constructs. The frequency of cells transduced with both constructs 
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was estimated to be 49% (multiplying the frequency of GFP+ cells in the single transduced 
cells ((54*91)/100). Overall, 13.5% of cells were CD8-, which equates to 28% of the 
estimated double transduced cells were CD8 negative (Figure 3.9A). The MFI of CD8 was 
reduced by 47% in the bulk GFP+ population of LZFN and RZFN transduced cells compared 
to the WT untransduced cells. The MFI of CD8 was increased by 15% in the RZFN transduced 
cells relative to the WT untransduced cells. Gating on the CD8-GFP+ population of LZFN and 
RZFN transduced cells shows a 100% reduction relative to the GFP+ population of the WT 
cells (Figure 3.9B). To confirm that the ZFN approach induced indels at a DNA level a 
surveyor assay was performed by extracting DNA from the wildtype and bulk LZFN and RZFN 
transduced cells. The DNA was amplified using CD8_surv_forward and CD8_surv_reverse 
primers which bound up and down stream of the ZFN binding sites. After annealing and 
digestion with the mismatch specific enzyme, additional bands were observed for the 
transduced cells on the agarose gel indicating that transducing cells with the LZFN and RZFN 
lead to indels at a DNA level (Figure 3.9C). 
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Figure 3.9. Validation of the ZFN gene editing approach in the Molt3 cell line. Molt3 cells were transduced with the LZFN, RZFN or both 
the LZFN and RZFN by lentiviral transduction the cells were cultures for 2 weeks after which the cells were monitored by flow cytometry. 
A) Dot plots displaying the FMO, WT and cells transduced with the LZFN, RZFN and both the LZFN and RZFN. B) Histogram plots were 
generated by gating on the GFP- population of the WT cells, GFP+ of the transduced cells and the CD8- population within the LZFN and 
RZFN transduced cells. The percentage of CD8 expressed by each of the samples was determined relative to the WT and FMO controls. C) 
The presence of mutations at a DNA level were identified by the surveyor assay. DNA was PCR amplified using the CD8_SURV_forward and 
CD8_SURV_reverse primers, which bound upstream and downstream of the LZFN and RZFN binding sites respectively.  400ng of PCR 
product from unmodified Molt3 (lane 4) or 200 ng of PCR product from Molt3 cells transduced with the LZFN and RZFN and 200 ng of PCR 
product from unmodified Molt3 cells (lane 5) or 400ng of PCR product from Molt3 cells transduced with the LZFN and RZFN (lane 6) were 
denatured, annealed and digested with the mismatch specific surveyor enzyme (section 2.4.12). Additional bands are observed in the DNA 
from the LZFN and RZFN transduced cells indicating mismatches at a DNA level were present. Denatured, annealed and digested controls 
are shown in lane 1 (C control), lane 2 (C+G control) and lane 3 (G control). Data shown is representative of 10 experiments. 
 
Sample Percentage of CD8 
expressed % 
FMO (GFP) 0 
Stained (GFP-) 100 
RZFN (GFP+) 116 
LZFN+RZFN (GFP+) 53 
LZFN+RZFN (CD8-GFP+) 0 
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3.3.6 Validation of CRISPR/Cas9 targeting the CD8A gene in Molt3  
Molt3 cells were transduced with the five crRNAs generated to target the CD8A gene by 
lentiviral transduction. 24 h post transduction; the untransduced and cells transduced with 
each of the CRISPR/Cas9 lentivirus were each split into two wells. One well was cultured 
with R10 and the other well was cultured with R10 supplemented with 2 μg/ mL puromycin 
as the lentiCRISPRv2 backbone contained a puromycin resistance gene to allow for selection 
of transduced cells. The cells were cultured for two weeks post transduction before being 
monitored by flow cytometry. Three patterns of CD8 expression were observed with the 
different crRNAs. crRNAs 1 and 2 failed to reduce CD8 expression suggesting they were non-
functional. crRNAs 3 and 5 generated a minor population of CD8 negative/low cells with 
puromycin selection. In contrast, crRNA4 induced reduction of CD8 expression in the 
majority of cells in the presence or absence of puromycin selection. The MFI of CD8 was a 
reduced by 96% in the puromycin selected cells relative to the wildtype cells. crRNA 4 was 
consistently the superior crRNA and was selected for further experiments. 
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Figure 3.10.  Validation of crRNAs targeting the CD8 in the Molt3 cell line. Molt3 cells were transduced with crRNAs 1, 2, 3, 4 and 5 by 
lentiviral transduction. Two weeks post transduction the cells were analysed by flow cytometry. A) The level of CD8 expression on the cell 
surface of cells was monitored by flow cytometry, the FMO control staining is shown as a solid light grey histogram, the WT is show as a 
dark grey histogram. The histograms for crRNAs 1, 2, 3, 4 and 5 are shown in red, orange, purple, blue and green respectively. Solid 
coloured histograms show bulk transduced cells without puromycin selection and coloured unfilled histograms show cells after puromycin 
selection. A population of CD8 negative cells is observable in cells transduced with crRNAs 3, 4 and 5. The percentage of CD8 expressed by 
each of the samples was determined relative to the WT and FMO controls. B) A dot plot displaying the FMO, WT and cells transduced with 
the 5 crRNA (after puromycin selection). The CD8 negative populations are gated within each of the samples. Data shown is representative 
of 3 experiments. 
 
3.3.7 Comparison of shRNA, ZFNs and CRISPR/Cas9 in Molt3 
In order to compare the shRNA, ZFNs and CRISPR/Cas9, Molt3 cells were transduced with 
gene editing tools by lentiviral transduction. The cells transduced with crRNA 4 were split 24 
h post transduction and one of the two wells was treated with puromycin at 2 μg/ mL. The 
cells were cultured for a period of 5 weeks and monitored by flow cytometry on a weekly 
basis. The shRNA, ZFN and the CRISPR/Cas9 approaches all resulted in a population of CD8 
negative cells (Figure 3.11A).  
Sample Percentage of CD8 
expressed % 
FMO 0 
WT 100 
crRNA 1 97 
crRNA 1 (puro selection) 98 
crRNA 2 108 
crRNA 2 (puro selection) 105 
crRNA 3 110 
crRNA 3 (puro selection) 31 
crRNA 4 4 
crRNA 4 (puro selection) 4 
crRNA 5 93 
crRNA 5 (puro selection) 54 
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The frequency of transduced cells was determined either by the expression of GFP or by 
survival of puromycin selection. The frequency of cells transduced with both the LZFN and 
RZFN was determined by multiplying the frequency of GFP+ cells in the single transduced 
samples to estimate the frequency of cells transduced with both.  
 
At two weeks post transduction, the MFI of the knock out population was reduced by 99, 
100 and 91% relative to the WT in the LZFN and RZFN, crRNA4 and shRNA transduced cells 
respectively (Figure 3.11B). Approximately 60% of the shRNA transduced cells were CD8 
negative after 1 week; over the remaining monitoring period the frequency of CD8 cells 
increased to a peak of 66% two weeks post transduction and then declined.  At 5 weeks post 
transduction approximately 29% of transduced cells were CD8 negative. Transduction with 
the LZFN and RZFN resulted in an observable knockout efficiency of 9% of dual transduced 
cells 1 week post transduction, the frequency of knockout cells within the dual transduced 
cell population reached 52% at three weeks post transduction and remained fairly 
consistent over the remaining monitoring period. The CRISPR/Cas9 approach lead to 
knockout of CD8 in approximately 67% of transduced cells one week post transduction, the 
frequency of knock out cells rose slightly with 80% of transduced cells expressing CD8 at 
levels equivalent to the FMO control at five weeks post transduction (Figure 3.11C). 
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Figure 3.11. Comparison of the shRNA, ZFN and CRISPR/Cas9 gene editing tools. Molt3 cells were transduced with each of the constructs 
by lentiviral transduction and cultured for five weeks. The cells were analysed by flow cytometry at weekly intervals. A) Dot plots of the 
transduced cells two weeks post transduction. B) Histogram plots of the transduced cells at two weeks post transduction, the FMO is 
shown in light grey, the WT is shown in dark grey, the RZFN is shown in red, LZFN and RZFN transduced cells are shown in blue, crRNA is 
shown in orange, shRNA trol in green and shRNA CD8A in pink. The corresponding gating is shown in brackets. The percentage expression 
of each of the samples was calculated as a percentage of the WT (black) after deducting the FMO (light grey). C) A graph displaying the 
frequency of CD8 negative cells within the transduced cell population relative to the WT as determined by flow cytometry based on 
triplicate repeats of the transductions. Data shown is representative of 2 experiments.  
Sample Percentage of CD8 
expressed % 
FMO (GFP) 0 
WT 100 
RZFN (GFP+) 62 
LZFN+RZFN (GFP+) 56 
LZFN+RZFN (CD8-GFP+) 1 
 crRNA control 101 
crRNA 4 (bulk) 34 
crRNA 4 (puro selection) 5 
crRNA 4 (puro selection)(CD8-) 0 
shRNA control (GFP+) 123 
shRNA CD8 (GFP+) 9 
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3.4 Discussion 
Several approaches have been utilised to induce targeted gene silencing and gene knockout 
in mammalian cells. Since shRNA was first manipulated to induce targeted gene silencing 
(Fire et al. 1998) it has been widely used to silence the expression of many genes. More 
recently, advances within the nuclease gene editing field have produced gene editing tools 
that induce gene knockout through the DSBs which when repaired by erroneous pathways 
lead to the introduction of mutations at a DNA level. Chronologically, ZFNs were identified 
first, followed by TALENs and most recently the CRISPR/Cas9 system. Each of these gene 
editing tools has been used widely since their discovery and each new technology has 
largely superseded its predecessors as the methodology of choice. As part of this project, 
plasmid systems were developed for each gene editing tool targeting the CD8A gene in 
order to validate and compare each of the systems. The TALEN approach (section 3.1.4) was 
not included in this study; the limitations of TALENs are discussed in section 3.4.2. The 
shRNA, ZFN and CRISPR/Cas9 approaches were validated and compared. Each of the 
approaches successfully induced gene silencing or gene knockout in the Molt3 cell line. The 
shRNA approach did not result in consistent gene silencing as the frequency of CD8 negative 
cells rose substantially throughout the monitoring period. The ZFN approach led to an 
approximate knockout efficiency of 20%, which was fairly consistent across the monitoring 
period. The CRISPR/Cas9 approach was found to lead to superior efficiency of gene 
knockout with approximately 80% of transduced cells expressing CD8A at levels equivalent 
to the FMO control consistently across the monitoring period when monitored by flow 
cytometry.  
 
3.4.1 Use of double reporter system for identification of cells transduced 
with both the left and right ZFN constructs 
In this thesis the ZFNs delivered by lentiviral transduction resulted in the knockout of CD8 
from the Molt3 cell line as demonstrated by flow cytometry. However, the frequency of 
cells expressing both the LZFN and RZFN proteins was not established as a GFP marker was 
present in both constructs and therefore single and double transductants were 
indistinguishable. To improve this system for future use a second reporter gene could be 
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cloned into one of the ZFN constructs to allow for detection of cells transduced with both 
the LZFN and RZFN.  
 
3.4.2 Generation of TALENs 
Assembly of TALENs was attempted using two commercially available kits by Cermak et al. 
2011 and Sanjana et al. 2012 (Methods can be found in Appendix Figure 2 and 3. The 
process of TALEN construction can be found in Appendix Figure 4 and 5). A TALEN targeting 
the CD8A gene was produced by the Cermak Kit (Appendix Figure 4); however, no TALENs 
were produced with the Sanjana kit (Appendix Figure 5). The TALEN approach was 
incompatible with lentiviral transduction due to unintentional rearrangements within the 
TALE sequence (Holkers et al. 2012). A pair of TALENs were synthesised (Eurofins) which 
were designed to minimise the repetitive nature of the TALE arrays. The TALE protein was 
cloned into the pRRL.sin.cppt.pgk-gfp.wpre lentivector backbone which contained a GFP 
reporter. However, attempts to transduce cells with the TALE protein were unsuccessful as 
no GFP was expressed (Appendix Figure 6). I spent considerable time in design and testing of 
TALENS. Once CRISPR came along I switched my efforts to this new tool. 
 
3.4.3 Design and construction of gene editing tools 
In order to generate shRNA targeting the CD8A gene for this project the target sequence 
published by the Broad institute was synthesised (Eurofins) and cloned into a lentiviral 
backbone. This process is fast and inexpensive as shRNA constructs can be generated within 
2 weeks dependent upon the synthesis of the target sequence. The ZFNs used in this project 
were produced by Sigma Aldrich, unless ZFNs targeting the gene of interest have previously 
been ordered from the company the production costs and timing are increased as due to 
the bespoke validation process. ZFNs for novel gene targets can take several weeks to 
produce and cost several thousand pounds per pair. Once the ZFN plasmid is delivered the 
gene must be cloned into a lentiviral backbone. The newer, CRISPR/Cas9 technology is by far 
the easiest and cheapest approach as altering the specificity of the simply involves design 
and ordering crRNA sequences. The oligos typically cost less than ten pounds per pair. The 
oligos are then cloned into the CRISPR/Cas9 lentiviral backbone, from start to finish this 
process can be completed within a week. Unless validated crRNA sequences for target genes 
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are published there is no guarantee that the crRNA sequences produced will be functional, 
however, using this system within our lab we have produced crRNAs targeting a range of 
genes and have found that designing and producing 5 crRNAs per target gene results in a 
minimum of 2 functional crRNAs. The efficiency, ease and low cost of CRISPR/Cas9 has 
resulted in this system now being the method of choice for gene silencing and the approach 
was awarded Breakthrough of the Year 2015 by Science magazine (Travis 2015). 
 
3.4.4 Gene silencing efficiency 
When directly compared against one another there was a reduction of MFI of 98, 100 and 
93% for shRNA, ZFN and CRISPR/Cas9 respectively. Although the reduction in MFI was 
comparable between these gene editing tools the frequency of CD8 negative cells in the 
transduced populations varied. At two weeks post transduction, the CRISPR/Cas9 approach 
resulted in a knockout efficiency of 84% in transduced cells. The ZFN approach had an 
efficiency of 20% while 67% of cells transduced with the shRNA approach had observable 
CD8 gene silencing. The level of CD8 expressed by the cells transduced with the shRNA did 
not remain silenced and at five weeks post transduction, only 35% of the transduced cells 
expressed CD8 at low levels. 
 
3.4.5 Summary 
In this chapter I began by comparing shRNA, TALEN and ZFN technologies for silencing of the 
CD8A gene. I put considerable effort into building the TALEN tools, unfortunately, these 
efforts were unfruitful. While struggling with TALENs, CRISPR/Cas9 technology became 
available so I adopted to utilise this methodology. Overall, in direct comparisons, the CRISPR 
technology proved to be preferable. I went on to use CRISPR technology to study antigen 
presentation to unconventional T-cells in chapter 6. Some concerns have been raised about 
the use of nuclease based gene editing for clinical application. I next set out to find an 
alternative technology that did not incorporate the inherent risks of off-target nuclease 
activity. I will further discuss the implications of all this work in chapter 4. 
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4 Development of non-nuclease gene silencing 
technology for therapeutic manipulation of T-cells 
 
4.1 Introduction 
As described in chapter 3, recent developments in gene editing resulted in genome editing 
with engineered nucleases being awarded method of the year 2011 by Nature Methods 
(Nature methods, 2012). More recently the CRISPR/Cas9 gene editing technique was named 
breakthrough of the year 2015 by Science magazine (Travis 2015). There has been particular 
interest in using genome-editing technology for therapeutic applications with T-cells being 
at the forefront of these advances. ZFN technology has been utilised to knockout the CCR5 
receptor to prevent entry of HIV into CD4+ T-cells, in order to render them resistant to viral 
attack (Holt et al. 2010; Tebas et al. 2014). The first clinical trial with CRISPR/Cas9 was 
approved in July 2016 and is due to have commenced in August 2016 (Cyranoski 2016).  
 
To date, the most effective gene silencing technologies, ZFNs, TALENs and CRISPR/Cas9, 
make use of targeted nuclease activity. All these technologies therefore bear an inherent 
risk of off-target nuclease activity that has potential to transform cells and render them 
malignant. There is an urgent need for gene silencing technology that circumvents these 
risks during therapeutic use. In addition, the debate that rages on about who owns CRISPR 
has introduced uncertainly in those that wish to use CRISPR in therapeutic approaches and a 
new approach to gene silencing would be most welcome.  
 
On this backdrop I decided to examine whether the precise DNA binding properties of ZFPs 
could be used to silence genes without the need to couple them to nucleases. In particular, I 
was interested in whether these domains could be successfully coupled to transcriptional 
repressor domains to enable precise silencing of genes in T-cells. Previously ZFPs have been 
fused to the KRAB repressor to silence specific promoters (SV40 promoter  (Liu et al. 1997), 
erbB-2 (Beerli et al. 2000) and PPARγ2 (Ren et al. 2002)) however, to date no studies have 
used ZFPs fused to repressor domains to target and silence specific genes. Since 
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commencing this project there have been several advances in the CRISPR interference field 
which are discussed in section 4.6.4 
 
4.1.1 Transcriptional repressors 
There are two types of mammalian repressors - passive and active repressors. Passive 
repressors do not have intrinsic repressing activity but instead compete with transcriptional 
activators for DNA binding which leads to repression of mRNA synthesis. In contrast, active 
repressors have intrinsic repression activity. Active repressors modify the chromatin state 
through histone deacetylation and heterochromatin formation leading to transcriptional 
repression and gene silencing (Reviewed by Thiel et al. 2004). This chapter is focused on 
active repressors and therefore passive repressors will not be discussed further. 
 
4.1.2 Gene transcription 
In eukaryotic cells DNA is wound around histones forming the classic “beads on a string” 
structure. The core histone complex is formed by an octamer of two copies of H2A, H2B, H3 
and H4 histone proteins (Kouzarides 2007). The gene transcription process is complex and 
involves the  interaction of DNA promoters with the RNA polymerase II enzyme, 
transcription factors and genomic regulatory elements. Gene transcription is highly 
regulated at each stage to ensure select proteins are expressed at the correct levels 
(reviewed by Maston, et al. 2006). Chromatin (DNA and associated histone proteins) 
undergo biochemical modifications of phosphorylation, methylation and acetylation which 
alters the state of the chromatin and thus the levels of gene transcription. Chromatin exists 
as heterochromatin and euchromatin (Heintzman et al. 2007). In the heterochromatin state 
the nucleosomes are compacted and the promoter regions are unable to interact with 
transcription factors and are therefore unable to be transcribed. Alternatively the 
euchromatin state is a less compact state and the transription promoters are accessible to 
transcription machinery and can therefore be transcribed (reviewed by Gaszner & 
Felsenfeld 2006; Kouzarides 2007). Transcription factors are formed by a DNA binding 
domain (typically a ZFP as described in section 3.1.2) and an activator or repressor domain. 
Transcription factors play a key role in the regulation of gene transcription as they bind to 
specific DNA sequences and allow for targeted transcriptional repression or activation. 
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4.1.3 Choice of Repressor Domains 
Several repressor domains have been described in the literature. I opted to test 7 previously 
described repressor domains for my work, namely KRAB, ARP1, GCN4-KRAB, HP1A, 
ScanKRAB, SID and TRIM28. Each is described below in turn. 
 
4.1.3.1 Krüppel-associated box (KRAB) 
In mammals ZF-KRAB family are the most common transcription factors, therefore the KRAB 
repressor domain has been well characterised (Bellefroid et al. 1991; Urrutia 2003). KRAB 
functions by binding to co-repressor proteins such as TRIM28 (Abrink et al. 2001) (section 
4.1.3.7), leading to the recruitment of chromatin-modifying factors such as heterochromatin 
proteins (Groner et al. 2010a). Regions of genes silenced by KRAB lose histone H3 
acetylation and acquire H3 lysine 9 trimethylation (H3K9me3) leading to prevention of RNA 
polymerase recruitment and formation of heterochromatin (Abrink et al. 2001; Huntley et 
al. 2006; Groner et al. 2010b), ultimately leading to the repression of DNA transcription and 
a loss of target protein production. KRAB proteins have been observed to mediate gene 
silencing several tens of kilobases away from the DNA binding sites (Groner et al. 2010b).  In 
mice, the ZF-KRAB approach was utilised to silence a PPARγ2-specific promoter leading to a 
50% reduction in PPARγ2 expression (Ren et al. 2002). Engineered ZF-KRAB proteins have 
been used to target erbB-2 specific promoters in the SKBR3 human breast cancer cell line 
resulting in a 7 fold reduction in erbB-2 expression (Beerli et al. 2000) and upstream of a 
SV40 promoter in a HeLa reporter cell line leading to a 93% reduction in luciferase 
transcription (Liu et al. 1997). 
 
4.1.3.2 ARP1 
ARP1, also referred to as COUP-TFII, has been described as both an activator and repressor 
of gene transcription. Binding of COUP-TFII to DNA leads to the recruitment of corepressor 
proteins such as nuclear corepressor (Bailey et al. 1997) leading to heterochromatin 
formation (reviewed by Litchfield & Klinge 2012). 
 
4.1.3.3 GCN4-KRAB 
The GCN4 transcription factor is primarily described as an activator of gene transcription 
and has been identified in a range of organisms (Ellenberger et al. 1992). In one study the 
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binding sites of 4 ZFPs were expressed in reporter plasmids upstream of a CMV promoter 
driving transcription of a AmCyan ﬂuorescent protein. Reporter cell lines were transfected 
with plasmids containing the corresponding ZFP fused to a GCN4-KRAB repressor domain. 
The GCN4-KRAB repressor domain was shown to lead to a 9-16 fold reduction in the 
expression of the AmCyan ﬂuorescent protein (Lohmueller et al. 2012). 
 
4.1.3.4 Heterochromatin protein 1a (HP1A) 
HP1a is recruited by transcription factors where it initiates silencing of gene transcription by 
histone 3 lysine 9 trimethylation of (H3K9me3) leading to heterochromatin formation and 
chromatin packaging (Fischle et al. 2005) ultimately inhibiting gene transcription.  
 
4.1.3.5 ScanKRAB 
The ScanKRAB domain is a variant of the KRAB repressor domain which is formed from the 
KRAB and the Scan box (Sander et al. 2003; Huntley et al. 2006). The KRAB domain initiates 
repression of gene transcription (section 4.1.3.1.) and the SCAN domain mediates protein 
dimerization to promote further epigenetic editing (Honer et al. 2001).   
 
4.1.3.6 mSin interaction domain (SID) 
SID repressor functions as a scaffold and interacts with histone deacetylases to induce 
compaction of the chromatin (Pang et al. 2003). The SID domain is thought to form a 
repressor complex which alters the structure of the chromatin blocking transcription (Ayer 
et al. 1996). SID has previously been shown to be an effective repression when fused to a 
TALE (Cong et al. 2012), suggesting it might also be effective when fused to a ZFP.  
 
4.1.3.7 TRIM28 
Trim28 is also known as KRAB associated protein 1 (KAP1). TRIM28 coordinates the 
assemble of a repressor complex composed of HP1, SETDB1, and Mi2α proteins 
(Ayyanathan et al. 2003; Sripathy et al. 2006) which provide a microenvironment which is 
favourable for heterochromatin formation by histone 3 lysine 9 trimethylation (Xiao et al. 
2011).   
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4.2 Rational 
In chapter 3, the frequency of biallelic inactivation of the CD8A gene in the Molt3 cell line 
was approximately 14% of bulk and 27% of cells transduced with both the LZFN and RZFN 
constructs, although this method of gene editing was shown to be successful the rate of 
biallelic inactivation was relatively low. Previous studies with ZFNs have similarly resulted in 
relatively low frequencies of biallelic knockout with ZFNs. In one study, modifications of the 
CCR5 gene were observed in 23% of clones, of which 33% of clones were shown to have 
homozygous mutations within the CCR5 gene (Perez et al. 2008). Holt et al. 2010, reported 
an estimated biallelic inactivation of between 5-7% within the CCR5 gene. ZFN induced 
biallelic modification of the IL2Rγ gene were observed in 7% of cells (Urnov et al. 2005). I 
wanted to develop a non-nuclease based gene silencing system. It was hypothesised that 
fusing a repressor domain to a single ZFP could be used to effectively silence gene 
expression at higher rates than biallelic inactivation with ZFNs. There are several advantages 
to the use of repressor domains over ZFNs: 1) repressor domains silence gene transcription 
in all cells carrying the construct; 2) potential off target effects can be monitored in an 
unbiased manner by gene microarray or RNAseq rather than having to sequence the whole 
genome; and 3) ZF repressor domains are small enough to allow co-delivery of a TCR within 
a single lentiviral construct thereby allowing repression of T-cell checkpoint inhibitors in 
redirected T-cells. 
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4.3 Aims 
In this chapter I aimed to test whether genes could be effectively silenced in the Molt3 cell 
line and in primary T-cells using a repressor domain fused to a single ZFP. As the ultimate 
aim was to develop the technology in T-cells for cancer immunotherapy I chose to use the 
CD8A gene for proof-of-concept using the ZFPs utilised in chapter 3. CD8 is highly expressed 
at the T-cell surface (>50,000 copies) allowing ready monitoring of gene silencing by flow 
cytometry. I also aimed to demonstrate that a single lentiviral construct could be used to 
deliver a TCR while simultaneously silencing a specific gene target via a ZF repressor protein. 
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4.4 Results 
 
4.4.1 Design and construction of repressor domains fused to a zinc finger 
protein 
I first aimed to test the activity of 7 known transcriptional repressor domains described in 
section 4.1.3 to assess the function of each when expressed as a fusion protein with a ZF 
domain. The RZF targeting CD8A was cloned into the pV2 cloning backbone (Addgene 
#32189) between an AgeI and BamHI restriction sites. A codon-optimised cDNA sequence 
for each of the 7 repressor domains described (ARP1, GCN4, HP1A, KRAB, ScanKRAB, SID 
and TRIM28) was synthesised (Eurofins) and cloned into the pV2 cloning backbone 
downstream of the RZF between BamHI and XbaI restriction sites (Figure 4.1). This cassette 
system allows easy substitution of both the ZFP and/or the repressor domain at a later date 
as required.   
 
 
 
 
 
 
 
 
 
Figure 4.1. Generation of the ZF repressor domain constructs. The codon optimised DNA sequence of the ARP1, GCN4, HP1A, KRAB, 
ScanKRAB, SID and TRIM28 repressor domains were synthesised by Eurofins flanked by BamHI and XbaI restriction sites. The repressor 
domains were cloned into the pV2 backbone downstream of a CMV promoter and the RZF targeting CD8.  
 
4.4.2 Design and construction of a reporter system to assess the 
functionality of the repressor domains  
To test the RZF repressor domains a reporter 293T cell line was produced. First, a single 
copy (referred to as 1x) or a triple copy (referred to as 3x) of the binding sites for the CD8 
ZFPs (separated by the 4bp linker) were synthesised (Eurofins). These binding sites were 
flanked by XhoI restriction sites and were cloned upstream of a hPGK promoter and a GFP 
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gene into the 2nd generation pRRL.sin.cppt.pgk-gfp.wpre lentivector backbone. 293T cells 
were transduced with the pRRL_1x and pRRL_3x lentiviral vectors. A diagrammatic 
representation of the reporter construct is shown in Figure 4.2A. To produce a clone for 
each of the reporter cell lines the transduced 293Ts were cloned by limiting dilution. 
Initially, 26 1x clones and 22 3x clones were screened (Appendix Figure 7 and 8) and the best 
four clones were expanded for each and screened again and a GFP+ clone was identified for 
both as shown in Figure 4.2B.  
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Figure 4.2. Generation of the GFP reporter system to validate the repressor domains. A) Diagrammatic representation of the 1x and 3x 
reporter system. The left and right zinc finger binding sites were flanked by XhoI restriction sites and the binding sites were separated by a 
6bp spacer sequence. Either 1 or 3 copies of the binding sites were cloned into the pRRL.sin.cppt.pgk-gfp.wpre lentivector backbone 
upstream of the hPGK promoter and GFP reporter gene.  293T cells were transduced with either the 1x (B) or 3x (C) reporter construct by 
lentiviral transduction. The bulk transduced cells were single cell cloned by limiting dilution. 26 1x clones and 22 3x clones were screened 
by flow cytometry (Appendix Figure 7 and 8) the FMO is shown as the dark grey histogram, the bulk transduced cells are shown in light 
grey, three clones representing the variety of GFP are shown by blue histograms and the 1x and 3x clones selected are shown by a red 
histogram. The MFI of each of the histograms is shown. 
 
 
4.4.3 Comparison of the repressor domain constructs in the reporter system 
To validate the effector domains generated in section 4.4.1 the 1x and 3x 293T reporter cells 
were transfected with each of the RZF repressor domain constructs by CaCl2 transfection. 
Cells were transfected as described in section 2.3.8. The incubation time post transfection 
was optimised and 16 h incubation time was found to lead to optimal levels of transfection 
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of a GFP control whilst minimising cell death (Appendix Figure 9). The MFI of GFP was 
consistently reduced in three of the seven repressor domains tested – GCN4, KRAB and 
TRIM28 suggesting that these repressor domains were effective at repressing the hPGK 
promoter (Figure 4.3). To assess the degree of MFI reduction, the transfections of the GCN4, 
KRAB and TRIM28 repressor domains were repeated in triplicate. In the 1x reporter system 
the overall MFI was reduced by 30, 45 and 33% for the GCN4, KRAB and TRIM28 repressor 
domains respectively. In the 3x system the overall MFI was reduced by 36, 62 and 32% for 
the GCN4, KRAB and TRIM28 repressor domains respectively Figure 4.3C and D. The true 
extent of the functionality of these repressors was difficult to determine as a population of 
GFP+ cells remained as the transfections were not 100% efficient. The KRAB repressor 
domain was consistently superior to the other repressor domains tested and was utilised for 
downstream experiments. 
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Figure 4.3. Validation of the 7 repressor domains in the 1x and 3x reporter cell lines. The 1x and 3x reporter cell lines were transduced 
with each of the 7 repressor domain constructs by CaCl2 transfection and the level of GFP extinction was determined by flow cytometry 
five days post transfection. A) Histogram plots of the 1x reporter cells transfected with the repressor domain constructs. The FMO (light 
grey; MFI = 10.7), Mock (dark grey; MFI =19599), ARP1 (red; MFI = 19269), GCN4 (blue; MFI =13958), HP1A (orange; MFI =19965), KRAB 
(green; MFI =10568), ScanKRAB (pink; MFI =17456), SID (purple; MFI =18666) and TRIM28 (light blue; MFI =13094). B) Histogram plots of 
the 3x reporter cells transfected with the repressor domain constructs. The FMO (light grey; MFI = 10.7), Mock (dark grey; MFI =41654), 
ARP1 (red; MFI = 48904), GCN4 (blue; MFI =28182), HP1A (orange; MFI =41657), KRAB (green; MFI =14958), ScanKRAB (pink; MFI =33077), 
SID (purple; MFI =43953) and TRIM28 (light blue; MFI =27382).  The data in Figure 4.3 A and B is representative of 5 experiments. The 1x 
(C) and 3x (D) reporter cell lines were transfected with the GCN4, KRAB and TRIM28 repressor domain constructs and the cells were 
analysed by flow cytometry 5 days post transfection. The graph shows the percentage reduction in GFP MFI in cells transfected with each 
of the three repressor domain constructs relative to the mock transfected cells. The standard error of the mean values of triplicate wells is 
shown.   
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4.4.4 Comparison of the LZFP and RZFP fused to the KRAB domain. 
The LZF as described in section 3.3.2 was cloned into the pV2 KRAB repressor domain 
construct as described in section 4.4.1 in the place of the RZF. The 1x and 3x reporter cell 
lines were transduced with the pV2 RZF-KRAB and pV2 LZF-KRAB repressor construct by 
CaCl2 transfection. The cells were monitored by flow cytometry 5 days post transfection. 
There was no observable GFP extinction in the cells transduced with the pV2 LZF-KRAB 
repressor construct. However, GFP extinction was observed in cells transduced with the pV2 
RZF-KRAB repressor construct (Figure 4.4).            
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4. Comparison of the LZF-KRAB and RZF-KRAB constructs.  The 1x (A) and 3x (B) reporter cell lines were transfected with either 
the LZF-KRAB or RZF-KRAB repressor domain constructs by CaCl2 transfection. The expression of GFP was analysed by flow cytometry 5 
days post transfection. A) WT 293T (light grey; MFI = 4.23), 1x mock (dark grey; MFI = 5182), 1x RZF-KRAB (red; MFI = 3045) and the 1x LZF-
KRAB (blue; MFI = 5211). B) WT 293T (light grey; MFI = 4.23), 3x mock (dark grey; MFI = 1313), 3x RZF-KRAB (red; MFI = 759) and the 3x 
LZF-KRAB (blue; MFI = 1390). GFP extinction in a population of cells is indicated by an arrow. The data is representative of 3 experiments. 
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4.4.5 Validation of the ZF-KRAB repressor domain in Molt3 
To establish whether the ZF-KRAB fusion was a valid alternative to the ZFN approach the RZF 
targeting CD8 fused to the KRAB repressor was cloned into the 2nd generation 
pRRL.sin.cppt.pgk-gfp.wpre lentivector backbone. Molt3 cells were transduced with the 
LZFN, RZFN, both the LZFN and RZFN or RZF-KRAB by lentiviral transduction. The cells were 
cultured and analysed by flow cytometry at day 3, 7, 14, 28, 35, 49 and 77 post 
transduction. Three days post transduction there was no observable knock out in the LZFN 
and RZFN transduced cells, yet, 97.1% of the cells transduced with the RZF-KRAB were CD8 
negative (after deducting background). There was an observable population of CD8low cells 
in the LZFN and RZFN transduced cells 7 days post transduction, this population was more 
clearly defined 14 days post transduction (Figure 4.5A). At two weeks post transduction, 
16% of cells predicted to be transduced with both the LZFN and RZFN constructs were CD8 
negative. In comparison, 99% of the cells transduced with the RZF-KRAB construct were CD8 
negative. The MFI of CD8 was reduced by 43% compared to WT in the GFP+ portion of the 
LZFN and RZFN transduced cells (deducting background) and a reduction of 99.7% was 
observed when gating on the CD8- GFP+ population within the LZFN and RZFN transduced 
cells (deducting background). In comparison the MFI of CD8 within the GFP+ population of 
RZF-KRAB transduced cells was reduced by 100% compared to WT cells (deducting 
background) (Figure 4.5B).  
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Figure 4.5. Comparison of ZFNs and ZF-KRAB gene silencing in Molt3 cells. Molt3 cells were transduced with the LZFN, RZFN, LZFN+RZFN, 
RZF-KRAB and KRAB x constructs by lentiviral transduction and monitored by flow cytometry at various time points. A) 2 weeks post 
transduction, cells transduced with the LZFN, RZFN and KRAB x constructs had an observable GFP+ population. The cells transduced with 
the RZF-KRAB had an observable GFP+CD8- population. There was a GFP+CD8- population present in the cells transduced with the LZFN + 
RZFN lentiviruses. B) The percentage reduction of CD8 MFI was determined relative to the WT untransduced cells (GFP- population), The 
FMO is shown in light grey (gating on GFP-), the WT is shown in dark grey (gating on GFP-), the RZFN is shown in blue (gating on GFP+), the 
KRAB x is shown in red (gating on GFP+), the LZFN+RZFN is shown in orange (gating on GFP+), the GFP+CD8- population within the 
LZFN+RZFN transduced cells is shown as an orange histogram with no filled colouring and the green histogram represents the GFP+ 
population of cells transduced with the RZF-KRAB lentivirus.  
  
Sample Percentage reduction 
of CD8 MFI (%) 
FMO 100 
WT 0 
RZFN (GFP+) -15 
KRAB x (GFP+) 12 
LZFN + RZFN (GFP+) 43 
LZFN + RZFN (CD8 low) 100 
RZF-KRAB (GFP+) 100 
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4.4.6 Long-term monitoring of the RZF-KRAB induced silencing in Molt3 
The cells were monitored by flow cytometry 3, 7, 14, 28, 35, 49 and 77 days post 
transduction, at each time point the percentage of transduced cells that were CD8 negative 
was calculated. The proportion of CD8 negative cells within the cells transduced with both 
the LZFN and RZFN was approximately 20% consistently after day 7 monitoring. By 
comparison, 97% of cells transduced with the RZF-KRAB lentivirus were CD8 negative at 3 
days post transduction, the frequency declined slightly over time with 87.8% of transduced 
cells being CD8 negative by day 77 (Figure 4.6). Cells transduced with the RZF-KRAB 
construct lost expression of GFP over time, at day 3 95% of cells transduced with the RZF-
KRAB by lentiviral transduction were GFP+. By day 77, 11% of the cell population were GFP+, 
however, 88% of cells transduced with the RZF-KRAB construct were CD8 negative.  
 
To determine whether repression of CD8 could be improved tandem repeats of the KRAB 
repressor fused to the RZF were generated and tested, however there was no benefit to 
tandem repeats of the repressor domain and this approach was not pursued further 
(Appendix Figure 10). 
 
 
 
 
 
 
 
 
 
 
Figure 4.6. Long-term monitoring of Molt3 cells transduced with both the LZFN and RZFN and RZF-KRAB constructs. A graph displaying 
the percentage of CD8- cells within the transduced cells population over a 77 day time course. The data is representative of 3 experiments. 
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4.4.7 Confirmation of CD8a repression by QPCR 
Cells were transduced with the RZFN and RZF-KRAB constructs by lentiviral transduction, the 
cells were analysed by flow cytometry 72 h post transduction by flow cytometry (Figure 4.7). 
At the 72 h time point RNA was extracted from the cells and the quality of the RNA was 
checked by running the samples on the bioanalyser. cDNA was synthesised from the RNA 
and used to perform QPCR. A 94% reduction in CD8A mRNA was observed in the RZF-KRAB 
transduced cells relative to the WT (Figure 4.7). The expression of CD8A in the RZFN was 
reduced by 41% relative to the WT despite the MFI of CD8 as measured by flow cytometry 
having no observable difference between RZFN and WT. 
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Figure 4.7. Assessment of the level of CD8 repression in Molt3 cells by QPCR. Molt3 cells were transduced with the RZFN and RZF-KRAB 
constructs by lentiviral transduction. Cells were monitored by flow cytometry 3 days post transduction. A) The dot plots of the cell samples 
3 days post transduction. B) The relative levels of CD8A mRNA expression in the cells was determined by QPCR using 18S and β-actin as 
endogenous controls.. The primers used for the QPCR are listed in the Table 2 of the Appendix. The CD8A mRNA expression is shown as a 
percentage of the WT. Standard error of the mean of 3 replicates is shown. The data is representative of 2 experiments. 
 
4.4.8 Long-term monitoring CD8 expression in Molt3 clones transduced with 
RZF-KRAB 
Cells transduced with the RZF-KRAB construct lost expression of GFP over time and the 
frequency of CD8+ cells rose over time. It was hypothesised that either the CD8- transduced 
cells were outgrown by the untransduced population or the transduced cells were able to 
overcome the suppression. Molt3 cells were transduced with the RZFN and RZF-KRAB by 
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lentiviral transduction and monitored at 72 h post transduction and clones were generated 
by single cell cloning. The clones were screened 1 month post transduction by flow 
cytometry and 5 CD8- clones were selected. The 5 clones were cultured for a further 2 
months before being analysed by flow cytometry to assess whether these clones harboured 
a CD8+ population after continuous culture. The CD8 expression by the 5 clones remained 
constant over the monitoring period suggesting that the cells were not overcoming the 
KRAB repression (Figure 4.8A). To assess the level of CD8A mRNA expressed by the clones, 
RNA was extracted from 5 of the clones in addition to cells transduced with the RZFN and 
RZF-KRAB and WT untransduced cells. cDNA synthesised from the RNA was analysed by 
QPCR. Expression of CD8A mRNA was reduced by 90% in the bulk RZF-KRAB transduced 
cells. Expression of CD8A mRNA was reduced by 89, 87, 85, 90 and 93% in clones 4, 6, 7, 10 
and 13 respectively (Figure 4.8B). Therefore, there was no improvement of CD8A repression 
in the clonal derivatives compared to the bulk RZF-KRAB transduced cells. There was a 41% 
reduction of CD8A expression in the RZFN transduced cells compared to the WT 
untransduced cells. 
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Figure 4.8. Monitoring of the clonal derivatives of RZF-KRAB transduced Molt3 cells. Clonal  derivatives of the bulk RZF-KRAB transduced 
Molt3 cells were monitored by flow cytometry and QPCR to assess  whether the population of CD8 negative cells remained constant over 
time and whether the level of CD8A mRNA expressed was reduced in the clonal derivatives compared to the bulk RZF-KRAB transduced 
cells. A) Dot plots of the WT, RZFN transduced, RZF-KRAB transduced and RZF-KRAB clones 4, 6, 7, 10 and 13 three months post 
transduction. B) A graph displaying the percentage of CD8A mRNA expressed in comparison to the WT untransduced cells of the bulk RZFN 
transduced, bulk RZF-KRAB transduced, RZF-KRAB clones 4, 6, 7, 10 and 13. QPCR was performed using 18S and β-actin as endogenous 
controls. The mean and standard error from the mean of 3 replicates is shown; the data is representative of 2 experiments. 
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4.4.9 Comparison of ZF-KRAB and ZFN in human primary T-cells  
In order to be useful therapeutically, a gene silencing system would need to be effective in 
primary T-cells. I next examined this possibility using CD8+ T cells isolated from the buffy 
coats of three donors (section 2.3.4). The CD8+ T cells were transduced with the LZFN, RZFN, 
LZFN and RZFN, RZF-KRAB and KRAB x constructs by lentiviral transduction and monitored 
by flow cytometry. The frequency of cells transduced with both the LZFN and RZFN was 
estimated by multiplying the frequency of cells transduced with the single transductants 
(LZFN or RZFN). Two weeks post transduction 10, 8 and 10% of GFP+ cells within the LZFN 
and RZFN transduced cells were CD8low in donors A, B and C, respectively after deducting 
background. This was estimated to represent 29, 28 and 24% of cells transduced with both 
the LZFN and RZFNs. In comparison, 82, 88 and 88% of cells transduced with the RZF-KRAB 
lentivirus were CD8low in donors A, B and C respectively after deducting background (Figure 
4.9) suggesting that the ZF-KRAB approach is far more effective at inducing loss of 
expression of CD8 from the cell surface than the ZFN approach in primary CD8 T-cells.  
 
 
Figure 4.9. Comparison of the ZF-KRAB approach in human CD8+ T-cells. CD8 T-cells from three donors were transduced with LZFN, RZFN, 
LZFN and RZFN, RZF-KRAB and KRAB x constructs by lentiviral transduction. Dot plots of the cells 2 weeks post transduction, a CD8- 
population is observed in cells transduced with the LZFN and RZFN and RZF-KRAB lentivirus in donors A, B and C. 
 
The level of CD8 expressed by the CD8low population of cells transduced with the LZFN and 
RZFN and RZF-KRAB lentivirus was determined by gating on the cells and calculating the 
percentage reduction in MFI of the different populations. For Donor A, there was a 91% and 
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Donor A Donor B Donor C 
anti CD8 (APCY) 
FMO 
WT 
RZFN GFP+ 
LZFN+RZFN GFP+ 
KRAB x GFP+ 
LZFN+RZFN CD8-GFP+ 
RZF-KRAB GFP+ 
RZF-KRAB CD8-GFP+ 
Donor A Donor B Donor C 
96% reduction in CD8 MFI of the CD8low cells transduced with LZFN and RZFN and RZF-
KRAB respectively. For Donor B, there was a 91% and 97% reduction in CD8 MFI of the 
CD8low cells transduced with LZFN and RZFN and RZF-KRAB respectively. For Donor C, there 
was a 91% and 96% reduction in CD8 MFI of the CD8low cells transduced with LZFN and RZFN 
and RZF-KRAB respectively (Figure 4.10). This suggests that the ZF-KRAB approach is a viable 
and more effective alternative to ZFNs in this system. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10. Comparison of the ZFN and ZF-KRAB approach in human CD8+ T-cells. CD8 T-cells from three donors were transduced with 
LZFN, RZFN, LZFN and RZFN, RZF-KRAB and KRAB x constructs by lentiviral transduction. A) Histogram plots of the CD8 MFI of donors A, B 
and C are shown. FMO shown in light grey, WT in dark grey, RZFN gating on GFP+ (blue), KRAB x gating on GFP+ (red), LZFN +RZFN gating 
on GFP+ (orange), LZFN +RZFN  gating on GFP+CD8-  (orange histogram with no coloured fill),  RZF-KRAB gating on GFP+ (green) and RZF-
KRAB  gating on GFP+CD8- (green histogram with no coloured fill). B) The percentage reduction in CD8 MFI of each of the samples relative 
to the WT is shown in the table below each of the histogram plots after deducting the background fluorescence. 
A 
B 
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Donor A 
Donor B 
Donor C 
4.4.10 Monitoring the longevity of gene silencing in T-cells 
T-cells transduced with the LZFN, RZFN, LZFN and RZFN, RZF-KRAB and KRAB x by lentiviral 
transduction were monitored by flow cytometry for 9 weeks. The CD8low cells within the 
LZFN + RZFN transduced and RZF-KRAB cell populations declined over the monitoring course 
and were barely detectable at the end of the monitoring period (Figure 4.11). The decline in 
CD8- cells suggests that the untransduced cells within these populations proliferated at a 
greater level than CD8- cells. However, this finding was not unexpected as CD8 is thought to 
be involved in basal signalling and T-cell turnover.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11. Monitoring the CD8low population within the ZFN and ZF-KRAB transduced T-cells. CD8 T-cells from three donors were 
transduced with LZFN, RZFN, LZFN and RZFN, RZF-KRAB and KRAB x constructs by lentiviral transduction. The cells were analysed by flow 
cytometry for nine weeks post transduction. A time course of the frequency of CD8- cells within the transduced cell population of cells 
transduced with the LZFN+RZFN and RZF-KRAB by lentiviral transduction for Donor A, B and C. The frequency was estimated using the 
frequency of GFP+ cells 2 weeks post transduction and the frequency of CD8- cells at each time point. The data is representative of 2 
experiments. 
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4.4.11 Confirming the reduction of CD8A using RZF-KRAB by QPCR in primary 
T-cells 
To determine whether the level of reduction of CD8 MFI correlated with the mRNA levels, 
the cells were sorted by flow cytometry gating on GFP+CD8- population of cells within the 
RZF-KRAB transduced sample, the GFP+ population of RZFN cells and KRAB x cells. RNA was 
extracted from the untransduced and sorted cells. QPCR confirmed that there was 100% 
reduction in CD8A mRNA in the CD8- cells transduced with the RZF-KRAB compared to WT 
untransduced cells in donor A, B and C (Figure 4.12). Expression of CD8A was consistent 
between the RZFN and KRAB x controls despite differing from the WT.  
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Figure 4.12. Confirmation of CD8A silencing by QPCR. CD8+ T-cells from three donors were transduced with RZFN, RZFKRAB and KRAB x 
by lentiviral transduction. The transduced cells were sorted from the bulk population by FACS, the purity of the sorted transduced T-cells 
was established by flow cytometry. A) Dot plots are shown for the three donors (A, B and C). B) QPCR was performed using RNA extracted 
from the sorted RZFN, KRAB x and RZF-KRAB cells in addition to the WT cells from donors A, B and C. β-actin and 18S were used as 
endogenous controls. All of the primer sequences can be found in Appendix Table 2. 
 
4.4.12 Assessment of off target effects by RNAseq  
The CD8A-specific ZF-KRAB domain was composed of 6 modules which targeted a 19bp 
stretch of DNA. RNAseq was performed to assess whether there were any off target effects 
as a result of using the ZF-KRAB approach to silence expression of the CD8A gene using RNA 
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extracted from the purified GFP+ RZFN, GFP+CD8- RZF-KRAB and WT T-cells from donor B in 
section 4.4.11. The RNAseq was performed by the University of Utah sequencing core as 
described in section 2.4.15  
 
The 19bp target sequence was run through the blastn aligorithm NCBI (Altschul et al. 1990) 
to identify any genes that were likely to be off target sites. The 5 most likely off targets sites 
were identified as the DDR1, PPP1R16B, ZNF844, WTIP and SLCO3A1 genes. Alignment of 
the ZF binding site to each of these genes is shown in Figure 4.13A. However, no significant 
alteration of the expression of these genes was observed in the RNAseq data. The analysis 
revealed that there was significant change (p=<0.05) of expression in 4 genes in the RZF-
KRAB transduced cells compared to the RZFN and WT cells. Of the 4 genes identified as 
being differentially expressed the CD8A showed the most significant change. The other 3 
genes identified were Adrenergic, Beta, Receptor Kinase 2 (ADRBK2), gephyrin (GPHN) and 
solute carrier family 17 member 9 (SLC17A9) (Figure 4.13B). There was a 98.84, 97.35, 91.87 
and 97.11% reduction in the number of reads detected for CD8A, ADRBK2, GPHN and 
SLC17A9 for the RZF-KRAB sample in comparison to the WT and RZFN samples (Figure 
4.13B). 
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A 
B 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.13. Analysis of RNAseq data. A) An alignment of the 5 most likely off target sites as determined by BLAST, the genes in which the 
sequences are found is listed. Mismatches are shown as ‘-‘. There was no significant difference between the expression pattern of these 
genes in the WT, RZFN and RZF-KRAB samples. B) A table displaying the percentage expression of the genes found to have significantly 
different expression patterns between the WT, RZFN and RZF-KRAB samples. 
 
The 19bp ZFP target sequence was aligned to the exonic sequence of the 4 genes identified 
by the RNAseq data (Figure 4.14). This alignment revealed that the ADRBK2, GPHN and 
SLC17A9 genes do not align with the 19bp target sequence. The longest sequence homology 
between the 19bp ZFP target sequence and the exonic sequences of ADRBK2, GPHN and 
SLC17A9 are 7, 6 and 6 bp respectively suggesting that the ZFP does not directly bind to 
these genes and induce gene silencing. It seems likely that the reductions observed by 
RNAseq for ADRBK2, GPHN and SLC17A9 are not genuine. QPCR experiments aimed at 
determining whether these potential off target effect are real are currently in progress. It 
will be important to establish whether silencing of CD8A could have an indirect effect on 
these genes. 
 
 
 
 
Sequence Gene 
TGTCGCCGCTGGATCGGAC CD8A 
-GTCGCCGCTGGAT-----  DDR1 
TGTCGCCGCTGGA------  PPP1R16B 
TGTCGCCGCTGGA------  ZNF844 
----GCCGCTGGATCGG--  WTIP 
-----CCGCTGGATCGGA- SLCO3A1 
 Sample 
Gene WT RZFN RZF-KRAB 
CD8A 100 94.23 1.16 
GPHN 100 74.94 2.65 
ADRBK2 100 100.95 8.13 
SLC17A9 100 156.99 2.89 
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Figure 4.14. Alignment of 19bp ZFP target site and exonic sequences of the genes identified by RNAseq. The alignments were performed 
using APE software. Mismatches are shown in red. The nucleotide position in the gene is shown  by the numerical values on the left of the 
alignment. 
 
 
 
ADRBK2 
GPHN 
SLC17A9 
… 
… 
… 
… 
CD8A 
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4.4.13 Assessment of level of gene expression of CD8A, GPHN, ADRBK2 and 
SLC17A9 by QPCR 
The data from the RNAseq experiments (Figure 4.13) revealed that the expression of 4 
genes (CD8A, GPHN, ADRBK2 and SLC17A9) were significantly reduced in the RZF-KRAB 
transduced cells compared to the WT and RZFN control samples. In order to confirm 
whether the expression of these genes was altered, QPCR was performed using the RNA 
from donor B on which the RNAseq was performed and on two additional donors (A and C). 
QPCR was performed on the RNA using the Taqman approach as described in section 
2.4.8.4. There was a 99.9% reduction in the expression of GPHN, ADRBK2 and SLC17A9 
mRNA compared to CD8A in the WT samples from all 3 donors, suggesting that GPHN, 
ADRBK2 and SLC17A9 are expressed at substantially lower levels relative to CD8A (Figure 
4.15A). The QPCR indicated that the levels of mRNA for CD8A, GPHN, ADRBK2 and SLC17A9 
were significantly reduced in the RZF-KRAB samples compared to the WT and RZFN samples 
in all three donors (Figure 4.15B) (p value <0.05).  
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Figure 4.15. Validation of gene expression by QPCR. CD8+ T-cells from three donors were transduced with RZFN, RZFKRAB and KRAB x by 
lentiviral transduction. The transduced cells were sorted and QPCR was performed on the extracted RNA. A) The relative mRNA expression 
of the GPHN, ADRBK2 and SLC17A9 compared to CD8A. B) The percentage of mRNA expressed for CD8A, GPHN, ADRBK2 and SLC17A9 
relative to the WT sample for each of the three donors. All data was normalised using β2m as an endogenous control.  The data shown is 
from a single epetition of the experiment 
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4.4.14 Combined delivery of ZF-KRAB and TCR in a single vector 
The use of T-cell checkpoint inhibitor antibodies for cancer immunotherapies has shown 
great promise. However, these systemic approaches ‘take the brakes off’ all T-cells and 
come with some severe side effects. Future approaches should aim to delimit only cancer-
specific T-cells. One way of doing this would be to knockdown genes like PD-1 and CTLA-4 in 
tumour-reactive TIL or to deliver a tumour-specific TCR to T-cells while simultaneously 
silencing genes that regulate T-cell responses. Combined delivery of ZF-KRAB with an 
antigen-specific TCR might enable such an approach. I next set out to test whether a ZF-
KRAB construct targeting CD8 could be delivered to Molt3 within a lentivirus that delivered 
a TCR to change their specificity. 
 
In order to generate a combined delivery vector, the MEL5 or PPI TCRα and TCRβ chains 
were cloned between NheI and XhoI restriction sites downstream of  the U6 promoter in the 
pELNSxv lentiviral backbone (Dull et al. 1998). This cassette system allowed for alterative 
TCR chains to be substituted in future experiments. The CD8 ZF-KRAB sequences were 
inserted downstream from the TCR chains between BamHI and SalI restriction sites to allow 
for substitution of these domains in future experiments. As a control, a construct was 
generated which was composed of the MEL5 or PPI TCRα and TCRβ chains in combination 
with a rCD2 marker. A diagram of these constructs is shown in Figure 4.16A. Molt3 cells 
were transduced with the rCD2 TCR or CD8 RZF-KRAB TCR by lentiviral transduction. The 
cells were cultured and monitored by flow cytometry 1 week post transduction. A 
population of TCR+ cells was observed within the Molt3 cells transduced with the rCD2 TCR 
and CD8 RZF-KRAB TCR constructs. The TCR+ population of CD8 RZF-KRAB TCR transduced 
cells expressed CD8 at a lower level than the untransduced cells indicating that the CD8 RZF-
KRAB protein was functional (Figure 4.16B).  
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Unstained Stained RZF-KRAB GFP 
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Figure  4.16. Validation of the TCR constructs. A) A diagrammatic representation of the ZF-KRAB TCR and rCD2 TCR constructs. B) Molt3 
cells transduced with the RZF-KRAB TCR and rCD2 TCR constructs by lentiviral transduction were analysed by flow cytometry 1 week post 
transduction.  
 
4.4.15 Dextramer staining in Molt3  
To determine whether the RZF-KRAB TCR construct could silence the CD8A gene and direct 
Molt3 cells to recognise the cognate antigen. Molt3 cells were transduced with the RZF-
KRAB, rCD2 PPI TCR and RZF-KRAB PPI TCR constructs by lentiviral transduction and stained 
with dextramers two weeks post transduction. The multimer staining process was optimised 
to maximise the frequency of cells which stained. Optimisation with PKI and tetramers / 
dextramers can be found in Appendix Figure 11. Dextramers were titrated using 
concentrations – 0.3, 0.03 and 0.003 μg/ µL, the cells were then analysed by flow cytometry. 
 
The RZF-KRAB TCR construct functioned well as CD8A silencing and expression of the PPI 
TCR was observed. Of the TCR+ population of cells 40, 26 and 5% stained with 0.3, 0.03 and 
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d 
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0 
0 
0 
0 
0 
52 
27 
5 
0 
0 
0 
0 
40 
26 
5 
0 
0 
0 
0.003 μg/ µL concentrations of RQF dextramer. In comparison 52, 27 and 5% of TCR+ rCD2 
PPI TCR transduced cells stained with the 0.3, 0.03 and 0.003 μg/ µL RQF dextramer (Figure 
4.17). The increased frequency of dextramer positive cells in the rCD2 PPI TCR transduced 
cells compared to the RZF-KRAB PPI TCR transduced cells was expected as CD8 plays an 
important role in stabilising the TCR/pMHC interaction (Wooldridge et al. 2005). 
 
 
 
 
 
 
 
 
 
 
Figure 4.17. Dextramer staining of Molt3 cells transduced with rCD2 TCR and RZF-KRAB TCR constructs. Molt3 cells were transduced 
with the RZF-KRAB, rCD2 PPI TCR and RZF-KRAB PPI TCR constructs by lentiviral transduction. Cells were incubated with PKI and stained 
with dextramer two weeks post transduction. A) Dot plots of the transduced cells and appropriate gate used to monitor dextramer 
staining. B) The histogram plots show the FMO (grey), cells stained with the RQF dextramer (blue), ELA irrelevant dextramer (red). The 
frequency of dextramer positive cells within the TCR positive population of transduced cells is shown. The data is representative of two 
experiments. 
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4.5 Discussion 
Nuclease based gene editing has risen in popularity over the last few years due to the ease 
and efficiency of gene disruption. However, there are risks associated with the expression of 
a nuclease, namely off target mutagenesis which can lead to malignancy. There is a need for 
non-nuclease based gene silencing technology as this would be safer in the clinic.  Here I 
developed a non-nuclease based gene silencing system utilising the ZFPs platform. Of the 7 
repressor domains tested the KRAB repressor domain was shown to be superior in the 
reporter cell line. The RZF-KRAB construct was validated in both the Molt3 cell line and in 
human primary T-cells and led to a reduction of CD8 expression on the cell surface as 
confirmed by flow cytometry and QPCR. RNAseq performed on RNA extracted from WT and 
T-cells transduced with the RZF-KRAB and RZFN constructs revealed three genes in addition 
to CD8A which showed reduced expression in the RZF-KRAB transduced cells relative to the 
RZFN transduced and WT untransduced cells. QPCR confirmed that expression of these 
genes was significantly altered in RZF-KRAB compared to WT and RZFN cells. An explanation 
for the alteration in expression of these genes has not yet been identified. A construct was 
generated which incorporated a ZF-KRAB and a TCR as a single entity. The TCR ZF-KRAB 
construct was validated in Molt3 cells which were found to express the TCR on the cell 
surface and expressed CD8A at a reduced level relative to untransduced and control cells. 
Overall, the RZF-KRAB construct is an effective and nuclease free use of ZFPs allowing for 
silencing of genes without the risk of potential off target nuclease activity. 
 
4.5.1 Length of ZF and affinity for target site 
The ZF pair used in this chapter consisted of a RZF formed by 6 ZF modules (targeting a 19bp 
stretch of DNA) and a LZF formed from 5 modules (targeting a 16bp stretch of DNA). The LZF 
and RZF were fused to the KRAB repressor domain and validated in the 1x and 3x reporter 
cell lines. Of the two constructs only the RZF-KRAB was functional. It is suspected that the 
RZF has an increased affinity for the DNA binding site due to the additional ZF module. 
Increased repression of a AmCyan fluorescent protein was observed when repressor 
domains were fused to a 6 module ZFP in comparison ZFPs with less modules (Lohmueller et 
al. 2012). These results indicate that the length of the ZFP affects the affinity that the ZFP 
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has for its corresponding target site. In addition, longer ZFPs may increase the specificity of 
the ZFP and reduce potential off target binding. 
 
4.5.2 RNAseq 
RNAseq identified 3 additional genes which had significantly altered expression in the RZF-
KRAB transduced cells compared to both the WT and RZFN transduced cells these were 
GPHN, SLC17A9 and ADRBK2. The GPHN membrane plays a key role in anchoring glycine 
receptors to cytoskeleton and subsynaptic microtubules (David-Watine 2001). The SLC17A9 
gene encodes a lysosomal ATP transporter which is expressed by chromaffin cells, 
pancreatic and T-cells (Cao et al. 2014). ADRBK2 encodes a β- adrenergic receptor kinase 
which phosphorylates GPCRs allowing β-arrestin binding and initiation of receptor 
endocytosis (Luttrell & Lefkowitz 2002; Feng et al. 2005). The function of these genes would 
suggest that repression of these genes is unlikely to be a result of the proteins being 
involved in the downstream pathways of CD8. The likelihood of direct off target binding was 
assessed by aligning the 19bp target sequence with the genomic sequences of the identified 
genes. There is minimal alignment of the 19bp target sequence and the genomic sequence 
suggesting that unlikely that the altered expression is due to a direct silencing. To assess the 
expression of CD8A, GPHN, SLC17A9 and ADRBK2 in the RZF-KRAB transduced cells relative 
to the WT and RZFN samples QPCR was performed using RNA extracted from three donors, 
the data from a single QPCR experiment suggested that expression of CD8A, GPHN, SLC17A9 
and ADRBK2 was significantly reduced in in the RZF-KRAB samples of three donors. 
Unfortunately, due to time constraints, the genes identified by the RNAseq data were not 
fully confirmed and further experiments are required to confirm the expression of these 
genes and to investigate the reasoning  
 
4.5.3 Immunogenicity and persistence 
In this study the frequency of CD8 negative cells within the bulk transduced population 
initially declined in Molt3 then remained stable over the monitoring period. The frequency 
of CD8 negative cells within the bulk transduced T-cell population declined steadily over 
time and the cells were undetectable at 11 weeks post transduction. This decline of CD8 
negative T cells over time is thought to be due to the untransduced T-cells outgrowing the 
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CD8 negative T-cells. The CD8 molecule is thought to play an important role in basal 
signalling in T-cells, therefore the CD8 negative cells generated in this chapter were at a 
survival disadvantage to the untransduced T-cells. Previous studies have highlighted the 
importance of ‘co-receptor tuning’ for homeostasis, suggesting that CD8 expression plays an 
important role in the long-term survival of T-cells (Park et al. 2007; Zuniga-Pflucker 2007), as 
basal signalling is thought to occur though interactions between TCR and self pMHC 
interactions (Reviewed by Hogquist & Jameson 2014). In hindsight, CD8A was not an ideal 
target as proof of principle in T-cells. 
 
A previous clinical trial evaluating the adoptive transfer of T-cells genetically modified to 
express a HIV specific TCR transfer via retroviral transduction revealed that genetic 
modification of T-cells led to cells becoming immunogenic whereby 5/6 patients rejected 
the genetically modified cells (Riddell et al. 1996). However, more recent clinical trials 
assessing the safety and persistence of genetically engineered T-cells have been promising. 
A clinical trial to evaluate the safety and feasibility of genetic modification of autologous T-
cells using ZFNs to modify the CCR5 gene concluded that the use of ZFNs did not lead to the 
cells becoming immunogenic as they were found to persist long-term after transfer and the 
frequency of biallelic knockout correlated to the level of viral load with high viral load being 
associated with lower frequency of CCR5 KO (Tebas et al. 2014). 
 
4.5.4 Advances in CRISPR interference technology 
Since the start of my PhD, CRISPR/Cas9 technology has been identified and utilised for gene 
editing. Recent developments have focused on gene silencing with CRISPR based 
technologies. An inactive form of Cas9 termed dCas9 was generated by two nucleotide 
substitutions D10A and H840A (Qi et al. 2013). Fusion of the nuclease inactive dCas9 and 
the KRAB repressor has led to epigenetic silencing of the TP53 gene (Lawhorn et al. 2014) 
and the HS2 enhancer (Thakore et al. 2015). The ZF-KRAB approach developed in this 
chapter has clear advantages over the CRISPR/dCas9-KRAB approach as the small size of the 
ZF-KRAB construct allows for co-transfer of TCR chains within a single viral vector.  
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4.5.5 Summary 
There is a significant need for the generation of novel non-nuclease based gene silencing 
technologies as nuclease based gene editing technologies have an inherent risk of 
malignancy resulting from off target nuclease activity. To address this issue I have 
developed a system which incorporates ZF DNA binding proteins and the KRAB repressor 
domain. The ZF-KRAB sequence was incorporated into a single plasmid with TCRα and TCRβ 
which allowed for specific gene knockout and redirection of Molt3 cells. Delivery of non-
nuclease based gene silencing tools and an antigen specific TCR within a single plasmid has 
great potential for therapeutic use. 
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5 Development of an ‘all in one’ CRISPR/Cas9 
lentiviral system to engineer isogenic cells deficient 
in MR1 
 
5.1 Introduction 
 
5.1.1 MAITS and MR1 restricted T-cells 
MAITs are the most frequently occurring unconventional T-cell subset (Sandberg et al. 2013) 
and are found at high frequencies in the gut lamina propria (Huang et al. 2009), liver and 
mucosal surfaces (Kurioka et al. 2015). Typically, MAIT cells are identified by their semi 
invariant TCRs (TRAV1-2, TRAJ33/12/20)  (Tilloy et al. 1999). A subset of MR1 restricted T-
cells have recently been identified which do not express the canonical TRAV1-2 chains 
(Meermeier et al. 2016) and it may yet prove that there is a wide family of MR1-restricted T-
cells in addition to MAITs. Unlike conventional T-cells, MAITs and MR1 restricted T-cells do 
not recognise peptide antigens restricted by classical MHCI or MHCII molecules. Instead, 
these unconventional T-cells are activated by pathogen-derived metabolites from a range of 
microbes (Le Bourhis et al. 2010) presented in the binding groove of MR1. MAITs are 
described as innate like as their effector functions are acquired during thymic selection and 
therefore MAITs have a rapid response time and  do not require prior antigen priming (Gold 
et al. 2013). MAITs play a key role in controlling yeast and bacterial infections and have been 
shown to be activated by metabolites produced by a range of yeast species Candida 
albicans, Candida glabrata and Saccharomyces cerevisiae (Le Bourhis et al. 2010) and 
bacterial species such as Escherichia coli (Gold et al. 2010), Klebsiella pneumoniae, 
Lactobacillus acidophilus (Le Bourhis et al. 2010), mycobacteria (Gold et al. 2010), 
Pseudomonas aeruginosa, (Le Bourhis et al. 2010), Staphylococcus aureus, (Gold et al. 2010; 
Le Bourhis et al. 2010), Shigella dysenteriae, Staphylococcus epidermidis and Shigella 
flexneri, (Le Bourhis et al. 2013). However, some bacterial species are unable to activate 
MAIT cells such as Enterococcus faecalis (Le Bourhis et al. 2010), Listeria monocytogenes 
(Kjer-Nielsen et al. 2012) and group A Streptococcus (Le Bourhis et al. 2010) and this is 
thought to be due to an inability of these bacteria to produce riboflavin metabolites, 
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potentially due to defects in the metabolic pathway (Le Bourhis et al. 2010). Activation of 
MAITs leads to the release of granzyme and cytokines (IFNγ and TNF) (Gold et al. 2008; Gold 
& Lewinsohn 2012) which result in target cell death. MAITs  have been shown to be CD4-
CD8- orCD8αβint (Dusseaux et al. 2011) and express a pattern of chemokine receptors which 
are associated with homing to tissues in the liver and intestines (Martin et al. 2009; 
Dusseaux et al. 2011). MAIT cells in the thymus and in the cord blood have a naïve 
phenotype, in contrast peripheral blood MAITs have a memory T cell phenotype (Dusseaux 
et al. 2011; Gold et al. 2013). Selection and expansion of MAITs is dependent upon the 
presence of B cells and commensal microbiota (Martin et al. 2009). The MAIT cell population 
is absent in patients and mice deficient in B cells and germfree mice (Treiner et al. 2003) 
suggesting that the presence of commensal microbiota is essential for their survival. It has 
been shown that MAITs with distinct TCR usage are activated by different pathogens (Gold 
et al. 2014). There is strong evidence that both the TCR receptors and MR1 molecule have 
been conserved throughout evolution due to their abilities in protecting the host from a 
wide range of microbes (Gold & Lewinsohn 2012).  
 
5.1.2 MR1 molecule 
The MR1 molecule has a high sequence homology with and similar structure to the classical 
MHCI molecules. The homology between the α1 and α2 domains of MR1 and the other 
MHCI molecules is approximately 90% in humans and mice (Yamaguchi et al. 1997; 
Tsukamoto et al. 2013). In a similar manner to the other classical MHCI molecules, the MR1 
molecule is formed from a heavy α chain and a light β2m chain. Within the α chain, the α1 
and α2 domains forming the antigen binding groove and the α3 domain covalently binding 
to the β2m molecule (Kjer-Nielsen et al. 2012) (Figure 5.1). The MR1 molecule presents 
small metabolites from vitamin B biosynthesis such as metabolites of folic acid (vitamin B9). 
However, only three examples of vitamin B2 derivatives have been shown to activate MAIT 
cells (rRL-6-CH2OH, RL-6-Me-7-OH and RL-6,7-diMe) (Kjer-Nielsen et al. 2012).  
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Figure 5.1. Schematic representation of MHC molecules (MHCI, MHCI like MR1 and MHCII). Classical MHCI and MHCII molecules present 
peptides, whilst the non-classical MHCI like MR1 molecules present metabolites.  
 
 
 
5.1.3 M. smegmatis as a model for studying T-cell responses to bacteria presented 
through MR1 
M. smegmatis was used as a model in this study as it is a non-pathogenic, fast growing class 
I bacterial strain, which can be handled in the biosafety level 1 facility available to me 
(Brown-Elliott & Wallace 2002). M. smegmatis has been shown to be phagocytosed and 
processed by APCs, which present the M. smegmatis antigens on MR1 in addition to the 
classical MHC molecules. Although M. smegmatis is non-pathogenic it has a high homology 
with Mycobacterium  tuberculosis, including 12/19 virulence factors, (Reyrat & Kahn 2001) 
and therefore serves as a good laboratory model for this human pathogen. 
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5.2 Rationale  
The invariant nature of MR1 across the human population and its established role in the 
presentation of pathogen-derived antigen are of outstanding interest for the potential 
development of universal therapeutic and diagnostic tools in infectious diseases. MR1 
expression also appears to be ubiquitous among different cells and tissues, which may 
indicate that MR1-driven antigen responses are relevant to the pathogenesis of a broad 
number of immune mediated diseases. However, the invariance and ubiquity of MR1 also 
complicate basic investigations of its ligand binding and antigen presentation properties as 
well as in the understanding of MR1-restricted T-cell biology. The presence of MR1 on most 
APC lines and primary cells that express other classical and non-classical HLA molecules can 
make the unambiguous identiﬁcation of microbe-speciﬁc MAIT cells and their distinction 
from conventional T-cells that express the TRAV1-2 TCR chain problematic. Currently, the 
role that MAITs play in autoimmune, non-infectious inflammatory and highly infectious 
disease is largely unknown despite localisation of MAIT cells at disease site in numerous 
diseases such as inflammatory bowel disease (Serriari et al. 2014), autoimmune arthritis 
(Billerbeck et al. 2010), multiple sclerosis (Annibali et al. 2011), autoimmune hepatitis, 
chronic hepatitis C, alcoholic liver disease, non-alcoholic steatohepatitis, primary biliary 
cirrhosis (Oo et al. 2016) and Mycobacterium  tuberculosis (Karp et al. 2015). Development 
of MR1 deficient cell lines will allow for studying the role of MAIT cells in autoimmune, non-
infectious inflammatory diseases and highly infectious diseases. 
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5.3 Aims 
When the CRISPR/Cas9 technology was first published, researchers required three individual 
plasmids for efficient targeted knockout that expressed tracrRNA, crRNA and Cas9 protein. 
One aim of this project was to combine all of these plasmids into a single gene knockout 
vector to allow easy testing of crRNA efficiency. I then aimed to show that CRISPR/Cas9 
technology could be useful for the study of antigen presentation to unconventional T-cell 
subsets. There has been much recent interest in the presentation of bacterial metabolites to 
MR1-restricted T-cells. I thus aimed to use the ‘all in one’ CRISPR/Cas9 system as a tool to 
produce MR1 deficient cell lines as a proof-of-concept that this approach could be used to 
study microbial antigen processing and presentation to human MAIT cells. 
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5.4 Results 
 
5.4.1 Generation of an ‘all in one’ lentiviral CRISPR/Cas9 system 
The existing CRISPR/Cas9 system described by Mali et al. 2013 consisted of two plasmids, 
one containing the Cas9 protein and the other containing the gRNA sequences. To improve 
the efficiency of knockout using the CRISPR/Cas9 system a single plasmid system was 
produced. The DNA sequence of the U6 RNApolIII promoter and a gRNA sequence which 
encompassed the MR1 specific crRNA A and the tracrRNA sequence were synthesised 
(Eurofins). The sequence was cloned into the pCDNA.3-TOPO_Cas9 upstream of the CMV 
promoter. To produce a lentiviral vector the pCDNA.3-TOPO_Cas9+gRNA plasmid was PCR 
amplified using pCDNA.3_Fwd and pCDNA.3_Rev primers to introduce an AgeI restriction 
site upstream of the U6 RNApolIII promoter and an NsiI restriction site downstream of the 
Cas9 sequence. Corresponding restriction sites were introduced into the 2nd generation 
pRRL.SIN.cPPT.pgk-gfp.WPRE lentivector backbone by PCR amplification with pRRL.0_Fwd 
and pRRL.0_Rev primers. The CRISPR elements were cloned into the pRRL.SIN.cPPT.pgk-
gfp.WPRE lentivector backbone (Figure 5.2). All primer sequences are found in Appendix 
Table 2. 
 
 
 
 
 
 
 
  
 
Figure 5.2. Development of the CRISPR/Cas9 “all-in-one” lentiviral system. Graphic representation of the “all-in-one” lentiviral system 
generated for this study. The synthesised gRNA sequence was cloned into pCDNA.3-TOPO_WT-Cas9 plasmid. The U6 promoter, gRNA 
sequence, CMV promoter and Cas9 elements were cloned into the 2nd generation pRRL.SINpRRLSIN.cPPT.WPRE lentivector backbone.  
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5.4.2 Production of 5 novel crRNA sequences targeting the MR1 gene  
5 crRNA target sequences were designed by identifying GN19GG DNA motifs present on 
either strand of the MR1 genomic DNA sequence. The crRNA sequences were run through 
the basic local alignment tool - nucleotide (blastn) aligorithm to identify likely off target sites 
(Altschul et al. 1990) and crRNA sequences with potential off target sites were excluded. 5 
non-overlapping target sequences were selected located in the first 3 exons of the MR1 
coding sequence. crRNA B targeting exon 1, crRNA A, C and D targeting exon 2 and crRNA E 
targeting exon 3. The novel crRNA sequences were cloned into the ‘all in one’ CRISPR/Cas9 
system for validation. The location and sequence of each crRNA is shown in Figure 5.3. 
  
 
 
 
 
Figure 5.3. Design of novel crRNA sequences targeting the MR1 gene. A) Positioning of 5 active crRNA target sequences with respect to 
the intron/exon structure of the MR1 gene. B) Table listing the CRISPR/Cas9 crRNA target sequences within the MR1 gene generated 
during this study. 
 
5.4.3 Comparison of the novel crRNA sequences targeting the MR1 gene 
 The level of MR1 expression on the cell surface of normal non-bacterially infected cells is 
low, so in order to test the 5 crRNAs a reporter cell line was generated by overexpressing 
the native MR1 sequence in HeLa cells (referred to as HeLa-MR1 cells). Lentivirus for each of 
the 5 crRNAs was produced as described in section 2.3.7.2 and used to transduce the HeLa-
MR1 cell line. 3/5 of the crRNAs, A, B and D, resulted in MR1 knock down/knock out as 
evident by flow cytometry. To assess whether mutations were present at a DNA level, DNA 
was extracted from WT HeLa-MR1 and HeLa-MR1 cells transduced with crRNAs A, B and D. 
The surveyor assay was performed as described in section 2.4.13. crRNA A was found to 
crRNA Target sequence PAM Exon Strand 
A GGATGGGATCCGAAACGCCC AGG 2 + 
B GGTGAAGCACAGCGATTCC CGG 1 - 
C GTCCCTGAATTTATTTCGGT TGG 2 - 
D GAACCTCGCGCCTGATCACT GGG 2 - 
E GCAGTATGCATATGACGGGC AGG 3 - 
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induce the greatest levels of knockout on a protein level (flow cytometry) and DNA level 
(Surveyor assay) (Figure 5.4). Therefore, crRNA A was chosen for downstream applications.  
  
 
 
 
 
 
 
 
 
 
 
. 
 
 
Figure 5.4.  Validation of crRNAs targeting the MR1 in the HeLa-MR1 cell reporter system. HeLa-MR1 cells were transduced with crRNAs 
A, B and D by lentivirus. A) The level of MR1 expression on the cell surface of cells was monitored by flow cytometry, the isotype control 
(solid light grey), crRNA A (dark green), crRNA B (light green), crRNA D (orange) and WT unmodified HeLa-MR1 cells (light blue). A 
population of MR1 negative cells is observable in cells transduced with crRNAs A, B and D. B) The presence of mutations at a DNA level 
was monitored by surveyor assay. DNA was PCR amplified using the MR1_SURV1_Fwd and MR1_SURV1_Rev primers, which bound 
immediately upstream of the MR1 cDNA start and downstream of the target site respectively. 400ng of PCR product from unmodified 
Hela-MR1 or 200 ng of PCR product from Hela-MR1 cells transduced with each crRNA target (crRNA A, B and D) and 200 ng of PCR product 
from unmodified Hela-MR1 cells were denatured, annealed and digested with the mismatch specific surveyor enzyme as described in 
section 2.4.13. Additional bands indicating mismatches at a DNA level were observed weakly in crRNA B and D wells and more strongly in 
the crRNA A well. 
 
5.4.4 Efficiency of MR1 knockout using lipofectamine transfection and 
lentiviral transduction 
The crRNA A was expressed in A549 cells either transiently by lipofectamine transfection or 
stably by lentiviral transduction. The cells were monitored by flow cytometry which showed 
that both transient and stable expression of the crRNA A led to an observable knock down/ 
knock out population and a reduction in the MFI of MR1 in A549 cells transfected with 
lipofectamine and transduced with lentivirus in comparison to the WT A549 cells (Figure 
5.5A). A surveyor assay confirmed the presence of mutations at a DNA level in A549 cells 
transfected with lipofectamine and transduced with lentiviral in comparison to the WT A549 
cells (Figure 5.5B).  
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Figure 5.5. Comparison of crRNA A lipofectamine transfection and lentiviral transduction.  MR1 deficient A549 cells were generated by 
lipofectamine transfection and lentiviral transduction. The cells were cultured for 8 days before being analysed by flow cytometry and 
surveyor assay. A) The cells were treated with acetyl-6-formylpterine (6-f-p) (50 mg/ mL) for 16 h and then were stained with the MR1 
antibody or with an isotype control. Cells were stained with the isotype control antibody (black; MFI = 2.78), mock lipofected cells (solid 
grey; MFI = 9.53), cells transduced with lentivirus (red; MFI = 5.84) and cells transfected with CRISPR/Cas9 plasmid DNA by lipofectamine 
(blue; MFI = 7.07). The lipofectamine and lentiviral transduction approaches both lead to a substantial MR1 negative population. B) The 
surveyor assay was performed with 500 ng of DNA extracted from WT unmodified cells and cells transduced or transfected with the crRNA 
lentivirus or lipofectamine. The DNA was amplified using MR1_SURV2_Fwd and MR1_SURV2_Rev primers. Homoduplex of WT DNA 
amplicons (lane 1) or heteroduplexes of annealed WT and amplicons from transduced cells (lane 2) or lipofected cells (lane 3) were 
digested with the Cel1 DNA-mismatch specific enzyme. The red arrows indicate the two bands expected after digestion with the mismatch 
specific Cel1 enzyme (521 and 331 bp). The surveyor assay kit controls - undigested (lane 4) and digested (lane 5) assay controls are 
shown. 
 
5.4.5 Generation of clonal A549 cell populations bearing CRISPR/Cas9 induced mutations 
in the MR1 locus 
The lentiviral transduction and lipofectamine transfection approaches both effectively 
knocked out the expression of MR1 from the cell surface of a substantial proportion of the 
A549 cells. Despite the lentiviral transduction approach leading to a higher frequency of 
knockout than the lipofectamine transfection approach, it was thought long-term 
expression of the CRISPR/Cas9 elements by integrated lentiviral transduction may increase 
the risk of off target mutations. Therefore, the bulk lipofectamine transfected cells were 
used to produce MR1 deficient A549 clones. MR1low cells were sorted by flow cytometry and 
cloned by limiting dilution to generate clonal populations. Eight clones were screened by 
flow cytometry, of these clones 1, 9 and 11 expressed the lowest levels of MR1 consistently 
(Figure 5.6A). The surveyor assay was performed on these clones to establish whether there 
were mismatches at a DNA level. The DNA flanking the crRNA sequence was amplified by 
PCR in each of the clones and the WT A549 cells using the MR1_SURV2_Fwd and 
MR1_SURV2_Rev primers which bound upstream and downstream of the crRNA 
respectively. Interestingly two bands were observed for clone 9 (one at the expected size of 
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Clone 2 (MFI= 7.54) 
Iso ctrl (MFI= 1.88) 
Clone 1 (MFI= 4.45) 
Clone 3 (MFI= 11.0) 
Clone 11 (MFI= 4.58) 
A549 WT (MFI= 9.28) 
  Clone 9 (MFI= 4.78) 
Clone 5 (MFI= 7.81) 
Clone 10 (MFI= 7.36) 
Clone 4 (MFI= 5.78) 
A B 
Non digested Cel-I digested 
anti MR1 (PE) 
852 bp and other 100-150 bp shorter), suggesting that there was a deletion on one allele. A 
surveyor assay was performed as described in section 2.4.13. Mismatches at the crRNA 
locus were expected to produce two products (approximately 520 and 330 bp) after 
digestion with the Cel1 mismatch specific enzyme. Additional products were observed for 
clone 9 and 11 indicating that there were mutations at a DNA level (Figure 5.6B). Clone 1 did 
not produce additional bands and was not taken forward. 
 
 
 
 
Figure 5.6. Generation of the MR1 negative A549 clones. Clonal derivatives were generated by single cell sorting of the bulk population of 
A549 cell population transfected with the crRNA CRISPR/Cas9 elements by lipofectamine. A) Eight clones and the WT A549 cells were 
treated with 6-f-p (50 mg/mL) for 16 h; cells were then stained with the MR1 antibody or with an isotype control antibody. Isotype control 
(red; MF1= 1.88), WT (blue; MFI=9.28) and clones shown as a variety of colours with MFIs ranging from 4.45 to 11. Clone 1, 9 and 11 were 
found to have to lowest MFI consistently and were chosen for downstream applications. B) DNA was extracted from clone 1, 9, 11 and WT 
A549 cells. The DNA was amplified by PCR using MR1_SURV2_Fwd and MR1_SURV2_Rev primers and the amplicons were run on an 
agarose gel in the absence of hybridisation and digestion WT A549 cells (lane 1) and A549 clone 11 (lane 2), clone 9 (lane 3) and clone 1 
(lane 4). The PCR amplicons were hybridised with WT DNA and digested with the Cel1 enzyme and run on an agarose gel homoduplex WT 
DNA (lane 5) or heteroduplexes of annealed WT and modified amplicons from clone 11 (lane 6), clone 9 (lane 7) or clone 1 (lane 8). Prior 
to digestion a second smaller band was observed in clone 9 suggesting a 100-150bp deletion on one allele. After digestion additional 
bands were observed in clone 9 and clone 11. 
 
5.4.6 Characterization of disruptive mutations in the MR1 gene of MR1-/- 
A549 clonal derivatives  
For further characterisation, the region of DNA flanking the crRNA binding site was 
amplified using the MR1_SURV_Fwd_BsaI and MR1_SURV_Rev_BsaI primers which bound 
upstream and downstream of the crRNA respectively and introduced BsaI restriction sites 
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onto the PCR product and the PCR products were cloned into a cloning vector 
(Addgene#32189). Ten colonies were selected for each clone and minipreps of the DNA 
were sequenced by Sanger sequencing using MR1_Seq_Fwd and MR1_Seq_Rev primers. 
Clone 9 was found to have a 126 bp deletion on allele 1. On allele 2 of clone 9 there was a 
single nucleotide deletion and two nucleotide substitutions. Clone 11 had an identical single 
nucleotide deletion on both alleles. The single nucleotide deletion in clone 9 and 11 were 
identical (Figure 5.7). All mutations induced a frameshift in the reading frame on both alleles 
of clone 9 and clone 11. Clone 9 allele 1 is disrupted from amino acid 23, the second allele of 
clone 9 and both alleles of clone 11 are disrupted from amino acid 34 onwards (Figure 5.7C). 
Taken in combination with the lack on MR1 staining on the cell surface, my results indicate 
that the CRISPR/Cas9 system effectively abrogated MR1 expression from the cell surface. 
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Sample  DNA sequence 
WT  GGAGCACTCGTGTGGGGCTAAATGAATGCAGTTGAAGGATCTGGATCATCTGGGACCCTACATGTCTTCC
TTCTTTGCCTCCTTTCCAGGGACGCACTCTCTGAGATATTTTCGCCTGGGCGTTTCGGATCCCATCCATG 
C9 a1 GGAGCACTCGTGTGGGGCTAAATGAATGCAGTTGAAGGATCTGGATCATCTGGGACCCTACATGTCTTCC
TTCTTTGCCTCCTTTCCAGGGACGCACTCTCTGAGATATTTTCGCCTGGGCGTTTCGGATCCCATCCATG 
 
 
 
Figure 5.7. Analysis of the mutations induced by CRISPR/Cas9 at a DNA level in A549 clone 9 and 11. The crRNA binding sequence is 
highlighted in yellow and the PAM sequence is highlighted in blue. Nucleotides in exon 2 are blue, red nucleotides with a strikethrough 
represent deleted nucleotides. A) The DNA sequence of A549 clone 9 allele 1. The reference WT sequence is shown above. A 126bp 
deletion is identifiable which encompasses a portion of the intron and the first 33bp of exon 2. B) The DNA sequence of A549 clone 9  
allele 2 and both alleles of clone 11, the WT sequence is shown above. All alleles share a single nucleotide deletion in the crRNA sequence 
4 bp upstream of the PAM sequence. C) The predicted primary structures of the mutant MR1 proteins were determined by translating the 
DNA sequences. MR1 amino acids 20 - 90 are shown. The WT MR1 protein sequence is shown above. Out of frame reads are highlighted in 
grey.  (C9 a1 = clone 9 allele 1, C9 a2 = clone 9 allele 2, C11 a1 = clone 11 allele 1 and C11 a2 = clone 11 allele 2). 
 
5.4.7 Identification of CRISPR/Cas9 mutagenesis off-target effects using genomics. 
To assess whether the CRISPR/Cas9 system targeting the MR1 gene was specific for MR1 
whole genome sequencing was performed using DNA extracted from clone 9 and clone 11. 
The data was analysed with the help of Dr. Thomas Connor using the methodologies 
described in section 2.4.15. The most likely off target sites were identified using the 
CRISPRdesign tool (MIT) and eCRISP software (German cancer research centre), using these 
algorithms 38 potential off target sites were identified for the crRNA A sequence. Table 2.3 
shows the 37 potential off target sites. A further, unanticipated, on-target site was 
predicted within the RP11-46A10.6 gene, which encodes an unexpressed partial MR1 
pseudogene. This site shares 23/23bp homology within the crRNA and the PAM sequence.  
5/38 of these predicted off target sites were within genes and varied from the crRNA site by 
Sample  DNA sequence 
WT  CTGAGATATTTTCGCCTGGGCGTTTCGGATCCCATCCATGGGGTCCCTGAAT 
C9 a2 CTGAGATATTTTCGCCTGGGCGTTTCGGATCCCATCCATGGGGTCCCTGAAT 
C11 a1 CTGAGATATTTTCGCCTGGGCGTTTCGGATCCCATCCATGGGGTCCCTGAAT 
C11 a2 CTGAGATATTTTCGCCTGGGCGTTTCGGATCCCATCCATGGGGTCCCTGAAT 
Sample Amino acid sequence 
WT SDSRTHSLRYFRLGVSDPIHGVPEFISVGYVDSHPITTYDSVTRQKEPRAPWMAENLAPDHWERYTQLLRG 
C9 a1 
C9 a2 
SDS?     SDSRTHSLRYFRLGFRIPSMGSLNLFRLGTWTRTLSPHMTVSLGRRSHGPHGWQRTSRLITGRGTLSC! 
C11 a1 
C11 a2 
SDSRTHSLRYFRLGFRIPSMGSLNLFRLGTWTRTLSPHMTVSLGRRSHGPHGWQRTSRLITGRGTLSC! 
SDSRTHSLRYFRLGFRIPSMGSLNLFRLGTWTRTLSPHMTVSLGRRSHGPHGWQRTSRLITGRGTLSC! 
A 
B 
C 
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3 or more nucleotides. 32/38 of these predicted off target sites were not located within 
gene encoding DNA. To ensure that no off target sites were excluded from the analysis, in 
excess of 7000 additional sites that varied from the crRNA sequence by 5bp or less were 
identified. All reads were aligned to the GRCh38 reference sequence and assembled using 
Artemis software. All of the potential off target sites were screened by eye. Only one case of 
an unintended mutation was identified in the RP11-46A10.6 pseudogene (as discussed in 
section 5.3.8.). The whole genome sequencing data analysis confirmed the mutations 
identified in the MR1 gene of clone 9 and clone 11 by Sanger sequencing (Figure 5.8). 
 
 
 
Figure 5.8. Confirmation of the mutations detected by PCR amplification of the MR1 gene by whole genome sequencing in clone 9 and 
clone 11. The ‘on target’ effects observed in the MR1 gene of A) clone 9 and B) clone 11. 
 
5.4.8 MR1 CRISPR/Cas9 mutagenesis resulted in an unintended DNA 
mutation in the RP11-46A10.6 pseudogene. 
The RP11-46A10.6 pseudogene exon 1 had a 94% sequence homology with MR1 exon 2 
(Figure 5.9) and 100% homology at the crRNA binding site. Whole genome sequencing 
identified a single base pair deletion in the A549 clones C9 and C11 which was identical to 
that observed in the MR1 gene in C9 allele 2 and clone 11 allele 1 and 2 (Figure 5.9). The 
RP11-46A10.6 gene is located in the intron region between exon 1 and 2 of the STX6 
protein-coding sequence. The exons of STX6 are a considerable distance from this mutation 
in the RP11-46A10.6 target sequence and therefore it is unlikely that this mutation will have 
any adverse effects on the STX6 gene. 
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Figure 5.9. A screenshot of the mutations identified in the RP11-46A10 gene by whole genome sequencing in clone 9 and clone 11 using 
the Artemis software. Both alleles of clone 9 and clone 11 show a single nucleotide deletion at the same position as the deletion observed 
in the MR1 gene of clone 9 and clone 11 (A and B respectively). 
 
In order to confirm the mutations induced in the RP11-46A10.6 which were identified by 
whole genome sequencing were present the DNA from the A549 clones 9 and 11 and WT 
cells was amplified using the RP11_FWD and RP11_REV primers which bind upstream and 
downstream of the crRNA sequence respectively. The amplified DNA was sequenced by 
Sanger sequencing which confirmed a single base pair deletion at the same site as observed 
in C9 allele 2 and C11 allele 1 and 2 MR1 crRNA binding site (Figure 5.10). 
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Figure 5.10. Analysis of the mutations induced by CRISPR/Cas9 at a DNA level in A549 clone 9 and 11 within the RP11-46A10.6 gene. A) 
The DNA sequence of A549 clone 9 allele 1, 2 and clone 11 allele 1 and 2, the WT sequence is shown above. Each of the alleles of C9 and 
C11 share a single nucleotide deletion in the crRNA sequence 4 bp upstream of the PAM sequence. (C9 a1 = clone 9 allele 1, C9 a2 = clone 
9 allele 2, C11 a1 = clone 11 allele 1 and C11 a2 = clone 11 allele 2). B) Exon 2 of MR1 and exon 1 of the RP11-46A10.6 gene were aligned 
using the EMBOSS MATCHER software. Exon 2 of MR1 is the top sequence and exon 1 of RP11-46A10.6 is shown as the bottom sequences. 
Mismatches between MR1 and the RP11-46A10.6 gene are shown as dots. The crRNA sequence is highlighted in yellow and the PAM 
sequence is highlighted in blue. 
 
5.4.9 A549 mutant clones infected with bacteria selectively fail to activate 
MAIT cell clones infected with M. smegmatis. 
To confirm that the MR1 deficiency on the cell surface led to a functional deficiency, WT and 
MR1 deficient A549 clones were infected with M. smegmatis bacteria and incubated with 
one of two MAIT clones (D426B1 and D481A9). Both clones expressed the TRAV1-2_TRAJ33 
MAIT TCR α-chain rearrangement, however, the MAIT clones expressed different CDR3 
Sample  DNA sequence 
WT TGAGATATTTTCGCCTGGGCGTTTCGGATCCCATCCATGGGGTCCCTGAATTTATTT 
C9 a1 TGAGATATTTTCGCCTGGGCGTTTCGGATCCCATCCATGGGGTCCCTGAATTTATTT 
C9 a2 TGAGATATTTTCGCCTGGGCGTTTCGGATCCCATCCATGGGGTCCCTGAATTTATTT 
C11 a1 TGAGATATTTTCGCCTGGGCGTTTCGGATCCCATCCATGGGGTCCCTGAATTTATTT 
C11 a2 TGAGATATTTTCGCCTGGGCGTTTCGGATCCCATCCATGGGGTCCCTGAATTTATTT 
A 
B 
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sequences and different β chain pairings (D426B1 expresses TRBV6-4 and D481A9 expresses 
TRBV20-1). An ELISA was performed on the supernatant after 16 h incubation with infected 
target cells. The infected WT A549 cells stimulated the MAIT cell clones to produce MIP1β 
and IFN-γ, in contrast, the MR1 deficient clones were unable to activate the MAIT clones 
and unable to drive cytokine release (Figure 5.11). These findings suggest that the MR1 
deficient A549 clones were unable to present bacterial antigens through MR1 on the cell 
surface. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.11. MR1 deficient A549 clones C9 and C11 infected with M. smegmatis fail to activate The D481A9 and 426B1 MAIT clones. The 
concentration of MIP-1 produced by the D481A9 MAIT cell clone (A) and D426B1 MAIT cell clone (B), were quantified by ELISA. The 
concentration of IFN- was also measured for the D481A9 MAIT cell clone (C) and D426B1 MAIT cell clone (D). Standard error of the mean 
values for 3 replicates are shown; data are representative of 3 experiments. 
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5.4.10 MR1 mutations do not affect the expression of classical HLA molecules 
in A549s. 
To assess whether the expression of classical HLA molecules was altered in MR1 deficient 
A549 cells the A549 WT and MR1 deficient cells were stained with a pan class I antibody and  
the expression was analysed by flow cytometry, an unpaired T test revealed there was no 
significant difference between the WT or MR1 deficient cells. WT and MR1 deficient cells 
were pulsed with the HLA- B*1801 restricted SELEIKRY peptide derived from EBV BZLF1173-
180 at concentrations ranging from 10
-6 to 10-10 M. The SELEIKRY-specific T-cell clone was 
incubated with the peptide pulsed A549 for 16 h after which an IFN-γ and MIP-1β ELISA 
were performed with the supernatants (Figure 5.12). The MR1 deficient A549 clones C9 and 
C11 were able to present the SELEIKRY peptide derived from the EBV protein by HLA-
B*1801 and activate the SELEIKRY-specific T-cell clone in a similar manner to the WT A549s 
as evidenced by equivalent cytokine release in peptide titration experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 137 
 
10 - 1 0 10 - 9 10 - 8 10 - 7 10 - 6 10 - 5
0
500
1000
1500
2000 WT A549
MR1-/- Clone 9
MR1 -/- Clone 11
Peptide conc (M)
IF
N
- 
 c
o
n
c
 (
p
g
/m
l)
10 - 1 0 10 - 9 10 - 8 10 - 7 10 - 6
0
500
1000
1500
2000
2500 WT A549
MR1-/- Clone 9
MR1 -/- Clone 11
Peptide conc (M)
M
IP
-1

 c
o
n
c
 (
p
g
/m
l)
A B 
C D 
Isotype  
WT A549 
Clone 11 
Clone 
9 
anti pan MHCI (APCY) 
10 - 1 0 10 - 9 10 - 8 10 - 7 10 - 6 10 - 5
0
500
1000
1500
2000 WT A549
MR1-/- Clone 9
MR1 -/- Clone 11
Peptide conc (M)
IF
N
- 
 c
o
n
c
 (
p
g
/m
l)
10 - 1 0 10 - 9 10 - 8 10 - 7 10 - 6
0
500
1000
1500
2000
2500 WT A549
MR1-/- Clone 9
MR1 -/- Clone 11
Peptide conc (M)
M
IP
-1

 c
o
n
c
 (
p
g
/m
l)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.12. MR1 disruption does not affect HLA class I expression. A) A549 WT and the MR1 deficient clones were stained with an 
isotype control or the pan class 1 antibody. The MFI values determined by flow cytometry were 56.4 (isotype control), 8,733 (WT A549), 
9,880 (clone 11) and 8,682 (clone 9). B) The MFI from 3 surface stainings with the pan class I antibody. The MFI data points are plotted in 
addition to mean values and the standard error bars. There is no significant difference in expression of classical MHC expressed by the WT 
or MR1 deficient clones C9 and C11, the P values were 0.81 and 0.94 respectively. C + D) The WT and MR1 deficient A549 cells were pulsed 
with the HLA-B*1801 restricted SEL peptide and incubated with the B9 T cell clone for 16 h after which  the supernatants were used to 
perform IFN-γ and MIP-1β ELISA (C and D respectively). 
 
 
 
5.4.11 Generation of MR1-/- THP-1 clones. 
The ‘all-in-one’ system was used to knockout MR1 in the THP-1 cell line to further 
demonstrate the versatility of this CRISPR/Cas9 system for targeted gene knockout. The 
crRNA A was expressed in THP-1 cells either transiently by lipofectamine transfection or 
stably by lentiviral transduction alongside a GFP control to establish the efficiency of 
transfection/transduction. The lipofectamine transfection was not a viable method for 
introducing the plasmid encoding the crRNA sequence into THP-1 as the efficiency was 
extremely low. However, the lentiviral transduction approach led to sufficient knockout to 
generate MR1 deficient THP-1 cells. 
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MR1 deficient THP-1 clones were generated by two methods from the bulk transduced THP-
1 cells. Either the bulk transduced THP-1 cells were infected with M. smegmatis and 
incubated with the D481A9 MAIT clone as described in section 2.3.16 which allowed for an 
enrichment of MR1 deficient THP-1 cells. Clones were then derived from the surviving cells 
by limiting dilution.  Alternatively, the MR1low cells were sorted from the bulk transduced 
THP-1 cells by flow cytometry. Clonal derivatives were produced by limiting dilution. 20 
clones were generated by limiting dilution of the THP-1 cells after selection with the D481A9 
MAIT clone and 10 clones were generated by limiting dilution of the THP-1 after cell sorting. 
 
The bulk population of cells derived by the enrichment process had a substantially reduced 
MFI compared to the WT cells (Figure 5.13A). The level of MR1 expressed by the 20 clones 
produced by MAIT enrichment and 10 clones produced by flow cytometry sorting was 
greatly reduced relative to the WT THP-1 cells (Figure 5.13B and D). The 5 clones expressing 
the lowest levels of MR1 on the cell surface for both the MAIT enrichment and flow 
cytometry sorting methods were subjected to a Surveyor assay. Mismatches were observed 
in the 10 clones produced indicating that mutations had been induced at a DNA level 
relative to the WT sequence (Figure 5.13C and E). 
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Figure 5.13. Generation of MR1 deficient THP-1 cells. THP-1 cells were transduced with CRISPR/Cas9 MR1 crRNA A by lentiviral 
transduction and the MR1 deficient THP-1 cells were enriched by MAIT cell selection with the 426B1 cell clone to derive MR1 deficient 
clones. A) Flow cytometry analysis of MR1 expression in THP-1 cells transduced with MR1 CRISPR/Cas9 lentiviral particles before and after 
enrichment of MR1 deficient cells by selection with the 426B1 MAIT clone MFI values were: Unstained 45.5, isotype control 53.9, WT THP-
1 1033, pre-selection edited cells 820 and post-selection edited cells 161. B) The 20 clones produced after single cell cloning of the THP-1 
cells after MAIT enrichment were stained with the MR1 antibody or an isotype control alongside the wildtype THP-1 cells. C) Surveyor 
assay performed on the WT and 5 clones (1.3, 1.6, 1.7, 1.11 and 1.13) which expressed the lowest levels of MR1 on the cell surface. Cel-I 
digested PCR amplicon homoduplex of WT THP-1 cells (lane 2), heteroduplexes of WT THP-1 cells DNA hybridized with DNA from bulk-
transduced THP-1 pre- (lane 3) and post-selection (lane 4), as well as clones 1.3 (lane 5), 1.6 (lane 6), 1.7 (lane 7), 1.11 (lane 8) and 1.13 
(lane 9). The Surveyor assay was performed with a total of 500 ng of PCR amplicon obtained from genomic DNA of unmodified THP-1 cells 
or from the different bulk and clonal populations. 
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5.4.12 THP-1 mutant clones infected with M. smegmatis bacteria selectively 
fail to activate MAIT cell clone D481. 
In order to determine whether the MR1 deficient THP-1 clones were able to function as 
APCs, the 10 THP-1 clones (C1.3, C1.6, C1.7, C1.11, C1.13, C2.1, C2.5, C2.7, C2.9 and C2.10) 
were infected with M. smegmatis and then incubated with the D481 A9 MAIT clone for 16 h. 
The supernatants were collected and used to perform an IFN-γ ELISA. The 10 THP-1 clones 
failed to activate the D481 MAIT clone relative to the WT THP-1 cells which were able to 
activate the D481 A9 clone as determined by the production and secretion of IFN-γ (Figure 
5.14). The results indicated that the mutations in the DNA of the MR1 gene lead to a loss of 
a functional MR1 protein. 
 
 
 
 
 
Figure 5.14. MR1 deficient THP-1 clones infected with M. smegmatis bacteria fail to activate the D481A9 MAIT clone. The concentration 
of IFN-γ produced by the D481A9 MAIT cell clone after a 16 h incubation with (A) the 5 MR1 deficient THP-1 clones derived by MAIT-cell 
enrichment and B) the 5 MR1 deficient THP-1 clones derived by cell sorting. ELISAs were carried out in triplicate wells. The mean and 
standard error of the mean values are shown. 
 
 
5.4.13 Genotype characterization of disruptive mutations in the MR1 gene of 
THP-1 MR1-/- clones 
5 clones were selected for downstream analysis (clone 2.1, 2.5, 2.7, 2.9 and 2.10) as they 
were generated without infecting the clones with M. smegmatis. To establish the mutations 
present in the 5 THP-1 MR1-/- clones the DNA was amplified, cloned and sequenced as 
described for the A549s in section 5.4.6. Clones 1, 5 and 10 harboured a biallelic single 
nucleotide deletion in the crRNA binding sequence 4 bp downstream of the PAM sequence. 
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Clone 7 harboured a biallelic 33bp deletion encompassing the entire crRNA. Clone 9 
harboured a single nucleotide deletion on allele 1 crRNA binding sequence 4 bp 
downstream of the PAM sequence and a 45bp deletion on allele 2 which encompassed the 
entire crRNA. All of the single nucleotide deletions identified in the THP-1 clones were 
identical to that observed in the A549 clone 9 allele 2 and both alleles of clone 11 (Figure 
5.15A). The amino acid sequence was interrupted from amino acid position 34 onwards in 
the case of clone 2.1 allele 1 and 2, clone 2.5 allele 1 and 2, clone 2.9 allele 2 and clone 2.10 
allele 1 and 2. Clone 2.7 allele 1 and 2 had an 11 amino acid deletion from amino acid 
position 32 to 43 and clone 9 allele 1 had an 15 amino acid deletion from amino acid 
position 27 to 42 (Figure 5.15B). 
 
Sample DNA sequence 
WT  GGACGCACTCTCTGAGATATTTTCGCCTGGGCGTTTCGGATCCCATCCATGGGGTCCCTGAATTTATTT  
1 a1 
1 a2 
GGACGCACTCTCTGAGATATTTTCGCCTGGGCGTTTCGGATCCCATCCATGGGGTCCCTGAATTTATTT 
GGACGCACTCTCTGAGATATTTTCGCCTGGGCGTTTCGGATCCCATCCATGGGGTCCCTGAATTTATTT 
5 a1 
5 a2 
GGACGCACTCTCTGAGATATTTTCGCCTGGGCGTTTCGGATCCCATCCATGGGGTCCCTGAATTTATTT 
GGACGCACTCTCTGAGATATTTTCGCCTGGGCGTTTCGGATCCCATCCATGGGGTCCCTGAATTTATTT 
7 a1 
7 a2 
GGACGCACTCTCTGAGATATTTTCGCCTGGGCGTTTCGGATCCCATCCATGGGGTCCCTGAATTTATTT 
GGACGCACTCTCTGAGATATTTTCGCCTGGGCGTTTCGGATCCCATCCATGGGGTCCCTGAATTTATTT 
9 a1 
9 a2 
GGACGCACTCTCTGAGATATTTTCGCCTGGGCGTTTCGGATCCCATCCATGGGGTCCCTGAATTTATTT 
GGACGCACTCTCTGAGATATTTTCGCCTGGGCGTTTCGGATCCCATCCATGGGGTCCCTGAATTTATTT 
10 a1 
10 a2 
GGACGCACTCTCTGAGATATTTTCGCCTGGGCGTTTCGGATCCCATCCATGGGGTCCCTGAATTTATTT 
GGACGCACTCTCTGAGATATTTTCGCCTGGGCGTTTCGGATCCCATCCATGGGGTCCCTGAATTTATTT 
 
 
Sample Amino acid sequence 
WT  SDSRTHSLRYFRLGVSDPIHGVPEFISVGYVDSHPITTYDSVTRQKEPRAPWMAENLAPDHWERYTQLLR 
1 a1 
1 a2 
SDSRTHSLRYFRLGFRIPSMGSLNLFRLGTWTRTLSPHMTVSLGRRSHGPHGWQRTSRLITGRGTLSC! 
SDSRTHSLRYFRLGFRIPSMGSLNLFRLGTWTRTLSPHMTVSLGRRSHGPHGWQRTSRLITGRGTLSC! 
5 a1 
5 a2 
SDSRTHSLRYFRLGFRIPSMGSLNLFRLGTWTRTLSPHMTVSLGRRSHGPHGWQRTSRLITGRGTLSC! 
SDSRTHSLRYFRLGFRIPSMGSLNLFRLGTWTRTLSPHMTVSLGRRSHGPHGWQRTSRLITGRGTLSC! 
7 a1 
7 a2 
SDSRTHSLRYF- - - - - - - - - - - PEFISVGYVDSHPITTYDSVTRQKEPRAPWMAENLAPDHWERYTQLLR 
SDSRTHSLRYF- - - - - - - - - - - PEFISVGYVDSHPITTYDSVTRQKEPRAPWMAENLAPDHWERYTQLLR 
9 a1 
9 a2 
SDSRTH - - - - - - - - - - - - - - FPEFISVGYVDSHPITTYDSVTRQKEPRAPWMAENLAPDHWERYTQLLR 
SDSRTHSLRYFRLGFRIPSMGSLNLFRLGTWTRTLSPHMTVSLGRRSHGPHGWQRTSRLITGRGTLSC! 
10 a1 
10 a2 
SDSRTHSLRYFRLGFRIPSMGSLNLFRLGTWTRTLSPHMTVSLGRRSHGPHGWQRTSRLITGRGTLSC! 
SDSRTHSLRYFRLGFRIPSMGSLNLFRLGTWTRTLSPHMTVSLGRRSHGPHGWQRTSRLITGRGTLSC! 
 
Figure 5.15. Analysis of the mutations induced in the MR1 gene of MR1 deficient THP-1 clones A) The DNA sequence of the WT THP-1 
cells is shown on top and each allele of the 5 MR1 deficient clones is shown. The PAM sequence is highlighted in blue and the crRNA 
sequence is highlighted in yellow. Deletions are shown as red letters with a strikethrough. Blue letters represent nucleotides present in 
exon 2 of the MR1 gene. B) The amino acid sequences were determined by translating the DNA sequence into the corresponding amino 
acid. Amino acids altered by a frameshift are highlighted in grey and deleted amino acids are shown by ‘–‘. 
A 
B 
A 
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5.4.14 MR1 mutations do not affect the expression of classical HLA I 
molecules in THP-1. 
To establish whether the expression of classical MHCI was altered in the 5 THP-1 MR1-/- 
clones relative to the WT THP-1 cells the MR1 deficient and WT THP-1 cells were stained 
with pan MHC class I antibody. There was no significant difference in the levels of MHCI on 
the surface of the WT or the 5 THP-1 MR1-/- clones suggesting that targeting the MR1 for 
gene knockout had no effect on the expression of MHCI molecules as shown by Figure 5.16.  
An unpaired T test revealed that there was no significant difference between expression of 
classical MHC on the surface of the WT and THP-1 clones. 
 
 
 
Figure 5.16. Expression of Pan MHCI in MR1 deficient THP-1 cells. A) The WT and the 5 THP-1 clones were stained with either an isotype 
control or with the pan MHC I antibody and the cells were analysed by flow cytometry. In MR1 deficient cells the expression of pan MHCI 
on the cell surface was not affected. The MFIs were isotype (22.5), WT (8051), C1 (7785), C5 (8025), C7 (8696), C9 (7914) and C10 (8244). 
B) The cells were stained in triplicate and the expression of pan MHCI was determined by flow cytometry. Individual MFI data points as 
well as mean values and standard error of the mean are shown. There was no significant difference between the expression of classical 
MHC on the WT and MR1 deficient clones. The P values were 0.4041, 0.6419, 0.7775, 0.6307 and 0.8515 for clone 1, 5, 7, 9 and 10 
respectively. 
 
5.4.15 Generation of MR1-/- MM909.24 clones 
To further validate that the ‘all in one’ CRISPR/Cas9 system developed during this project 
was an effective system for producing MR1-/- cells, the MM909.24 tumour cell line was also 
targeted. The crRNA A was expressed either by lipofectamine transfection or by lentiviral 
transduction alongside a GFP control to establish the efficiency of transfection/transduction. 
Similarly to the THP-1 cells, the lipofectamine transfection was not a suitable method for 
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introducing the plasmid encoding the crRNA sequence into MM909.24 cells as the efficiency 
was extremely low. However, MR1 deficient MM909.24 cells were generated using the 
lentiviral transduction approach. Unlike the A549 and THP-1 cells the MM909.24 stained 
poorly for MR1 even after incubation with 6-f-p as analysed by flow cytometry. MR1 
deficient clones were produced by incubating the bulk transduced MM909.24 cells with the 
MC7G5 MR1-restricted T-cell clone which enriched the MR1neg MM909.24 cells. 21 clones 
were isolated from the enriched cells by single cell cloning. As the MM909.24 cells 
expressed low levels of MR1 on the cell surface, the MR1 deficient cells were identified by 
incubating the WT MM909.24 and the 21 clones with the MC7G5 MR1-restricted T-cell 
clone for 16 h and performing a MIP-1β and a TNF-α ELISA with the supernatants to assess 
whether the clones could activate the MAITs at a similar level to the WT MM909.24 cells. 
The 21 clones appeared to be MR1 deficient as they were unable to activate the MC7G5 
MAIT clone unlike the WT MM909.24 which was able to activate the MC7G5 MR1-resticted 
T-cell clone and induce the production of MIP-1β and TNF-α (Figure 5.17A and B). A surveyor 
assay was performed as described in section 2.4.12 using DNA extracted from the WT, pre 
selection, post selection and clones 1, 4, 8, 9 and 11. Mismatches at the crRNA locus were 
expected to produce two products (approximately 520 and 330 bp) after digestion with the 
Cel1 mismatch specific enzyme. Mismatches were observed in all 5 of the clones tested 
(Figure 5.17C) 
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Figure 5.17. Phenotypic characterisation of MM909.24 clones generated by selection with the MC7G5 MR1 restricted T-cell clone. The 
21 clones and WT MM909.24 cells were incubated it the MC7G5 MR1-restricted clone for 16 h after which the supernatants were 
collected and used to perform ELISAs to determine the concentration of A) MIP-1β and B) TNF-α produced respectively. C) The surveyor 
assay was performed on the WT (lane 1), pre-selection (lane 2), post-selection (lane 3) and clones 1 (lane 4), 4 (lane 5), 8 (lane 6), 9 (lane 
7) and 11 (lane 8). The surveyor assay was performed using 500ng of DNA which was amplified using the MR1_SURV2_Fwd and 
MR1_SURV2_Rev primers amplified and annealed DNA from the WT and each of the clones. The red arrows indicate the presence of 
additional products for each of the clones. 
 
5.4.16 Genotype characterization of disruptive mutations in the MR1 gene of 
MM909.24 MR1-/- clones 
DNA was extracted from 5 of the MR1 deficient MM909.24 clones (clones 1, 4, 8, 9 and 11) 
in order to characterise the mutations present in the MR1 gene. The DNA was sequenced as 
described for the A549 and THP-1 cells by amplifying the DNA flanking the crRNA 
sequencing with  MR1_SURV_Fwd_BsaI and MR1_SURV_Rev_BsaI primers which bound 
upstream and downstream of the crRNA respectively and introduced BsaI restriction site to 
the PCR product. The amplified DNA was cloned into a cloning vector (Addgene#32189). 10 
colonies were selected for each MM909.24 clone and a miniprep of DNA was prepared and 
sequenced by Sanger sequencing. 
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On allele 1 of clone 1 there was a 91bp deletion and a nucleotide substitution (A>G) on the 
5’ end of the crRNA sequence. On allele 2 of clone 1 there was a 23bp deletion (Figure 
5.18A). There was a 7bp deletion on allele 1 of clone 4 that encompassed the PAM sequence 
and 4bp of the crRNA, on allele 2 there was a 2bp deletion within the crRNA sequence. 
Clone 8 contained a biallelic single nucleotide deletion 4 bp from the PAM sequence. There 
was a biallelic single nucleotide deletion 4 bp from the PAM sequence on both alleles of 
clone 9, with the second allele containing an addition single base pair deletion 3bp from the 
PAM sequence. Both alleles of clone 11 encompassed a single bp deletion, on allele one the 
deletion was 4 bp from the PAM sequence and on allele 2 the deletion was 3 bp from the 
PAM sequence (Figure 5.18B). 
 
Each mutation resulted in a frameshift the MR1 reading frame (Figure 5.18A and B). Thus, if 
these mutated alleles do express any protein it will not be functional MR1 (Figure 5.18C). 
The amino acid sequence of clone 1 is disrupted from amino acid 23 on allele 1 and amino 
acid 32 on allele 2 (Figure 5.18C). The amino acid sequence of clone 4 is disrupted from 
amino acid 32 on allele 1 and amino acid 33 on allele 2. The amino acid sequence of clone 8 
and 9 is disrupted from amino acid 34 on both alleles. The amino acid sequence of clone 11 
is disrupted from amino acid 34 on allele 1 and amino acid 33 on allele 2. 
 
The lack of MAIT cell activation and the mutations presence within the MR1 gene suggest 
that the CRISPR/Cas9 system effectively abrogated MR1 expression from the cell surface of 
these MM909.24 clones. 
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A 
Sample DNA sequence 
WT  
 
GCAGTTGAAGGATCTGGATCATCTGGGACCCTACATGTCTTCCTTCTTTGCCTCCTTTCCAGGGACGCACTC
TCTGAGATATTTTCGCCTGGGCGTTTCGGATCCCATCCATGGGGTCCCTGAATTTATTT 
C1 a1 
 
GCAGTTGAAGGATCTGGATCATCTGGGACCCTACATGTCTTCCTTCTTTGCCTCCTTTCCAGGGAC 
GCACTCTCTGAGATATTTTCGCCTGGGCGTTTCGGATCCCATCCGTGGGGTCCCTGAATTTATTT 
C1 a2 GCAGTTGAAGGATCTGGATCATCTGGGACCCTACATGTCTTCCTTCTTTGCCTCCTTTCCAGGGACGCACTC
TCTGAGATATTTTCGCCTGGGCGTTTCGGATCCCATCCATGGGGTCCCTGAATTTATTT 
 
B 
Sample DNA sequence 
WT GGACGCACTCTCTGAGATATTTTCGCCTGGGCGTTTCGGATCCCATCCATGGGGTCCCTGAATTTATTT 
C4 a1 
C4 a2 
GGACGCACTCTCTGAGATATTTTCGCCTGGGCGTTTCGGATCCCATCCATGGGGTCCCTGAATTTATTT 
GGACGCACTCTCTGAGATATTTTCGCCTGGGCGTTTCGGATCCCATCCATGGGGTCCCTGAATTTATTT 
C8 a1 
C8 a2 
GGACGCACTCTCTGAGATATTTTCGCCTGGGCGTTTCGGATCCCATCCATGGGGTCCCTGAATTTATTT 
GGACGCACTCTCTGAGATATTTTCGCCTGGGCGTTTCGGATCCCATCCATGGGGTCCCTGAATTTATTT 
C9 a1 
C9 a2 
GGACGCACTCTCTGAGATATTTTCGCCTGGGCGTTTCGGATCCCATCCATGGGGTCCCTGAATTTATTT 
GGACGCACTCTCTGAGATATTTTCGCCTGGGCGTTTCGGATCCCATCCATGGGGTCCCTGAATTTATTT 
C11 a1 
C11 a2 
GGACGCACTCTCTGAGATATTTTCGCCTGGGCGTTTCGGATCCCATCCATGGGGTCCCTGAATTTATTT 
GGACGCACTCTCTGAGATATTTTCGCCTGGGCGTTTCGGATCCCATCCATGGGGTCCCTGAATTTATTT 
 
C 
Sample Amino acid sequence 
WT SDSRTHSLRYFRLGVSDPIHGVPEFISVGYVDSHPITTYDSVTRQKEPRAPWMAENLAPDHWERYTQLLR 
C1 a1 
C1 a2 
SDSLGSHPWGP! 
SDSRTHSLRYFRWGP! 
C4 a1 
C4 a2 
SDSRTHSLRYFRFRIPSMGSLNLFRLGTWTRTLSPHMTVSLGRRSHGPHGWQRTSRLITGRGTLSC! 
SDSRTHSLRYFRLRFGSHPWGP! 
C8 a1 
C8 a2 
SDSRTHSLRYFRLGFRIPSMGSLNLFRLGTWTRTLSPHMTVSLGRRSHGPHGWQRTSRLITGRGTLSC! 
SDSRTHSLRYFRLGFRIPSMGSLNLFRLGTWTRTLSPHMTVSLGRRSHGPHGWQRTSRLITGRGTLSC! 
C9 a1 
C9 a2 
SDSRTHSLRYFRLGFRIPSMGSLNLFRLGTWTRTLSPHMTVSLGRRSHGPHGWQRTSRLITGRGTLSC! 
SDSRTHSLRYFRLGFGSHPWGP! 
C11 a1 
C11 a2 
SDSRTHSLRYFRLGFRIPSMGSLNLFRLGTWTRTLSPHMTVSLGRRSHGPHGWQRTSRLITGRGTLSC! 
SDSRTHSLRYFRLAFRIPSMGSLNLFRLGTWTRTLSPHMTVSLGRRSHGPHGWQRTSRLITGRGTLSC! 
 
Figure 5.18. Characterisation of the MM909.24 clonal derivatives in the MR1 gene. A) The DNA sequence of the MR1 gene was 
determined by Sanger sequencing. The WT sequence is shown above and both alleles of clone 1 are shown below. B) The DNA sequence of 
the region flanking the crRNA binding sequence of MR1 in clones 4, 8, 9 and 11 was determined by Sanger sequencing. The WT sequence 
is shown above and all alleles of the clones are shown below. Nucleotide substitutions are shown as green highlighted letters. Deletions 
are shown as red strikethrough letters. Nucleotides in exon 2 of the MR1 gene are blue in colour and nucleotides in the intron upstream of 
exon 2 are shown as black letters. C) The predicted amino acid sequence was determined by translating the DNA sequences. The WT 
amino acid sequence from position 20 to 90 is shown above. Out of frame reads are highlighted in grey. Stop codons appear as ‘!’. (C1 = 
clone 1, C4 = clone 4, C8 = clone 8, C9 = clone 9, C11 = clone 11, a1 = allele 1 and a2 = allele 2. 
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A 
Isotype 
WT 
Clone 1 
Clone 4 
Clone 8 
Clone 9 
Clone 11 
B 
anti pan MHC class I (APCY)  
5.4.17 Mutations do not affect the expression of classical HLA molecules in 
MM909.24s. 
The WT and 5 MR1 deficient MM909.24 clones characterised in section 5.4.16 were stained 
with pan MHC class I antibody and analysed by flow cytometry to assess whether knocking 
out MR1 affected the expression of the classical MHC on the cell surface. There was no 
significance difference in the expression of the classical MHC molecules on the cell surface 
the WT MM909.24 and MR1-/- clones (Figure 5.19).  
 
 
 
 
 
Figure 5.19. Expression of Pan MHCI in MR1 deficient MM909.24 cells. A) The WT and the 5 MM909.24 clones were stained with either 
an isotype control or with the pan MHCI antibody and the cells were analysed by flow cytometry. In MR1 deficient cells the expression of 
pan MHCI on the cell surface was not affected. The MFIs were isotype (19.5), WT (815), C1 21), C4 (613), C8 (785), C9 (610) and C11 (764). 
B) The WT, clone 4 and clone 11 cells were stained in triplicate and the expression of pan MHC I was determined by flow cytometry. 
Individual MFI data points as well as mean values and standard error of the mean are shown. There was no significance difference in pan 
MHCI expression between WT and the MR1 deficient MM909.24 clones. The p values were 0.3195 and 0.1109 for clones 4 and 11 
respectively. 
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5.5 Discussion 
Since the CRISPRCas9 system was first used for gene editing in 2013 (Mali et al. 2013; van 
der Oost 2013; Cong et al. 2013) it was been shown to be an efficient and reliable tool for 
knocking out a broad spectrum of human genes (Sanjana et al. 2014) in a range of cell lines 
and primary cells. As part of this project an “all-in-one” lentiviral vector single plasmid 
system was produced which allowed for simultaneous delivery of the Cas9 endonuclease 
and an associated gRNA sequences by modifying the two plasmid system produced by Mali 
et al. 2013. Five crRNA target sequences were designed to target the MR1 gene, after an 
initial screen in a reporter system a superior crRNA sequence (crRNA A) was identified. The 
CRISPR/Cas9 system with the verified crRNA sequence was efficient at inducing targeting 
knockout of the MR1 gene and was used to produce MR1 deficient A549, THP-1 and 
MM909.24 clones.  MR1 deficient A549 clones were derived by cell sorting MR1low cells 
from the bulk transfected A549 and deriving clones by limiting dilution, 16 clones were 
screened by flow cytometry and 8 clones were observed to consistently express MR1 MFIs 
lower than the parental cells. A surveyor assay was performed on the 3 clones expressing 
the lowest levels of MR1, which revealed that mismatches were present at a DNA level in 2 
of these clones. MR1 deficient THP-1 clones were derived by either positive enrichment 
with MAIT cells or by cell sorting the MR1low cells from the bulk transduced cells, in each 
case clones were derived through limiting dilution. The 20 clones derived from positive 
enrichment with MAIT cells and 10 clones derived from cell sorting were stained and the 
surface expression of MR1 was assessed. All of the clones appeared to be MR1 deficient. A 
surveyor assay was performed on 5 clones derived from positive enrichment with MAIT cells 
and 5 clones derived by cell sorting, leading to the confirmation of mismatches in all 10 
clones. MR1 deficient MM909.24 clones were derived by selection with an MR1-restricted 
T-cell clone and MM909.24 clones were derived by limiting dilution. The 21 MM909.24 
clones were determined to be MR1 deficient as they were unable to activate the MR1-
restricted clone (MC7GS). A surveyor assay was performed on 5 of the clones, which 
revealed that mismatches were present in each of the 5 clones. As all of the THP-1 and 
MM909.24 clones derived from positive selection were unable to activate MAIT cells 
confirms that the positive selection approach is an effective method of selecting a 
potentially low frequency of MR1 deficient cells from a bulk population of cells. The positive 
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selection approach would be particularly beneficial in the context of primary cell lines. 
Disruption of the MR1 gene completely abrogated the level of MR1 expressed at the cell 
surface and the cells ability to present and activate MAIT cells when the clones are infected 
with M. smegmatis in the case of the A549 and THP-1 clones. In the case of the MM909.24 
MR1 deficient clones the mutant forms of MR1 completely abrogated the cells ability to 
present to an MR1-restricted T cell. The MR1 deficient A549, THP-1 and MM909.24 clones 
produced were found to harbour mutations at a DNA level (as identified by Surveyor assay 
and Sanger sequencing of the region flanking the crRNA). Processing and presentation of 
antigen through the classical MHCI pathway was shown to be unaffected indicating that the 
CRISPR/Cas9 induced gene editing was specific for the MR1 gene.  
 
5.5.1 Lipofectamine transfection vs lentiviral transduction approaches 
The A549, THP-1 and MM909.24 cell lines were transfected transiently with lipofectamine 
and transduced stably with lentivirus. An MR1 deficient population was observable in the 
A549 cells using both approaches (Figure 6.4). In contrast, lipofectamine transfection in 
THP-1 and MM909.24 was very poor and MR1 deficient clones were generated by lentiviral 
transduction. There were no apparent adverse effects observed in cells transduced with the 
lentivirus. However, the lipofectamine approach is preferred as continuous expression of 
the CRISPR/Cas9 elements may have potential off target effects at later time points as Cas9 
is continually transcribed.  
 
5.5.2 Monitoring of MR1 expression on the surface of different cell lines 
To confirm that CRISPR/Cas9 was a valid approach to knockout MR1 from cell lines the A549 
were chosen to initially test the approach and once validated I extended the approach to 
THP-1 and MM909.24 cell lines. In the case of the A549s the cells required a 16 h incubation 
with 6-f-p to enhance the expression of MR1 on the cell surface after which a population of 
MR1 deficient cells was identifiable from the bulk transfected population. The THP-1 cell line 
expressed sufficient MR1 on the cell surface that the cells did not need to be pre-treated 
with 6-f-p prior to staining. Even after incubation with 6-f-p there were not sufficient levels 
of MR1 on the cell surface of MM909.24 cells to be detectable using a fluorochrome 
conjugated MR1 antibody. 
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5.5.3 Characterisation of mutations within the MR1 gene of the A549, THP-1 
and MM909.24 clonal derivatives  
Sanger sequencing revealed that mutations had been introduced into the MR1 loci in all of 
the A549, THP-1 and MM909.24 clones sequenced. Of particular note are A549 clone 9 
allele 1 (126bp deletion), THP-1 Clone 7 allele 1 and 2 (33bp deletion), THP-1 clone 9 allele 1 
(45bp deletion), MM909.24 clone 1 allele 1 (91bp deletion) and MM909.24 clone 1 allele 2 
(23bp deletion) as each of these alleles encompasses a fairly large deletion. Large deletions 
are not typically observed as a result of NHEJ DNA repair. The mutations observed in the 
alleles of the remaining clones are more typically, of what is normally observed as a result of 
NHEJ DNA repair in the literature. 
 
5.5.4 Monitoring the expression of the classical MHCI molecules on the 
surface of the MR1 deficient clonal derivatives 
Despite there being little homology between the MR1 target sequence and sequences 
present within the other classical HLA genes, it was important to ensure that targeting MR1 
did not affect the expression of the other classical HLA molecules or interfere with the 
antigen presentation pathways. Although this method was not extensive, the analysis of the 
surface expression of classical HLA class I molecules in A549, THP-1 and MM909.24 clonal 
derivatives was not significantly different to the WT cell line (Figure 5.11 and 5.15). In 
addition, the presentation of cognate exogenous peptide to an HLA-B*1801-restricted CD8+ 
T-cell clone by the A549 derivatives led to production of cytokines at the same level in MR1 
deficient and unmodified A549 cells. Collectively, these results indicate that the expression 
and processing of HLA alleles and peptide presentation are intact within these cells.  
 
5.5.5 Monitoring of off target mutations 
The morphology and growth rate of the MR1 knockout cells were unaffected compared to 
the WT. However, this does not exclude other potential off target sites in other unrelated 
genes. To assess the frequency and occurrence of mutations in undesired off target sites 
whole genome sequencing was performed in the A549 clone 9 and 11. Several off target 
sites were predicted by the CRISPRdesign tool (MIT) and eCRISP software (German cancer 
research centre) (Table 1 and 2). In addition, analysis of the reads identified approximately 
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1400 sites where reads harboured potential off target mutations. Analysis of these sites 
manually did not identify any off target mutations. On target mutations were confirmed at 
the MR1 locus and at an additional unintentional target site within the RP11-46A10.6 
pseudogene which shared the crRNA target sequence with the MR1 gene. Interestingly, the 
mutations observed in both A549 clones (clone 9 and clone 11) within the RP11-46A10.6 
gene were identical to the most common mutation observed within the MR1 gene (a single 
base deletion at position 17 of the crRNA sequence). Although unintended, this mutation is 
considered on target as the crRNA sequence was present in both MR1 and the RP11-
46A10.6 gene. The initial assessment of potential off target sites using the BLAST tool did 
not identify the RP11-46A10.6 gene, as the BLAST tool was limited to coding genomic 
regions. Given that this RP11-46A10.6 gene is noncoding there should be no consequences 
to this off target mutation. The introduction of mutations within both the MR1 and RP11-
46A10.6 gene highlights both the high efficiency and specificity of the CRISPR/Cas9 system. 
Since the initial screening of the crRNA sequences was performed several algorithms have 
become available online (CRISPRdesign tool (MIT) and eCRISP software (German cancer 
research centre)) which allow for rapid identification of all potential off target sites within 
coding and non-coding DNA. These algorithms take into account data from previous studies 
which have shown that the 13 nucleotides proximal to the PAM sequence (3’ end) are 
crucial for crRNA binding. Differences between the target sequence and crRNA sequence at 
the 3’ end abolish binding and vastly reduce the frequency of gene editing. In contrast up to 
6 mismatches at the 5’ end of the crRNA sequence can be tolerated (Jinek et al. 2012). 
These algorithms can be used to identify crRNA sequences with low potential for off target 
binding. These programmes can be used to identify the most likely off target sites which can 
then by screened to assess the occurrence and frequency of off target mutations by 
amplicon sequencing to identify the presence of off target mutations at  a lower cost than 
whole genome sequencing. 
 
5.5.6 Summary 
In this chapter I produced an ‘all in one’ CRISPR/Cas9 plasmid which incorporated all of the 
CRISPR/Cas9 elements in a single plasmid as initial studies with CRISPR/Cas9 required 
multiple plasmids for gene disruption. Using this ‘all in one’ CRISPR/Cas9 system I generated 
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A549, THP-1 and MM909.24 clonal derivatives which were MR1 deficient. The clonal 
derivatives did not express MR1 on the cell surface and were unable to activate MAIT cells 
indicating that the cells were MR1 deficient. It is hoped that the cells produced in chapter of 
the thesis will be used to understand the biology of MR1 and MR1 restricted T-cells. We 
have already had many requests for these cells since publication in June this year (Laugel et 
al. 2016) and it seems likely that they will go on to make a substantial contribution to the 
field. Thus far, my laboratory has already collaborated to use these cells to confirm the 
existence of a new family of MR1-restricted T-cells that do not express the canonical TRAV1-
2 chains or recognise canonical MAIT antigens (Meermeier et al. 2016).  
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6 General discussion  
The discovery and development of gene editing tools that can induce targeted knockout of 
specific genes has been revolutionary by enabling researchers to study the function of 
proteins and pathways in ways not previously possible. Genome editing was awarded 
method of the year in 2011 by Nature (http://www.nature.com/nmeth/journal/v9/n1/full/ 
nmeth.1852.html), and genome engineering was runner up to breakthrough of the year 
awarded by Science in both 2012 and 2013.  More recently, the CRISPR/Cas9 system was 
awarded breakthrough of the year by Science in 2015 (Travis 2015). These awards serve to 
highlight the importance of the topic. 
 
6.1 Summary of work 
In this thesis, shRNA, ZFN and CRISPR/Cas9 gene editing tools were generated that targeted 
the CD8A gene as proof of concept. The shRNA, ZFN and CRISPR/Cas9 approaches all 
functioned, resulting in a CD8 negative population within the transduced cells. Of the 3 
approaches the CRISPR/Cas9 system was superior in terms of cost of production, ease of 
development and efficiency of gene knockout (chapter 3).  
 
A novel non-nuclease based gene silencing system was generated as an alternative to the 
current nuclease systems by fusing the ZFP targeting the CD8A gene to the KRAB repressor 
domain as proof of concept. This system was shown to induce silencing of CD8 in both the 
Molt3 cell line and primary CD8+ T-cells. The ZFP-KRAB fusion was combined in a single 
plasmid with a TCR which allowed for silencing of CD8 in combination with delivery of a TCR 
(chapter 4).  
 
A single plasmid system incorporating all of the CRISPR/Cas9 elements was developed to 
improve knockout efficiency of the two plasmid system described by Mali et al. 2013. The 
‘all in one’ CRISPR/Cas9 system was utilised to knock out MR1 from a range of APCs to 
generate MR1-deficient cells. The MR1 deficient APC clones derived during this project were 
infected with M. smegmatis were unable to activate MAIT cells clones indicating that the 
mutations induced by the CRISPR/Cas9 system abolished MR1 expression from the cell 
surface (Laugel et al. 2016) (chapter 5). 
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6.2 Implications of findings 
 
6.2.1 CRISPR/Cas9 system 
Of the three gene editing approaches utilised in this thesis the CRISPR/Cas9 approach was 
the most cost effective, most efficient and easiest system to modify to incorporate new 
targets, this corroborates with the published literature and thus CRISPR/Cas9 would be the 
approach of choice for inducing targeted knockout within cell lines. However, the safety of 
transducing cells modified with CRISPR/Cas9 into human patients has yet to be tested, with 
the first clinical trial for CRISPR/Cas9 being approved in July 2016 and commencing in 
August 2016 (Cyranoski 2016). There is currently an ongoing debate regarding the 
ownership of the CRISPR/Cas9 technology which once resolved could lead to licensing costs 
and future limitations to the use of CRISPR/Cas9 technology. This could have severe 
consequences for translational exploitation of CRISPR/Cas9 by researchers worldwide 
(Sherkow 2016). 
 
6.2.2 The ZF-KRAB approach  
The ZF-KRAB gene silencing approach which was developed during this thesis (chapter 4) 
was shown to be a valid alternative to the nucleases approaches. The ZF-KRAB construct 
induced gene silencing in the majority of transduced cells. The absence of nuclease activity 
is advantageous as it eliminates the risk of off-target DNA damaging DSBs within the DNA. 
Repair of DSBs can cause translocations and genomic instability which can lead to 
tumorigenesis (reviewed by Khanna & Jackson 2001; Aparicio et al. 2014). This ZF-KRAB 
gene silencing system could benefit T-cell based immunotherapies as the ZF-KRAB DNA 
sequence can be incorporated into a single plasmid with a TCR which would allow for 
targeted gene knockout and re-direction of a T-cell in a single plasmid. The knockout of PD1 
or CTLA-4 checkpoint inhibitors in primary T-cells while simultaneously introducing a 
tumour-specific TCR would be of particular interest as it would allow checkpoint control of 
only tumour-specific responses as opposed to the systemic blocking antibody approaches 
currently in use and that are known to induce autoimmune side effects. 
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6.2.3 Generation of MR1 deficient cells 
The APCs generated in this thesis will enable fundamental investigations into the biology of 
MR1 and MR1-restricted T-cells. 1) The use of MR1 deficient cells will help identify MR1 
restricted T-cells better than current techniques such as antibody blockade which can lead 
to incomplete blockade. The MR1 deficient A549 clones produced during this work have 
been used to identify a population of MR1 restricted T-cells which do not express the 
canonical TCR chains (Meermeier et al. 2016). 2) Using MR1 deficient APCs, in combination 
with WT APCs in in vitro activation experiments will allow for the characterisation and 
quantification of MR1-restricted T-cells within the bulk pathogen-specific T-cell response. 3) 
MR1 deficient cells may proof useful for delineating the mechanisms behind the processing 
and loading of antigen on MR1 molecules. Currently, whether T-cells can discriminate 
between distinct MR1 antigen complexes and the chemical and structural variability of 
bacterial antigens presented by MR1 is unknown. However, pulsing MR1 sufficient and 
deficient cells with chemically pure compounds could be utilised to assess the response of T-
cell clones with distinct TCR usage. 4) The production of MR1 deficient cell lines will enable 
researchers to experiment with altered versions of MR1 proteins to establish whether 
improved or chimeric versions can improve function and allow characterisation of the 
cellular biology of MR1 such as distribution in cellular compartments and trafficking. The 
invariant nature of MR1 across the population makes MR1 an attractive target for the 
development of therapeutic and diagnostic tools and thus further investigations into MR1 
biology and MR1-restricted T-cells may prove valuable for universal therapies. 
 
6.3 Implications of adoptive cell transfer with genetic engineered 
cells  
The process of adoptive cell therapy (ACT) of autologous tumour infiltrating lymphocytes to 
treat cancer was first described in 1988 (Rosenberg et al. 1988). Since this initial publication, 
ACT protocols have improved through lymphodepletion prior to ACT which was shown to 
improve the level of cancer regression (Dudley et al. 2002; Dudley et al. 2005) and 
administration of IL-2 which improved the therapeutic potency of T-cells (Rosenberg et al. 
1986). ACT has proven to be effective at inducing clearance of cancers in a variety of studies 
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(Yee et al. 2002; Mackensen et al. 2006). The transfer of T-cells genetically engineered to 
express cancer specific TCRs has resulted in successfully tumour clearance (Morgan et al. 
2006). The ZFN and CRISPR/Cas9 systems have great potential in the ACT setting as T-cells 
can be further engineered to improve function while simultaneously re-programming to 
target a specific antigen. The ZF-KRAB TCR system described in this thesis could potentially 
be utilised to genetically engineer cells for ACT by silencing genes such as those encoding 
immune checkpoint inhibitors and re-directing T-cells to target tumour associated antigens 
through the transfer of a tumour specific TCR.  
 
6.3.1 Long-term effects of genetic engineered cells 
There are several potential issues with transferring genetic engineered T-cells into patients, 
such as TCR chain mispairing, lentiviral integration into unknown sites in the genome and 
immunogenicity.   
 
6.3.1.1 TCR mispairing 
When transducing T-cells with a TCR there is potential for the TCR α or β chains to mispair 
with the endogenous TCR chains, resulting in the expression of a TCR with an unknown 
specificity. Such TCR mispairing in mice led to autoimmunity (Bendle et al. 2010), however 
this has not been recorded in human clinical trials (Rosenberg 2010). TCR mispairing has 
been shown to be minimised by the use of murinised TCRs which are expressed at higher 
levels in human T-cells than human TCRs (Cohen et al. 2006). Fusion of human TCR variable 
chains to mouse constant domains promotes pairing of the exogenous chains 
(Sommermeyer & Uckert 2010). Furthermore, an additional disulphide bond between the 
TCR α and β chains through the addition of an cysteine residues on each chain additionally 
promotes pairing of the exogenous chains (Kuball et al. 2007). Knocking out the expression 
of  the existing endogenous TCR chains using gene editing tools (Provasi et al. 2012) can also 
be used to minimise TCR chain mispairing. Finally transfer of CD3 components in addition to 
TCR α and β chains promotes pairing and surface expression of the exogenous TCR chains 
(Sebestyen et al. 2008; Ahmadi et al. 2011). While TCR chain mispairing might cause some 
problems, there are therefore several novel ways to minimise this potential problem. 
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6.3.1.2 Integrating versus non-integrating approaches for expression of gene editing 
tools 
Long-term expression of the gene editing tools and TCR chains in cells in this thesis was 
achieved by integrating lentiviral transduction. One of the major risks of integrating 
lentivirus as a delivery system is integration mutagenesis. Integration near a promoter may 
alter gene expression (Reviewed by Sinn et al. 2005) and integration near oncogenes can 
drive cellular proliferation and lead to the development of cancers (Hacein-Bey-Abina et al. 
2003). In addition, the transgene is continually expressed within the cell and in the case of 
TCR transduction this is desirable. In contrast, in the case of gene editing tools this could be 
problematic as continual expression of the nuclease protein may result in off target 
mutagenesis after transduction. Nevertheless, comparison of plasmid transfection and 
lentiviral transduction of ZFN resulted in similar levels of off target disruption (Cai et al. 
2014). There are alternative methods of transgene transfer including non-integrating 
lentivirus and plasmid transfection. Non-integrating lentiviral transduction has been 
successful used to express ZFNs transiently to induce knockout of the CCR5 gene (Holt, et al. 
2010). Cationic lipid based transfection methods have been used to transiently express gene 
editing tools in human cells (Miller et al. 2007; Zuris et al. 2014). The presence of mutations 
at undesired locations induced as an off target effect of gene editing tools can easily be 
detected by whole genome sequencing as performed in chapter 5 (Laugel et al. 2016) and 
other studies to detect off target effects (Smith et al.2014; Veres et al. 2014). 
 
6.3.1.3 Suicide genes 
To improve the safety of genetically engineered cells for ACT it would be advantageous to 
incorporate a suicide gene into the construct containing the gene editing tool, which would 
allow for eradication of transduced cells in the event of adverse effects post adoptive 
transfer. One way of inducing suicide is with the use of a prodrug. The first prodrug used for 
transduced T-cells which has been through clinical testing was Herpes simplex virus 
thymidine kinase/ ganciclovir (HSV-TK/ GCV). GCV was introduced into cells with an adeno 
associated virus. When active, HSV-TK phosphorylates GCV which interferes with DNA 
synthesis killing the transduced cells (Pan et al. 2012), however, this approach was slow as 
interference with DNA can take several days to induce cell death. As an alternative 
approach, a iCasp9 transgene was expressed in transduced cells, administration of the 
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AP1903 drug causes dimerization and activation of the iCasp9 gene resulting in the 
induction of the apoptotic pathway and cell death (Di Stasi et al. 2011).  
 
6.4 Future work 
The generation of CD8 deficient T-cells allows for investigation of the CD8 molecule in 
greater detail as previous studies have worked with antibody blocking (MacDonald et al. 
1982) or with mutated MHC (Laugel et al. 2007), whereas this approach would allow for 
studying T-cells with CD8 abolished from the cell surface. Comparison of T-cell activation in 
the presence and absence of the CD8 molecule ± HLA with and without the ability to engage 
CD8 will allow dissection of which CD8-mediated events occur via CD8-HLA interaction and 
those that are independent of this interaction and occur, for instance via the TCR-CD8 
interaction (Arcaro et al. 2000; Arcaro et al. 2001). There is potential to target many other 
genes encoding proteins expressed by T-cells, of particular interest are checkpoint inhibitors 
such as CTLA-4 and PD1 for which blocking antibodies have shown to be effective for 
tumour clearance in mice (Fecci et al. 2007; Hirano et al. 2005) and humans (Hodi et al. 
2010; Topalian et al. 2012). It is thought that cell specific knockout of checkpoint inhibitors 
will minimise the adverse effects that have been observed with systemic delivery of blocking 
monoclonal antibodies. There may also be the potential in future to modify and improve the 
function of TCR-modified Treg via gene knockout once the mechanisms by which these cells 
operate are delineated. 
  
There is potential to substitute the ZFP and TCR chains contained within the ZF-KRAB TCR 
construct to produce a toolkit of constructs that would allow for the generation of T-cells 
deficient in numerous checkpoint inhibitors with different specificities. These T-cells could 
be useful in determining whether this approach would have any benefit to the clinic. 
 
A loss of function was observed in the A549, THP-1 and MM909.24 as a result of an MR1 
deficiency, however, to validate this I plan to re-express the MR1 protein in these cells and 
repeat the M. smegmatis infection and activation experiments to show that function is 
restored upon re-expression of MR1. Another line of work which I wish to pursue is the 
generation of APCs deficient in members of the CD1 family, HLA-E or other MHCIb genes 
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that may serve as ligands for the TCR (Attaf et al. 2015). This would generate additional cell 
lines for the study of these other invariable T-cell ligands. 
 
6.4.1 Concluding remarks 
Gene editing tool technology has developed rapidly over recent years. To date there have 
been no studies which have compared all of the shRNA, ZFN and CRISPR/Cas9 systems in 
parallel. As part of this thesis I compared these systems. The CRISPR/Cas9 system was found 
to be the most efficient and cost effective system. Therefore, the CRISPR/Cas9 system 
would be the method of choice for generating knockout cells in the future.  
 
There are risks associated with the expression of nuclease proteins in cells to generate cells 
deficient in a target protein, particularly if these cells are to be transfused into patients for 
therapy. Therefore, a non-nuclease based gene silencing system was generated by the 
fusion of a ZFP targeting the CD8A gene to the KRAB repressor domain. This system was 
shown to induce silencing of the CD8 protein at levels comparable to the ZFN approach. The 
ZF-KRAB was cloned into a lentiviral vector alongside a TCR, enabling expression of a specific 
TCR and silencing of the CD8 as proof of concept. There is great potential for this system in 
the immunotherapy field as the ZF-KRAB approach would lead to specific gene silencing 
whilst eradicating DNA damage and breakages. Although not tested in this thesis there is 
potential to utilise ZFPs targeting PD-1, CTLA-4 or other checkpoint inhibitors in this system 
which could improve the functionality of transduced T-cells whilst simultaneously 
expressing an alternate TCR to redirect T-cells. 
 
Finally, an ‘all in one’ CRISPR/Cas9 system was developed which was effectively utilised to 
generate MR1 deficient clonal derivatives of the A549, THP-1 and MM909.24 cell lines. The 
generation of MR1 deficient cells will be useful for fundamental investigations into the 
biology of MR1 and MR1-restricted T-cells and the development of therapeutic and 
diagnostic tools which aim to utilise this invariant non-classical HLA molecule. It is hoped 
that the generation cell lines deficient in HLA-E, members of CD1 family and other MHCIb 
molecules will enable a greater understanding into the biology of the HLA-E, CD1 and other 
MHCIb molecules and the T-cells that recognise antigen presented by these molecules. 
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8 Appendix 
 
HLA-A2 heavy chain sequence: 
MGSHSMRYFFTSVSRPGRGEPRFIAVGYVDDTQFVRFDSDAASQRMEPRAPWIEQEGPEYWDGETRK
VKAHSQTHRVDLGTLRGYYNQSEAGSHTVQRMYGCDVGSDWRFLRGYHQYAYDGKDYIALKEDLRSW
TAADMAAQTTKHKWEAAHVAEQLRAYLEGTCVEWLRRYLENGKETLQRTDAPKTHMTHHAVSDHEA
TLRCWALSFYPAEITLTWQRDGEDQTQDTELVETRPAGDGTFQKWAAVVVPSGQEQRYTCHVQHEGL
PKPLTLRWEPGLNDIFEAQKIEWHE 
 
β2-microglobulin sequence: 
MIQRTPKIQVYSRHPAENGKSNFLNCYVSGFHPSDIEVDLLKNGERIEKVEHSDLSFSKDWSFYLLYYTEFT
PTEKDEYACRVNHVTLSQPKIVKWDRDM 
 
Appendix Figure 1. The amino acid sequence of the HLA-A2 heavy chain and β2-microglobulin. The biotin tag is underlined in red. 
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Appendix Table 1. Cloning methods used to generate each of the constructs used in this thesis. 
Plasmid 
Backbone 
Insert Cloning method Chapter 
pLKO.1 shRNA CD8 
shRNA MR1 
Inserts ordered were flanked by NdeI and EcoRI 
restriction sites. Inserts and pLKO.1 backbone were 
digested with NdeI and EcoRI enzymes. DNA was purified 
and ligated. 
3 
pRRL  LZFN 
RZFN 
The LZFN and RZFN DNA sequences were PCR amplified 
from the transfer plasmid using L_ZFN_XbaI_F or 
R_ZFN_XbaI_F and L_Fok1_NsiI_R or R_Fok1_NsiI_R to 
introduce XbaI and NsiI restriction sites, the PCR product 
was treated with DpnI. The treated PCR product and 
pRRLSIN.cPPT.PGK-GFP.WPRE 
backbone were digested with XbaI and NsiI. DNA was 
purified and ligated. 
3 
GECKO  CD8 crRNA 1  
CD8 crRNA 2  
CD8 crRNA 3  
CD8 crRNA 4  
CD8 crRNA 5 
Cloning is described in section 2.4.17.3 
 
 
 
 
3 
 
 
 
pRRL  ZF binding 
site (1x) 
ZF binding 
site (3x) 
The inserts ordered were flanked by XhoI restriction sites. 
The inserts and pRRLSIN.cPPT.PGK-GFP.WPRE 
backbone were digested with XhoI enzymes. DNA was 
purified and ligated. 
4 
 
pV2  HP1A 
KRAB 
ScanKRAB 
TRIM28  
ARP1 
GCN4 
SID 
pV2 backbone was amplified with pV2_ backbone_XbaI_ 
F and pV2_Age1prox_Rev to introduce AgeI and XbaI 
restriction sites, the PCR product was treated with DpnI. 
The treated PCR product and ZFP sequences (left or right) 
flanked with AgeI and XbaI were digested with AgeI and 
XbaI restriction enzymes. The DNA was purified was 
ligated. The pV2 backbone containing the LZF or RZF was 
PCR amplified with pV2_ZF_R_Codop_R or 
pV2_ZF_L_Codop_R and pV2_ backbone_XbaI_ F to 
introduce BamHI and XbaI restriction sites. The PCR 
products were treated with dpnI. The treated PCR 
product and each of the repressor domains was digested 
with BamHI and XbaI. The DNA was purified was ligated. 
4 
 
 
 
 
 
 
pRRL  RZF-KRAB The pV2 RZF-KRAB construct was PCR amplified with 
pV2_ZF_R_codop_BamHI_Forward and 
KRAB_Xba1_Reverse, the PCR product was treated with 
DpnI. The pRRL 2AGFP backbone and PCR product was 
digested with BamHI and XbaI. DNA was purified and 
ligated. 
4 
pRRL KRAB x The pRRL RZF-KRAB construct was amplified with  
ZFless_fwd and ZFless_rev primers to insert a NdeI 
restriction site upstream and downstream of the ZF 
sequence. The PCR product was treated with dpnI and 
digested with NdeI. DNA was purified and ligated. 
4 
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pELNSxv  rCD2 PPI 
 
The PPI TCRα and TCRβ chains separated by a 2A 
sequences were synthesised flanked by NheI and XhoI 
restriction sites. The pELNSxv backbone and TCR 
sequences were digested with NheI and XhoI. The DNA 
was purified and ligated. 
4 
 
 
 
pELNSxv CD8 KRAB 
PPI 
The pRRL R ZF KRAB construct was PCR amplified with 
pV2_ZF_R_codop_BamHI_Forward and 
KRAB_Sal1_Reverse, the PCR product was treated with 
DpnI. The PCR product and pELNsxv PPI CD8 KRAB 
backbone were digested with BamHI and SalI. DNA was 
purified and ligated.  
4 
 
pRRL MR1 crRNA 1 
MR1 crRNA 2 
MR1 crRNA 3 
MR1 crRNA 4 
MR1 crRNA 5 
Cloning is described in section 2.4.17.2 
 
5 
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Appendix Table 2. Name and sequence of all primers used in thesis 
Comments Primer name Sequence 
Primers to insert XbaI and NsiI 
restriction sites of pRRL LZFN 
cloning 
L_ZFN_XbaI_F TCTAGACAGTGTGGTGGAATTCGCC 
L_Fok1_NsiI_R  GTGACCGAGTTCAAGTTCCTGTTATGCAT  
Primers to insert XbaI and NsiI 
restriction sites of pRRL RZFN 
cloning 
R_ZFN_XbaI_F TCTAGAcagtgtggtggaattcgcc 
R_Fok1_NsiI_R  AACAACGGCGAGATCAACTTCATGCAT 
Primers to insert XbaI and 
AgeI restriction sites in pV2 
backbone for cloning 
pV2_ backbone_XbaI_ 
F  
tctagaaaaatcagcctcgactgtgccttc  
pV2_Age1prox_Rev Gcgcaccggtggtggccgtacgcc 
Primers to insert XbaI and 
BamHI restriction sites 
flanking the LZF and RZF for 
cloning 
pV2_ backbone_XbaI_ 
F  
tctagaaaaatcagcctcgactgtgccttc  
pV2_ZF_L_Codop_R  ggatccTGCGCAGATGGATTTT 
pV2_ZF_R_Codop_R ggatccGCGCAGATGGATCTT 
Primers to insert XbaI and 
BamHI restriction sites 
flanking the RZFKRAB for 
cloning 
pV2_ZF_R_codop_Ba
mHI_Forward  
ggatccATGCGGTCAGACTACAAAG 
KRAB_Xba1_Reverse  tctagattaAACCAGCCAAGGTTCTTCTCC 
Primers used to insert NdeI 
restriction sites flanking the 
RZF of ‘pRRL_RZF_KRAB’ 
allowing for removal of ZF 
ZFless_fwd GGCATATGCGGACTCTGGTGACCT 
ZFless_rev  GGCATATGCCCTGGGGAGAGAGGTCG 
Primers used to insert BamHI 
and SalI restriction sites to 
clone RZFKRAB into pELNSxv 
backbone 
pV2_ZF_R_codop_Ba
mHI_Forward  
ggatccATGCGGTCAGACTACAAAG  
KRAB_Sal1_Reverse GTCGACttaAACCAGCCAAGGTTCTTCTCC 
CD8 crRNA target sequence 
PCR cloning primers 
CD8_crRNA1_F CACCGGAGCAAGGCGGTCACTGGTA 
CD8_crRNA1_R  AAACTACCAGTGACCGCCTTGCTCC 
CD8_crRNA2_F  CACCGGCTGCTGTCCAACCCGACGT 
CD8_crRNA2_R AAACACGTCGGGTTGGACAGCAGCC 
CD8_crRNA3_F CACCGTCCGATCCAGCGGCGACACC 
CD8_crRNA3_R  AAACGGTGTCGCCGCTGGATCGGAC 
CD8_crRNA4_F  CACCGAACAAGCCCAAGGCGGCCGA 
CD8_crRNA4_R  AAACTCGGCCGCCTTGGGCTTGTTC 
CD8_crRNA5_F  CACCGCTCTCGGCGGAAGTCGCTCA 
CD8_crRNA5_R  AAACTGAGCGACTTCCGCCGAGAGC 
Primers for genomic CD8 PCR 
and SURVEYOR assay 
CD8_surv_forward GAAGGGCGCAACTTTCCC 
CD8_surv_reverse GTAGCCCTCGTTCTCTCGG 
Primers for genomic MR1 PCR 
and SURVEYOR assay  
MR1_SURV1_Fwd  GCATGTGTTTGTGTGCCTGT 
MR1_SURV1_Rev  GGTGCAATTCAGCATCCGC 
Primers for MR1 cDNA PCR 
and SURVEYOR assay  
MR1_SURV2_Fwd  GGTCTTACTGACATCCACTTTGC 
MR1_SURV2_Rev  CAGTGATCAGGCGCGAG 
MR1 amplicon cloning primers   
 
MR1_SURV_Fwd_BsaI  gcgcGGTCTCcGCATGTGTTTGTGTGCCTGT 
MR1_SURV_Rev_BsaI  gcgcGGTCTCcTGCCGGTGCAATTCAGCATCCGC 
Primers used to sequence 
MR1 amplicons  
MR1_Seq_Fwd  CCAGTTGCTGAAGATCGCGAAGC 
MR1_Seq_Rev  TGCCACTCGATGTGATGTCCTC 
gRNA/pCMV-Cas9 PCR 
amplification in pCDNA.3  
pCDNA.3_Fwd  GCACCGGTTGTACAAAAAAGCAGGCTTTA 
pCDNA.3_Rev  GCATGCATTCACACCTTCCTCTTCTTCT 
“Empty” pRRL vector PCR pRRL.0_Fwd  GCATGCATAATCAACCTCTGGATTACAAAATTTG 
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amplification  pRRL.0_Rev  ACCGGTGCTAGTCTCGTGATCGATAAAAT 
MR1 crRNA target sequence 
PCR cloning primers 
 
MR1crRNA_A_Fwd  GAAACGCCCGTTTTAGAGCTAGAAATAGCAAGTTAA 
MR1crRNA_A_Rev  GGATCCCATCCGGTGTTTCGTCCTTTCC 
MR1crRNA_B_Fwd  CAGCGATTCCGTTTTAGAGCTAGAAATAGCAAGTTAA 
MR1crRNA_B_Rev  TGCTTCACCGGTGTTTCGTCCTTTCC 
MR1crRNA_C_Fwd  AATTTATTTCGGTGTTTTAGAGCTAGAAATAGCAAGTTAA  
MR1crRNA_C_Rev  CAGGGACGGTGTTTCGTCCTTTCC 
MR1crRNA_D_Fwd  GCCTGATCACTGTTTTAGAGCTAGAAATAGCAAGTTAA 
MR1crRNA_D_Rev  GCGAGGTTCGGTGTTTCGTCCTTTCC 
MR1crRNA_E_Fwd  TATGACGGGCGTTTTAGAGCTAGAAATAGCAAGTTAA 
MR1crRNA_E_Rev  TGCATACTGCGGTGTTTCGTCCTTTCC 
Primers for sequencing the 
region of the RP11 gene 
which contains the crRNA A 
target site 
RP11_FWD  gctaaatgaatgcagttgaaggacctg  
 
RP11_REV CAGTGATCAGGCACGAGGTTCTC 
Colony PCR primers flanking 
gRNA target sites  
pLKO.1-A  GACTATCATATGCTTACCGT 
gRNAcolPCR_R  CACTTGATGTACTGCCAAGT 
For sequencing CMV_fwd CGCAAATGGGCGGTAGGCGTG 
hPGK_fwd GTGTTCCGCATTCTGCAAG 
eGFP_rev CGTCGCCGTCCAGCTCGACCAG 
QPCR primers RTPCR_CD8a_F GACGTGTTTGCAAATGTCCC 
RTPCR_CD8a_R AAAATGAAAGGGAAGGACTTGCT 
RTPCR_18S_F GTAACCCGTTGAACCCCATT 
RTPCR_18S_R CCATCCAATCGGTAGTAGCG 
RTPCR_ACTB_F          GACCCAGATCATGTTTGAGACCTT   
RTPCR_ACTB_R          CAGAGGCGTACAGGGATAGCA 
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Appendix Figure 2. TALEN construction with the Cermak kit (Cermak et al., 2011). TALENs were assembled in two steps. Step 1 involved 
the modular assembly of the monomers 1-11 of the TALE in a pFUS_A backbone and the assembly of monomers 12-19 of the TALE in a 
pFUS_B backbone in a golden gate reaction using the restriction endonucleases BsaI and Esp3I. The golden gate reaction was treated with 
endonuclease and transformed onto Xgal IPTG spectinomycin plates. DNA from the colonies was digested with BsmBI and run on an 
agarose gel. Plasmids containing the correct size fragments were selected and used for stage 2 of the assembly. The second stage involved 
ligating the 10 monomer plasmid from pFUS_A and 8 monomer plasmid from pFUS_B with the final half repeat and the destination 
backbone to produce complete constructs by a golden gate reaction. The golden gate reaction was treated with endonuclease and 
transformed onto a Xgal IPTG spectinomycin plate. DNA was extracted from the colonies, digested with BsmBI and run on an agarose gel. 
Samples containing the correct size fragment were sequenced by Sanger sequencing.  
NLS - nuclear localization signal. AD - transcriptional activation domain. tet - tetracycline resistance. spec - spectinomycin resistance. amp - 
ampicillin resistance. 
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Appendix Figure 3. TALEN construction with the Sanjana kit (Sanjana et al., 2012). Assembly of the TALENs with the Sanjana kit had 6 
stages. Stage 1 - Monomers were produced with specific ligation adapters by PCR amplification. Stage 2 – Hexameric tandem repeats were 
assembled from the purified monomers from stage 1 by a Golden Gate reaction. Stage 3 - The hexamer reactions were treated with 
exonuclease. Stage 4 - Hexamers were PCR amplified and purified. Stage 5 - The three adjacent hexamers were ligated into the TALEN 
backbone. Stage 6 - The assembled TALEN was transformed into competent cells and DNA from clones was sequenced by Sanger 
sequencing. 
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Appendix Figure 4. Generation of TALENs with the Cermak kit. A)  DNA extracted from colonies transduced with the 10mer pFUS_A 
plasmids were digested with BsmBI and run on a 1% agarose gel. Lane 1 .Bioline hyper ladder 1. Lanes 2 – 6 minipreps from 5 different 
colonies. Lanes 3 and 4 contain a fragment of the correct size ~ 1000bp (shown by arrow). B) DNA extracted from colonies transduced with 
the 8mer pFUS_B plasmids were digested with BsmBI and run on a 1% agarose gel. Lanes 1 – 5 minipreps from 5 different colonies. Lanes 
2 and 5 contain a fragment of the correct size ~ 800bp (shown by arrow). All minipreps were sequenced to ensure RVDs had been 
assembled in the correct order before continuing to the next stage of the assembly. C) DNA extracted from colonies transduced with the 
final half repeat backbone ligated to the 18mer TALE were digested with BsmBI and run on a 1% agarose gel. Lane 1 .Bioline hyper ladder 
1. Lanes 2 – 9  PCR amplification from 10 different colonies. Lane 8 (shown by arrow) contains a fragment of the correct size ~ 2200bp. 
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Appendix Figure 5. A) PCR amplification of NI monomer with ligation adapter primers for each of the 18 positions on a 1% agarose gel 
(representative of NN, NG and HD). Lane 1. Bioline hyper ladder 1. Lanes 2 – 19 monomers for each position. Monomers in positions 1, 6, 
7, 12, 13 and 18 were 170bp in length, the monomers in the remaining positions were 150bp in length. B) PCR amplification of hexamer 
units three for each TALE on a 1% agarose gel. Lane 1. Track it 100bp DNA ladder. Lanes 2 -4 the three hexamers of the left TALE.  Lanes 5 -
7 the three hexamers of the right TALE. C) The 3 hexamer units were ligated into the FokI backbone and transformed into XL10 Gold. 5 
colonies were screened by colony PCR for each TALE and run on a 1% agarose gel. Lane 1 - Bioline hyper ladder 1. Lanes 2 – 6 5 colonies 
for the left TALE. Lanes 7 - 13 5 colonies for the right TALE. Correctly assembled TALEs should have resulted in a fragment of 2175bp, none 
of the colonies screened were the correct size. Sequencing confirmed that the TALEs were not assembled correctly. 
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GFP 
 
 
 
 
 
 
 
 
 
Appendix Figure 6. Transduction of Molt3 cells with the left or right TALE constructs by lentiviral transduction. The cells were cultured 
for 48 hours post transduction and analysed by flow cytometry. There is no GFP+ population observed in the cells transduced with the left 
TALE (red) or right TALE (blue) compared to the FMO control (grey).  
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Appendix Figure 7. Screening of 26 clones produced by limiting dilution of the bulk 293T cells transduced with the pRRL_1x reporter 
construct by lentiviral transduction  
Sample Geometric mean GFP 
FMO 6.12 
1 868 
2 1345 
3 1277 
4 2925 
5 1830 
6 7.17 
7 933 
8 2377 
9 1543 
10 1186 
11 1662 
12 131 
13 947 
14 819 
15 874 
16 67.4 
17 1453 
18 2606 
19 405 
20 1705 
21 261 
22 677 
23 661 
24 1031 
25 539 
26 77.9 
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Appendix Figure 8. Screening of 22 clones produced by limiting dilution of the bulk 293T cells transduced with the pRRL_3x reporter 
construct by lentiviral transduction   
Sample Geometric mean GFP 
FMO 6.12 
1 2037 
2 14.2 
3 480 
4 1356 
5 1372 
6 1701 
7 791 
8 1614 
9 366 
10 650 
11 772 
12 75.4 
13 5.17 
14 2928 
15 451 
16 5.28 
17 262 
18 1252 
19 122 
20 2320 
21 658 
22 150 
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Appendix Figure 9. Optimisation of incubation time post CaCl2 transfection. WT 293T cells were transfected with a plasmid containing 
the GFP reporter gene by CaCl2 transfection and incubated for 2, 4, 6, 8, 16 or 24 hours after which the supernatant was removed and 
replaced with 4 mL of fresh medium. The cells were cultured for a further 48 h and then stained with a live / dead stain and analysed by 
flow cytometry. All transfections were carried out in triplicate wells. Standard error of the mean of 3 replicates is shown. The data is 
representative of 2 experiments. 
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Appendix Figure 10. Generation and validation of tandem repressor module constructs A) A diagrammatic representation of the RZF-
KRAB, RZF-KRAB-KRAB and RZF-KRAB-SID repressor domain constructs. B) Molt3 cells were transduced with the RZFN, the RZF-KRAB, RZF-
KRAB-KRAB and RZF-KRAB-SID constructs by lentiviral transduction. The cells were cultured and monitored 2 weeks post transduction by 
flow cytometry, a CD8- population was observable in the samples transduced with each of the repressor domain constructs. C) The CD8 
histograms of FMO is shown in light grey, WT is shown in dark grey, RZFN (GFP+) is shown in blue, RZF-KRAB (GFP+) is shown in orange,  
RZF-KRAB-KRAB (GFP+) is shown in red and RZF-KRAB-SID (GFP+) is shown in green. The table displays the percentage reduction of CD8 
MFI relative to the WT after deducting background is shown. The data is representative of 2 experiments. 
Sample Percentage reduction 
of CD8 MFI (%) 
FMO 100 
WT 0 
RZFN (GFP+) -4 
RZF-KRAB (GFP+) 99 
RZF-KRAB-KRAB 
(GFP+) 
99 
RZF-KRAB-SID 
(GFP+) 
98 
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Appendix Figure 11. Optimisation of multimer staining. Molt3 cells were transduced with the rCD2 PPI construct by lentiviral 
transduction. At two weeks post transduction the Molt3 cells were stained with multimers. A) Dot plot showing Molt3 stained with RQF 
tetramers and dextramers, ELA tetramers and dextramers as irrelevant controls or without tetramers and dextramers as FMO controls. B)  
Dot plot showing Molt3 incubated with and without PKI prior to staining with RQF and ELA dextramers. The dot plots were gated on the 
TCR+ population within the transduced cells. This data is representative of 2 experiments. 
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The Journal of Immunology
Engineering of Isogenic Cells Deficient for MR1 with a
CRISPR/Cas9 Lentiviral System: Tools To Study Microbial
Antigen Processing and Presentation to Human
MR1-Restricted T Cells
Bruno Laugel,*,1,2 Angharad Lloyd,*,2 Erin W. Meermeier,† Michael D. Crowther,*
Thomas R. Connor,‡ Garry Dolton,* John J. Miles,x Scott R. Burrows,x Marielle C. Gold,†
David M. Lewinsohn,‡ and Andrew K. Sewell*
The nonclassical HLA molecule MHC-related protein 1 (MR1) presents metabolites of the vitamin B synthesis pathways to
mucosal-associated invariant T (MAIT) cells and other MR1-restricted T cells. This new class of Ags represents a variation
on the classical paradigm of self/non-self discrimination because these T cells are activated through their TCR by small organic
compounds generated during microbial vitamin B2 synthesis. Beyond the fundamental significance, the invariant nature of MR1
across the human population is a tantalizing feature for the potential development of universal immune therapeutic and
diagnostic tools. However, many aspects of MR1 Ag presentation and MR1-restricted T cell biology remain unknown, and
the ubiquitous expression of MR1 across tissues and cell lines can be a confounding factor for experimental purposes. In this
study, we report the development of a novel CRISPR/Cas9 genome editing lentiviral system and its use to efficiently disrupt
MR1 expression in A459, THP-1, and K562 cell lines. We generated isogenic MR12/2 clonal derivatives of the A549 lung
carcinoma and THP-1 monocytic cell lines and used these to study T cell responses to intracellular pathogens. We confirmed
that MAIT cell clones were unable to respond to MR12/2 clones infected with bacteria whereas Ag presentation by classical
and other nonclassical HLAs was unaffected. This system represents a robust and efficient method to disrupt the expression of
MR1 and should facilitate investigations into the processing and presentation of MR1 Ags as well as into the biology of
MAIT cells. The Journal of Immunology, 2016, 197: 971–982.
M
ucosal-associated invariant T (MAIT) cells are the most
abundant nonconventional T cell subset, accounting for
up to 5% of all T cells in humans, and are thought to be
important for the control of a number of bacterial, fungal, and yeast
infections (1–5). These so-called innate-like T cells, which are
mostly found in the blood, the liver, and at mucosal surfaces,
express a semi-invariant TCR consisting of an a-chain using the
canonical TRAV1-2–TRAJ33/12/20 (Va7.2-Ja33/12/20) rear-
rangements (6). MAIT cells acquire effector functions during
thymic selection and readily respond to Ags derived from many
(but not all) bacteria such as Escherichia coli, Klebsiella pneu-
moniae, Mycobacterium tuberculosis, or Staphylococcus epider-
mis as well as several yeast species in the periphery without prior
priming (3, 7). MAIT cell activation is mediated by the interaction
between the TCR and microbe-derived Ags presented by the
nonclassical MHC-related protein 1 (MR1) and results in the
secretion of cytokines as well as in granzyme- and perforin-
dependent cytoxicity (2, 8). The nature of these Ags has been
recently discovered by Kjer-Nielsen et al. (9) who showed that
MR1 binds and presents small organic metabolite compounds
derived from the vitamin B synthesis pathways (10). A number of
intermediates of the folic acid (vitamin B9) and riboflavin (vitamin B2)
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pathways act as ligands for MR1 (10, 11). However, only com-
pounds derived from the riboflavin pathway, which is absent
in mammals but present in microbes, were found to activate
MAIT cells, therefore providing a molecular basis for the specific
recognition of microbially infected cells (9). Our recent study
showed that human MAIT cells isolated from a single individual
use distinct TCR repertoires to recognize cells infected with
different bacteria in an MR1-specific manner (12). Moreover,
Gherardin et al. (13) have recently characterized the crystal
structure and biophysical properties of TCRs from T cells with
discrete Ag specificity for folate- or riboflavin-derived compounds
presented by MR1. Remarkably, several of these MR1-restricted
T cell clonotypes did not express the canonical MAIT TRAV1-2
TCR a-chain (13), indicating that non-MAIT ab T cells are also
able to recognize MR1 Ags. This TCR usage heterogeneity may
provide a degree of specificity in MAIT- and MR1-restricted
T cell activation and hints that different pathogens could gener-
ate MR1-restricted Ags of varied structure and chemical compo-
sition. In addition to MR1-restricted activation, MAIT cells
respond to proinflammatory innate cytokines such as IL-12 and
IL-18 (1, 14), which can act as autonomous stimuli or combine
with TCR signals to potentiate MAIT cell activation (15). This
Ag-independent activation process may be relevant to the patho-
genesis of a number of inflammatory conditions in which the
number, distribution, phenotype, and functions of MAIT cells
were found to be altered (1, 16–18).
The biology of MR1-restricted T cells is a rapidly emerging field
in immunology. The invariant nature of MR1 across the human
population and its established role in the presentation of pathogen-
derived Ags are of outstanding interest for the potential devel-
opment of universal therapeutic and diagnostic tools in infectious
diseases. MR1 expression also appears to be ubiquitous among
different cells and tissues (19, 20), which may indicate that MR1-
driven Ag responses are relevant to the pathogenesis of a broad
number of immune-mediated diseases. However, the invariance
and ubiquity of MR1 also complicate basic investigations of its
ligand-binding and Ag presentation properties as well as in the
understanding of MR1-restricted T cell biology. Indeed, the
presence of MR1 on most APC lines and primary cells that also
express other classical and nonclassical HLA molecules can make
the unambiguous identification of microbe-specific MAIT cells
and their distinction from conventional T cells that express the
TRAV1-2 TCR chain problematic. Besides, solely relying on
known MAIT cell phenotypic markers could result in the exclu-
sion of previously undescribed bona fide MR1-restricted T cells.
So far, confirmation of MR1 restriction has exclusively relied on
the use of an anti-MR1 blocking mAb to abrogate activation (21),
yet this type of functional validation can sometimes produce in-
conclusive experimental data because of incomplete blockade. In
this context, the availability of isogenic model cell lines bearing
MR1 knockout mutations would be a valuable tool for reverse
genetics and loss of function studies.
The clustered regularly interspaced palindromic repeats
(CRISPR) and CRISPR-associated protein 9 (Cas9) genome
editing platform has recently been developed as a powerful tool to
induce targeted disruptive mutations in, or edit the DNA sequence
of, a specific gene (22–28). Current CRISPR/Cas9 genome editing
approaches rely on targeting the endonuclease activity of Strep-
tococcus pyogenes or Staphylococcus aureus (29) Cas9 to a 17- to
23-nt-long genomic DNA sequence using a single-guide RNA
(sgRNA) polynucleotide that acts both as a scaffold for Cas9 and
as a DNA tethering agent. Cas9 induces DNA strand breaks near a
so-called proto-spacer–associated motif (PAM) that are repaired
either via nonhomologous end joining, often introducing inser-
tions or deletions that disrupt the translational reading frame, or
via homologous recombination using a repair template (25).
CRISPR/Cas9 has been used to rapidly generate transgenic ani-
mals, correct deleterious mutations causing congenital diseases in
cell lines and pluripotent stem cells, or identify and validate
therapeutic targets. In this study, we report the generation of a
novel versatile all-in-one CRISPR/Cas9 lentiviral vector and its
use to derive isogenic clonal variants of carcinomic human alve-
olar basal epithelial A549 cells and of leukemic monocytic THP-1
cells commonly used to study the immune response to several
intracellular bacteria, including M. tuberculosis and Mycobacte-
rium smegmatis (2).
Materials and Methods
Generation of an all-in-one CRISPR/Cas9 lentivector
A synthetic polynucleotide sequence containing the canonical U6 RNA
polymerase III promoter and an sgRNA sequence containing the trans-
activating CRISPR RNA and the MR1-specific target sequence, based on
the design of Mali et al. (24), was purchased from Eurofins MWG Operon
(Ebersberg, Germany) and introduced in pCDNA.3-TOPO_wt-Cas9
(Addgene no. 41815) by nondirectional cloning at the unique Spe1 re-
striction site immediately upstream of the CMV promoter. To generate the
all-in-one lentivector construct, the plasmid region containing the U6
promoter–sgRNA as well as the CMV promoter and Cas9 sequences was
PCR amplified with primers containing Age1 and NsiI (pCDNA.3_Fwd
and pCDNA.3_Rev) restriction sites from the pCDNA.3-TOPO_U6-
sgRNA_wt-Cas9. This fragment was fused to a PCR amplicon consist-
ing of the second generation pRRL.sin.cppt.pgk-gfp.wpre lentivector
backbone developed by Didier Trono’s laboratory (Addgene no. 12252)
devoid of the human PGK promoter and GFP cDNA. This amplicon was
obtained by PCR amplification with primers containing matching restric-
tion sites (pRRL.0_Fwd and pRRL.0_Rev). The final sequence of the
resulting pRRL.sin.CRISPR/Cas9 plasmid and all the primer sequences are
provided in Supplemental Fig. 1 and Supplemental Table I, respectively.
Introduction of novel sgRNA target sequences
Repurposing of the CRISPR/Cas9 system was performed by introducing
new 19-nt target sequences using a PCR cloning approach whereby the new
sequence is fused to 59-phosphate–modified primers complementary to
plasmid sequences immediately flanking the target sequence (forward
primer. 59-GTTTTAGAGCTAGAAATAGCAAGTTAAx9-39, reverse primer,
59-GGTGTTTCGTCCTTTCCx10-39, where x represents nucleotides of the
target sequence). PCR amplification conditions were as follows: an initial
2-min denaturation step at 95˚C followed by 30 three-step cycles (30 s
denaturation at 95˚C, 30 s annealing at 53˚C, 5 min elongation at 72˚C)
and a final elongation step of 5 min at 72˚C using the Phusion high-fidelity
DNA polymerase (Thermo Scientific, Cambridge, U.K.). The PCR product
corresponding to the full-size plasmid (∼11 kbp) was gel extracted, puri-
fied, and circularized by ligation with standard T4 DNA ligase (Promega,
Southampton, U.K.). Ligation products were then transformed into
Escherichia coli XL10 Gold (Stratagene, La Jolla, CA). Bacteria were
plated onto Luria–Bertani agar containing 100 mg/ml carbenicillin (Bio-
chemical Direct) following a 1-h recovery step at 37˚C in SOC medium
(Invitrogen, Paisley, U.K.). After an overnight incubation at 37˚C, 10
colonies per new target sequence were tested by colony PCR to assess
plasmid integrity and confirm the presence of the sgRNA region of interest
(forward primer pLKO1.A; reverse primer gRNAcolPCR.R). PCR prod-
ucts of the expected size (450 bp) were purified, cleaned on DNA Clean
and Concentrator columns (Zymo Research, Irvine, CA), and sent for
sequencing. A total of five sgRNA target sequences were introduced for
testing: one targeting exon 1, three targeting exon 2, and one specific for a
site on exon 3 (Table I).
Cell culture and clonal expansion of MR12/2 cells
Adenocarcinoma HeLa (ATCC CCL-2), human acute monocytic leukemia
THP-1 (ATCC TIB-202), lymphoblastic chronic myelogenous leukemic
K-562 (ATCC CCL-243), and carcinomic alveolar basal epithelial A549
(ATCCCCL-185) cell lines were maintained in RPMI 1640 growth medium
(Life Technologies, Paisley, U.K.) supplemented with 2 mM glutamine, 50
U/ml penicillin, and 50 mg/ml streptomycin (Life Technologies) and 10%
FBS (Life Technologies), referred to as R10 hereon. Cells were passaged
when reaching 80% confluence using enzyme-free cell-dissociation buffer
HBSS (Life Technologies). Bulk A549 cells transfected with the CRISPR/
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Cas9 plasmid were sorted by flow cytometry by gating on the MR12
population. MR12/2 cells were isolated from bulk THP-1 cells transduced
with the CRISPR/Cas9 lentivector and subjected to MAIT cell positive
selection. The selection was performed by using THP-1 cells infected with
M. smegmatis at a 20:1 multiplicity of infection. Target cells were
cocultured for 7 d with the MAIT cell clone D481A9 at an E:T ratio of 1:2.
After the selection period, cells were transferred to flasks for a larger cell
culture and further expanded. Subsequently, the resulting cells were
clonally expanded by isolating single cells using a limiting dilution ap-
proach. An average of 0.3 cell was plated in individual wells of four flat-
bottom 96-well plates containing 200 ml medium. A total of 16 clonal
A549 and 20 THP-1 populations were then screened by flow cytometry.
Three A549 and five THP-1 clones were ultimately selected and analyzed
using a mismatch-specific endonuclease assay as described in Results.
T cell clones were cultured in RPMI 1640 media supplemented with 2 mM
glutamine, 50 U/ml penicillin, and 50 mg/ml streptomycin (Life Tech-
nologies), 10% FBS, 0.01 M HEPES buffer, nonessential amino acids,
sodium pyruvate (Life Technologies), 25 ng/ml IL-15 (PeproTech, Rocky
Hill, NJ), and either 20 or 200 IU/ml IL-2 (aldesleukin [Proleukin]; Pro-
metheus, San Diego, CA), depending on the stage of culture.
MAIT and T cell clones activation
IFN-g ELISPOT assays with the HLA-E–restricted T cell clone D160 1–23
were performed as described in Lewinsohn et al. (30). Briefly, A549 cells
or MR12/2 A549 cells (104/well) were incubated with 5 mg/ml M. tu-
berculosis pronase-digested cell wall (31) in RPMI 1640 medium sup-
plemented with 10% human serum for 2 h. D160 1–23 (104/well) was then
added to each well. The plate was incubated overnight at 37˚C and then
developed using an AEC Vectastain kit (Vector Laboratories). PHA stim-
ulation was used as a positive control for T cell signaling viability. Data
shown are representative of three independent experiments. The D426B1
and D481 MAIT cell clones were washed with RPMI 1640 medium and
then rested in RPMI 1640 supplemented with 50 U/ml penicillin and 50
mg/ml streptomycin, 2 mM L-glutamine, and 5% FBS overnight. A549
cells (wild-type [WT] and MR1 knockouts) were cultured in antibiotic-free
R10 overnight. A549 and THP-1 cells were exposed to M. smegmatis at a
multiplicity of infection of 100:1 (bacteria to cells) for 2 h in antibiotic-
free R10, followed by 2 h incubation with R10 containing 50 U/ml peni-
cillin and 50 mg/ml streptomycin (Life Technologies). A549 and THP-1
cells were washed to remove extracellular M. smegmatis. Control cells
were mock treated as if they had been coincubated with bacteria. A549 and
THP-1 cells were then plated into 96U-well plates at a density of 6 3 104
cells per well. MAIT cells (3 3 104) were then added to each well and
cultured overnight. Supernatant (60 ml) was then harvested, diluted to 120
ml with R5, and assayed for MIP-1b, TNF-a, and IFN-g ELISA (R&D
Systems) according to the manufacturer’s instructions. Data were plotted
and analyzed with GraphPad Prism software version 5.03. Activation of
the CD8+ T cell clone B9 specific for an octameric peptide (SELEIKRY)
derived from the EBV BZLF1 protein and presented by HLA-B*1801 (32)
was done by coculturing T cells with A549 WTor MR12/2 cells overnight
in 200 ml R5. A549 cells (1 3 106) were pulsed with each peptide con-
centration in 100 ml R5 for 2 h at 37˚C. The cells were washed with 10 ml
R5 five times, aspirating all excess supernatant between washes. The A549
cells were counted and resuspended at 6 3 105 cells/ml in a final volume
of 700 ml. Then, 100 ml cell suspension (i.e., 60,000 cells) was plated into
96-well plates. T cells (3 3 104) in 100 ml R5 were added into each well.
Then, the remaining APCs were centrifuged and the supernatant was
plated with T cells as a control to ensure that the T cell response was
mediated through APC presentation and not T:T presentation. Each assay
condition was performed in triplicate. For ELISAs, 50 ml supernatant per
well was used for TNF-a and IFN-g ELISA and 25 ml supernatant diluted
with 25 ml of R5 per well was used for MIP-1b. Supernatants were frozen
and assayed for MIP-1b and IFN-g in a sandwich ELISA assay (R&D
Systems) according to the manufacturer’s instructions.
Flow cytometry
The PE-conjugated anti-MR1 Ab clone 26.5 (BioLegend, London, U.K.)
was used to stain HeLa-MR1, A549, and THP-1 cells at the dilution rec-
ommended by the manufacturer. To stabilize the cell-surface levels of MR1,
A549 cells were incubated overnight in the presence of 50 mg/ml acetyl-6-
formylpterine (Schircks Laboratories, Jona, Switzerland) prior to staining
(11). Where indicated, the W6/32 monoclonal anti–HLA-ABC Ab con-
jugated to APC (eBioscience, Hatfield, U.K.) was also used to monitor
classical HLA-I levels on the cell surface. 7-Aminoactinomycin D (BD
Biosciences, Oxford, U.K.) or the viability Vivid Dye (Molecular Probes,
Life Technologies) was added to all the staining before data acquisition on
a FACSCalibur instrument (Becton-Dickinson, UK) or a FACSCanto II
(Becton Dickinson, Oxford, U.K.). Data analysis was performed with
FlowJo software (Tree Star, Ashland, OR) by drawing a population gate
on the forward scatter area/side scatter area plot and on viable cells
(7-aminoactinomycin D2 or Vivid2).
Monitoring of mutations at the MR1 locus
Genomic DNA from A549 and THP-1 cells was isolated with the GenElute
mammalian genomic DNA miniprep kit (Sigma-Aldrich, Gillingham, U.
K.). Mutations at the target site were detected using the CEL-I enzyme, as
part of the Surveyor assay (Transgenomic, Glasgow, U.K.), which cleaves
DNA duplexes bearing base pair mismatches, caused by insertions or
deletions at proximity of the PAM sequence, within the PCR amplicons
generated with primers flanking the genomic target site. The PCR forward
primer (SURV1_Fwd) is located in the intron region upstream of the target
site, and the reverse primer (SURV1_Rev) is located downstream on exon 2.
The predicted size of the full-length PCR product was 852 bp, and the
expected position of Cas9 cleavage (immediately downstream of the PAM
sequence) is located 521 bp downstream of the start of the forward primer
and 331 bp from the reverse primer. In the case of HeLa-MR1 cells, which
overexpress MR1 cDNA, a PCR amplicon flanking the sgRNA target se-
quences was obtained by amplifying a 360-bp region from template DNA
isolated as described above using a forward primer complementary to a
plasmid region immediately upstream of the MR1 cDNA (SURV2_Fwd)
and a reverse primer downstream of the target site (SURV2_Rev). To se-
quence the modified MR1 locus in the A549 clonal derivatives clone 9 and
clone 11, the same primers fused to the type IIs endonuclease BsaI were
used to amplify the genomic DNA and clone the amplicons into a cloning
vector (Addgene no. 32189). Plasmid minipreps from 10 colonies obtained
from the resulting transformation for each clone were sent for Sanger
sequencing at Eurofins MWG Operon.
Identification of CRISPR/Cas9 mutagenesis off-target effects
using genomics
Undertaking a BLAST search against the human genome refseq database
using the guide RNA (gRNA) sequence, we identified six sites (excluding
MR1) located within genes that contained sequence that differed at four or
fewer sites compared with the gRNA. Having identified these genes, we
undertook whole-genome sequence of two samples, clone 9 and clone 11, to
assess whether these genes contained off-target effects. To sequence the
sample, we extracted the genomic DNA from the two A549 clones using the
GenElute mammalian genomic DNA miniprep kit (Sigma-Aldrich). We
fragmented 1 mg DNA to an average of 300 bp fragments by sonication
and prepared libraries using NEBNext ultra library preparation kits (New
England Biolabs, Herts, U.K.). The libraries were sequenced using a
NextSeq 500, running high output 150-bp paired end sequencing to a depth
of .203 coverage for each genome. Taking the sequence reads generated,
we mapped these against the gene sequences of the target sites, and in five
of the six cases using the Burrows–Wheeler alignment tool (33), visual-
izing the mapping results using Artemis (34). To identify inserts that are
larger than those that could be detected by mapping, we screened all of the
Table I. CRISPR/Cas9 sgRNA target sequences within the MR1 gene tested in this study
gRNA Target Sequence (59→39) PAM (59→39) Exon Strand
A GGATGGGATCCGAAACGCCC AGG 2 +
B GGTGAAGCACAGCGATTCC CGG 1 2
C GTCCCTGAATTTATTTCGGT TGG 2 2
D GAACCTCGCGCCTGATCACT GGG 2 2
E GCAGTATGCATATGACGGGC AGG 3 2
Target sequences were identified by searching for GN19GG DNA motifs on either strand of the MR1 cDNA sequence. We selected five nonoverlapping target sequences
located in the first half of the MR1 coding sequence.
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FIGURE 1. Description of the lentiviral CRISPR/Cas9 system and identification of gRNA target sequences efficiently disrupting MR1 gene expression.
(A) Graphic representation of the all-in-one lentiviral system generated for this study. The CRISPR/Cas9 elements derived from the pCDNA.3-TOPO_wt-
Cas9 plasmid were incorporated within the second generation pRRLSIN.cPPT.WPRE lentivector backbone between the Age1 and Nsi1 unique restriction
sites. (B) Positioning of three active sgRNA target sequences with respect to the intron/exon structure of the MR1 gene. (C) Disruption of MR1 protein
surface expression on HeLa reporter cells overexpressing MR1 transduced with lentiviruses expressing Cas9 in concert with a control gRNA (light blue
histogram), MR1 gRNAs A (dark green histogram), B (light green histogram), or D (orange histogram). Isotype control staining is shown as a solid light
gray histogram. The histogram plot shown is representative of four independent staining experiments. (D) Monitoring of mutations within the genomic
DNA of transduced HeLa cells. MR1 cDNA PCR amplicons generated with the genomic DNA of WT cells or of cells transduced with lentiviruses
expressing each sgRNA target were denatured, annealed, and digested with the CEL-I enzyme as described in Materials and Methods. Four hundred (WT
lane) or 200 ng of PCR products from unmodified HeLa-MR1 cells mixed with 200 ng amplicon generated with DNA obtained from cells transduced with
each sgRNA target (gRNA D, B, and A lanes) were used. Digestion of PCR amplicons was only obvious for the WT/gRNA A (Figure legend continues)
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reads generated using the sequence 20 bp on the 59 side of each of the off-
target sites identified above. Extracting these reads, we identified any cases
where larger deletions were present within these reads by manually ex-
amining the sequence of the reads by eye against the expected reference
sequence. Following this we also undertook an analysis to identify other
potential off-target sites that may not have been in genes, or detected by
our screen of the human genome. To do this, we identified all of the se-
quence reads that contained a sequence matching, or complementary to,
the gRNA at 15 of 20 bases, and extracted these into a set of fastq files. We
then assembled these sequences using Velvet and extracted all contigs with
a sequence length of .200 bp. In total, this analysis identified 7574 lo-
cations in sample clone 9 and 7516 locations in clone 11 for further in-
vestigation. Extracting the BLAST alignments for each of the sequences
queried, we examined, by eye, all of the alignments containing insertions
within the contig for evidence of insertions within 100 bp of the match to
the gRNA. In total, other than the known deletion within MR1 and the
detected RP11-46A10.6 site, we found no other cases where there
appeared to have been an off-target effect in either of our samples.
Sequencing data were submitted to the EMBL-EBI European Nucleo-
tide Archive (http://www.ebi.ac.uk/ena). The study accession number is
PRJEB12991. Sample accession and secondary accession numbers for
A549 clone 9 are ERS1078785 and SAMEA3891651. Sample accession
and secondary accession numbers for A549 clone 11 are ERS1078786 and
SAMEA3891652. Experiment accession and run accession numbers for
A549 clone 9 are ERX1378672 and ERR1307049. Experiment accession
and run accession numbers for A549 clone 11 are ERX1378673 and
ERR1307050.
Production of lentiviral particles and cell transduction
The pRRL.sin.CRISPR/Cas9 lentivector was cotransfected with the second
generation VSV.G envelope pMD2.G (Addgene no. 12259) and packaging
pCMV-dR8.74 (Addgene no. 22036) plasmids in HEK-293T cells by CaCl2
transfection in six-well plates. Lentiviral supernatants (∼10 ml total vol-
ume) were collected at 24 and 48 h, filtered using a 0.45-mm cellulose
acetate syringe filter, concentrated by centrifugation at 28,000 rpm for 2 h,
and resuspended in 0.5 ml R10. HeLa-MR1, THP-1, K562, or A549 cells
grown to ∼50% confluence in six-well plates were transduced with the
concentrated viral supernatant diluted 3-fold in a final volume of 3 ml.
Results
Development of a versatile all-in-one lentiviral CRISPR/Cas9
system
We chose to adapt the two plasmid delivery platform described
by Mali et al. (24), whereby the Cas9 and sgRNA elements are
expressed on separate plasmids, to generate a single delivery system
embedded within a second generation lentivector backbone. We
reasoned that such a tool would combine the ease of an all-in-one
delivery method with the high infectivity and broad cellular tropism
of lentiviruses. For this purpose, we introduced a codon-optimized
version of S. pyogenes Cas9 under the control of the CMV promoter
as well as a U6 RNA polymerase III promoter sgRNA complex
within the self-inactivating second generation lentivirus pRRL.sin.
cppt.pgk-gfp.wpre (Fig. 1A), a well-characterized lentiviral system
that produces high-titer viral particles. We designed the sgRNA so
that the 19-nt target sequence could be easily swapped through a
cloning PCR approach, a feature that distinguishes our lentivector
from other available CRISPR/Cas9 systems.
Generation of cell populations bearing CRISPR/Cas9-induced
mutations in the MR1 locus
A total of five lentivectors, each containing a different CRISPR target
sequence specific for the MR1 gene (Fig. 1B, Table I), were generated
and tested in a reporter system consisting of HeLa cells overexpressing
native human MR1 cDNA. MR1low/2 cells could be identified by flow
cytometry within HeLa-MR1 cell populations transduced with three of
the five lentiviruses (Fig. 1C). gRNA.A showed the highest disruption
efficiency both at the protein and DNA levels (Fig. 1C, 1D). Based on
these results, we selected gRNA.A to edit the genome of the A549 cell
line. We compared MR1 gene modifications induced in A549 cells in
which Cas9 and the MR1 gRNA.A were either stably or transiently
expressed using lentiviral transduction or plasmid DNA transfection,
respectively. Flow cytometry analysis showed that for both transient
and stable CRISPR/Cas9 expression, the overall mean fluorescence
intensities (MFIs) with anti-MR1 Ab were decreased and the pro-
portion of cells appearing MR1 low or negative was increased com-
pared with the control WT A549s (Fig. 1E). At the DNA level, the
Surveyor assay revealed that DNA mismatches were introduced at the
expected positions, as digestion of heteroduplex PCR amplicons
containing the CRISPR/Cas9 target sites from WT and modified cells
yielded two digestion products of the expected sizes (Fig. 1F). We also
used our CRISPR/Cas9 system to disrupt the endogenous MR1 genes
of the THP-1 and K562 cell lines. Transient transfection of K562 and
THP-1 cells with CRISPR/Cas9 plasmid DNA did not allow MR1
gene editing with high enough frequencies for monitoring with the
Surveyor assay. However, CRISPR/Cas9 lentivirus transduction suc-
cessfully generated MR1 indels in both cell lines (Fig. 1G, 1H). In the
case of THP-1, we used an enrichment strategy based on the positive
selection of MR1 mutants able to escape killing by a MAIT cell clone.
Following 7 d of coculture with MAIT cells at an E:T ratio of 1:2, we
observed an increase in the frequency of mutations in the MR1 gene
within the expanding THP-1 population, suggesting that the process
allowed for the selection of disruptive MR1 mutations (Fig. 1H).
Generation of MR12/2 A549 clones: phenotypic and genotypic
characterization
Although CRISPR/Cas9 gene disruption by lentiviral transduction
appeared more efficient than transient expression, we reasoned that
continuous expression of the gene-editing elements from a stable,
integrated vector within the cells was more likely to generate
detrimental off-target DNA cleavage, and we therefore elected to
heteroduplexes (lane gRNAA). Data shown are representative of two independent experiments. (E) A549 cells were lipofected with plasmid DNA containing
the CRISPR/Cas9 elements (including the gRNA A target sequence) or transduced with lentiviral particles made from the same plasmid. Eight days after
transduction/lipofection, cells were treated overnight with acetyl-6-formylpterine (50 mg/ml) prior to flow cytometry analysis. A549 cells stained with an
isotype control Ab are shown as a black histogram (MFI = 2.78), mock lipofected cells as a solid gray histogram (MFI = 9.53), cells transduced with
lentivirus as a red histogram (MFI = 5.84), and those lipofected with the CRISPR/Cas9 plasmid DNA as a blue histogram (MFI = 7.07). The data shown are
representative of three stainings. (F) Surveyor assay performed with a total of 500 ng PCR amplicon obtained from genomic DNA of unmodified A549 cells
or from cells lipofected or transduced with gRNA.A CRISPR/Cas9. Homoduplex WT DNA (lane 1) or heteroduplexes of annealed WT and modified
amplicons from transduced cells (lane 2) or lipofected cells (lane 3) were digested with the CEL-I DNA-mismatch–specific enzyme. Two bands matching
the sizes of the expected digestion products (521 and 331 bp) can be identified (indicated with red arrows). Undigested (lane 4) and digested (lane 5) assay
controls are shown. The gel shown is representative of at least five different experiments. (G) Surveyor assay performed with a total of 500 ng PCR
amplicon obtained from genomic DNA of unmodified K562 cells or from cells transduced with gRNA.A CRISPR/Cas9. Homoduplex WT DNA (lane 1) or
heteroduplexes of annealed WT and modified amplicons from transduced cells (lane 2) were digested with the CEL-I DNA-mismatch–specific enzyme.
Two bands matching the sizes of the expected digestion products (521 and 331 bp) can be identified (indicated with red arrows). (H) Surveyor assay
performed with a total of 500 ng PCR amplicon obtained from genomic DNA of unmodified THP-1 cells or from cells transduced with gRNA.A CRISPR/
Cas9. Homoduplex WT DNA (lane 1) or heteroduplexes of annealed WT and modified amplicons from transduced cells before and after MAIT cell
selection (lanes 2 and 3) were digested with the CEL-I DNA-mismatch–specific enzyme. Two bands matching the sizes of the expected digestion products
(521 and 331 bp) can be identified (indicated with red arrows). The data shown in Fig. 1G and 1H are representative of two independent experiments.
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use bulk-transfected A549 cells to derive MR12/2 clonal pop-
ulations by limiting dilution. Following a first screen by flow
cytometry of 16 clonal A549 derivatives (not shown), we se-
lected 8 candidates showing homogeneous cell surface MR1
protein expression. The putative clones 1, 9, and 11 consistently
displayed the lowest MFIs (Fig. 2A) and were taken forward for
further molecular analysis of their genomic DNA. Interestingly,
PCR amplification of the region flanking the sgRNA.A target
sequence yielded two products in the case of clone 9 (Fig. 2B).
In addition to a PCR amplicon of the predicted size (852 bp)
common to all samples, a smaller fragment, shorter by 100–150
bp, was amplified, likely indicating a deletion near the site of
Cas9 cleavage. Digestion of DNA heteroduplexes with the CEL-
I enzyme generated additional bands matching digestion prod-
uct sizes predicted by the positioning of the gRNA.A target and
PAM sequences within the amplicon (∼520 and 330 bp) for
clones 9 and 11 but not clone 1 (Fig. 2B). In the case of clone 9,
further characterization of PCR products by Sanger sequencing
revealed a 126-nt deletion spanning the intron/exon junction and
resulting in the partial deletion of the CRISPR/Cas9 target se-
quence on one allele (Fig. 2C). The other allele bore a single
nucleotide deletion as well as two base substitutions compared
with the MR1 reference sequence (Fig. 2C), in line with the
PCR analysis. Although it is unclear what the exact consequence
FIGURE 2. Characterization of A549 clonal derivatives bearing biallelic disruptive mutations in the MR1 gene. (A) Flow cytometry analysis of MR1
expression in eight different A549 clones obtained by limiting dilution and comparison with the bulk-transfected A549 parental cell line. Cells were treated
overnight with acetyl-6-formylpterin (50 mg/ml) prior to staining with a PE-conjugated anti-MR1 Ab and data acquisition. The histogram plot shown is
representative of three experiments. (B) Molecular characterization of mutations at the MR1 locus target site. PCR amplicons of WTA549 cells (lane 1) and
A549 clones 11 (lane 2), 9 (lane 3), and 1 (lane 4) are shown in the absence of hybridization and CEL-I digestion. The Surveyor assay was performed with a
total of 500 ng PCR amplicon obtained from genomic DNA of unmodified A549 cells or from the three different clones. Homoduplex WT DNA (lane 5) or
heteroduplexes of annealed WT and modified amplicons from clone 11 (lane 6), clone 9 (lane 7), or clone 1 (lane 8) were digested with the CEL-I DNA-
mismatch–specific enzyme. The gel shown is representative of at least four independent experiments. (C) Analysis of the MR1 genomic sequences re-
covered from A549 clone 9. The reference WT sequence is shown on top and the sequences recovered from clone corresponding to each allele are shown
underneath. (D) WT MR1 reference sequence (top) and sequences corresponding to each allele of A549 clone 11 are shown. Nucleotide deletions are shown as
red hyphens, and substitutions are shown as purple characters. Nucleotides corresponding to the sequence of the exon 2 MR1 are shown as green characters, the
19-nt gRNA.A target sequence is shown in blue characters, and the PAM sequence is shown in orange. (E) Predicted primary structures of the mutant MR1
proteins as determined by translating PCR amplicon DNA sequences. MR1 amino acids 26–50 are shown as alignments. The WT MR1 protein sequence is
indicated as gray shadows and out-of-frame reads are shown as pink shadows. C9A2, clone 9 allele 2; C11A1, clone 11 allele 1; C11A2, clone 11 allele 2.
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the large deletion has on MR1 protein structure, the latter mutation
likely disrupts the protein reading frame from amino acid 34 on-
ward (Fig. 2E). In the case of clone 11, an identical single nucle-
otide deletion within the sgRNA target sequence could be detected
on each allele (Fig. 2D). The reading frame on both alleles of clone
11’s coding sequence therefore shows the same frame shift as allele
2 of clone 9, where the native MR1 protein sequence is disrupted
from amino acid 34 onward (Fig. 2E). Collectively, the lack of MR1
staining by flow cytometry and the presence of disruptive mutations
on each allele for both clones indicated that MR1 expression was
almost certainly abrogated as a result of CRISPR/Cas9 mutagene-
sis.
MR1 CRISPR/Cas9 mutagenesis resulted in an unintended
nucleotide deletion in the RP11-46A10.6 pseudogene
To establish whether there were off-target effects resulting from
the CRISPR/Cas9 modification, we undertook whole-genome se-
quencing for A549 clones 9 and 11. We identified likely off-target
sites that occurred within genes (defined as sites varying at up to
five bases compared with the MR1gRNA target sequence), totaling
six possible genes where off-target effects could have been ob-
served. Mapping the whole-genome sequence data back to the
reference sequences for these genes, and for MR1, we identified
only one case of unintended mutation. This was in a pseudogene
bearing a high degree of sequence homology (94%) with the
targeted MR1 region (Fig. 3A) and containing the exact same
gRNA target sequence (Fig. 3B). In both samples the same nu-
cleotide deletion at position 16 of the gRNA sequence was ob-
served at this locus as on both clone 11 MR1 loci and on one MR1
locus of clone 9 (Figs. 2C, 2D, 3C). Another coding gene (STX6)
sits within the RP11-46A10.6 region. However, the exons making
up the STX6 protein–coding sequence are a considerable distance
from the RP11-46A10.6 target sequence (Fig. 3A). We also ex-
amined our sequence reads to identify any other off-target effects
that had longer deletions. Other than the one identified in MR1 for
clone 9, we observed no evidence for other long deletions in the
reads generated as part of the whole-genome sequencing (not
shown).
FIGURE 3. Results of whole-genome sequencing to identify off-target effects. (A) Figure generated from the Artemis comparison tool comparing the
DNA sequence of MR1 to the RP11-46A10.6 pseudogene (located between exon 1 and 2 of STX6 gene). The red ribbons indicate large contiguous regions
of 90%+ homology between the two genes, with the yellow ribbon being the region that contains the sequence targeted by the gRNA. The exons of MR1,
STX6, and the RP11-46A10.6 pseudogene are annotated in this region and are shown in turquoise, dark gray, and white, respectively. (B) Unintended on-
target effects within RP11-46A10.6 in samples clone 9 and clone 11. Two potential effects appear to be evident: one single base deletion seen in both clone
9 and clone 11, and one longer deletion in clone 9 (third read down from the top). The gRNA sequence is highlighted in yellow, and SNPs relative to the
reference are shown in red characters. (C) On-target effects on MR1 in samples clone 9 and clone 11. The single base deletion observed in both clones,
which is identical to that in RP11-46A10.6 relative to the gRNA target sequence, is evident for the vast majority of reads. The gRNA sequence is
highlighted in yellow, and single nucleotide polymorphisms relative to the reference are shown in red characters.
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A549 mutant clones infected with bacteria selectively fail to
activate MAIT cell clones
Next we sought to confirm MR1 deficiency at the functional level.
WTA549 cells or clones 9 and 11 infected withM. smegmatiswere
cocultured with the MAIT cell clones D426B1 and D481A9
known to express canonical TRAV1-2_TRAJ33 MAIT TCR
a-chain rearrangement differing in their CDR3 sequences and two
distinct b-chains (TRBV6-4 for D426B1 and TRBV20-1 for
D481A9) (2, 12). In contrast to infected WT A549s, which trig-
gered efficient MIP-1b and IFN-g release, MR1-deficient clones 9
and 11 failed to activate either MAIT cell clone (Fig. 4). These
results show that both A549 clonal derivatives are unable to pre-
sent bacterial Ags in the context of cell-surface MR1. Such a
distinct phenotype implies that CRISPR/Cas9 mutagenesis in-
duced biallelic disruptive mutations, resulting in loss of MR1
protein function in both A549 clones.
MR1 mutations do not affect the expression of nonclassical or
classical HLA molecules
To further assess the genetic integrity of both mutant A549 clones,
we performed additional phenotypic and functional experiments.
These established that cell-surface expression levels of classical
HLA-I molecules were not affected in MR1-deficient cells
(Fig. 5A, 5B). Moreover, both MR12/2 A549 clones were able to
present HLA-B*1801–restricted peptides derived from the EBV
protein BZLF1 to a CD8+ T cell clone with efficiencies similar to
the WTA549 cells, as evidenced by equivalent cytokine release in
peptide titration experiments (Fig. 5C, 5D). Finally, when cocul-
tured with the HLA-E–restricted CD8+ T cell clone D160 1–23,
the A549 clones 9 and 11 presenting M. tuberculosis cell wall
fractions triggered similar IFN-g secretion levels compared with
the WT A549 cells (Fig. 5E, 5F). Collectively, these data suggest
that classical and nonclassical HLA-I Ag presentation is intact in
the MR1-deficient cells.
Generation and functional characterization of MR12/2 THP-1
clones
The monocytic THP-1 cell line is a broadly used and well-
characterized tool to study bacterial phagocytosis and Ag presen-
tation (35). The availability of MR12/2 THP-1 cells would likely be
of interest to study MAIT cell responses to a range of pathogens.
Following the selection of bulk-transduced THP-1 cells bearing
increased MR1 mutations that conferred resistance to MAIT cell
killing (Fig. 1H), we sought to derive clonal populations by single-
cell dilution and assessed their MR1 phenotype. MR1 protein ex-
pression, as measured by flow cytometry, was markedly reduced in
bulk THP-1 cells that underwent the positive selection process
compared with the initial transduced preselection population
(Fig. 6A), confirming the mismatch nuclease assay (Figs. 1H, 6C).
All 20 tested THP-1 derivatives isolated by single-cell dilution of
the selected population showed MR1 expression levels similar to
those of the negative control used in the assay (Fig. 6B). Moreover,
CEL-I digestion of five of these cell populations pointed to the
presence of mismatch mutations at high frequencies within MR1
(Fig. 6C). Taken together, these data suggested that many, if not
most, THP-1 derivatives bore biallelic disruptive MR1 mutations.
Next we tested the ability of THP-1 cells to activate MAIT cells
following M. smegmatis infection. Similar to the A549 clone 9 and
clone 11, all the tested THP-1 derivatives failed to activate both
D426B1 and D481A9 MAIT cell clones, as measured in cytokine
release assays (Fig. 7), whereas the infected parental THP-1 cells
induced the secretion of high levels of both TNF-a and IFN-g by
FIGURE 4. MAIT cells fail to recognize A549 derivatives clone 9 and clone 11 infected with M. smegmatis. The D481A9 and 426B1 MAIT cell clones
were cocultured with the indicated A549 APCs infected with M. smegmatis or not as described in Materials and Methods. Supernatants were collected
following overnight incubation. MIP-1b produced by MAIT cell clones D481A9 (A) and D426B1 (B), respectively, were quantified by ELISA. IFN-g levels
were also measured for both D481A9 (C) and D426B1 (D). Assays were carried out in triplicate wells. Means 6 SEM are shown on the graph using data
representative of three experiments.
978 NEW TOOLS AND REAGENTS TO STUDY MAIT CELL BIOLOGY
 by guest on February 22, 2017
http://w
w
w
.jimmunol.org/
D
ow
nloaded from
 
D481A9 (Fig. 7A, 7C) by D426B1 (Fig. 7B, 7D), thereby dem-
onstrating that these cells are unable to present MR1-restricted Ags
and confirming their knockout status.
Discussion
RNA-guided genome engineering with CRISPR/Cas9 is a versatile
and efficient tool to manipulate the genome of cell lines, including
somatic and germinal cells. We have adapted this technology in a
novel all-in-one lentiviral vector for the simultaneous delivery of
the Cas9 endonuclease and an associated sgRNA. We designed
sgRNA target sequences specific for the human MR1 locus and,
following an initial screen in a reporter system, selected a target
sequence we used to efficiently disrupt the expression of endog-
enous MR1 in three cell lines. We subsequently expanded clonal
A549 and THP-1 populations bearing disruptive biallelic MR1
mutations. T cell assays where MAIT cells were activated by the
parental A549 and THP-1 cell lines but failed to recognize cells
obtained by limiting dilution upon infection with M. smegmatis
confirmed MR1 protein loss of function. Importantly, CRISPR/
Cas9-directed mutagenesis in these cells did not alter Ag pro-
cessing and presentation by classical and nonclassical HLAs,
highlighting the specificity of the genome editing approach and
validating the use of these two clones to accurately characterize
MR1-restricted Ags and their recognition by MAIT cells.
The two MR1-deficient A549 clones characterized in this study
were generated from transient expression of an sgRNA and Cas9
elements in the parental cell line. The expression level of MR1 on
the surface of A549 cells is relatively weak, and monitoring by flow
cytometry, even after stabilization with high acetyl-6-formylpterine
concentrations, did not allow us to unambiguously identify a
population of MR12 cells in the bulk-transfected population
(Fig. 1E). However, the CEL-I mismatch-specific nuclease assay
clearly showed that mutations were introduced at the intended site
within the MR1 gene (Fig. 1F). The level of MR1 disruption was
increased following flow cytometry cell sorting of an MR12/low
population (not shown) from which we isolated and expanded
individual clones by limiting dilution. A screen of 16 clonal
populations identified eight derivatives that exhibited MR1 MFIs
consistently lower than those of the parental cells (Fig. 2A). Three
of these clones appeared MR12 by flow cytometry and were taken
forward for molecular analysis of genomic DNA. Disruptions at
the MR1 locus could be identified in two clones using the CEL-I
assay, and Sanger sequencing confirmed the presence of frame-
shift mutations on both alleles for each clone (Fig. 2C). Overall 2
of 16 of the clones (12.5%) displayed the genotype of interest.
This suggested that extending the induction of disruptive MR1
mutations in other cell lines and, possibly, in primary cells using
this system should be possible. We confirmed this by applying
FIGURE 5. MR1 disruption does not af-
fect HLA class Ia and HLA-E Ag presen-
tation. (A) Representative cell surface HLA-
I expression by A549 cells. MFI values were
56.4 (isotype control), 8733 (WT A549),
9880 (clone 11), and 8682 (clone 9). (B)
MFI from three surface HLA-I staining of
A549 WT and MR12/2 cells. Individual
MFI datum points as well as mean values 6
SEM are shown. The data shown are rep-
resentative of two independent staining ex-
periments. (C and D) Secretion of IFN-g and
MIP-1b cytokines by CD8+ T cell clones B9
in response to increasing concentrations of
an agonist peptide (SELEIKRY) derived
from the EBV BZLF1 protein and presented
by HLA-B*1801 expressed on the surface of
WT A549, clone 9, or clone 11 as indicated
in the key. (E) Activation of the D160 1–23
HLA-E–restricted CD8+ T cell clone in re-
sponse to increasing numbers of WT A549
or A549 MR12/2 clone 9 cells exposed to
pronase-digested M. tuberculosis cell wall
extracts. (F) Activation of the D160 1–23
HLA-E–restricted CD8+ T cell clone mea-
sured as spot-forming units in response to
increasing numbers of WT A549 or A549
MR12/2 clone 11 exposed to pronase-
digestedM. tuberculosis cell wall extracts in
ELISPOT assays. The data shown are rep-
resentative of two independent experiments.
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CRISPR/Cas9 mutagenesis to K562 and THP-1 cells. In both lines
we were able to show the induction of MR1 mutations at the
intended target site with the mismatch nuclease assay (Fig. 1G,
1H). In the case of the highly phagocytic THP-1 cell line, we set
up a mutation enrichment strategy relying on the positive selection
of THP-1 mutants unable to present MR1 Ags following infection
with M. smegmatis and on MAIT cell cytotoxicity as a selecting
force. The frequency of MR1 mutations was markedly increased
by this selection process (Figs. 1H, 6A, 6C), and we were able to
isolate monoclonal THP-1 cells by limiting dilution and expan-
sion. All these derivatives failed to stain with anti-MR1 Ab
(Fig. 6A, 6B), and the five we tested functionally did not activate
MAIT cells in cytokine release assays (Fig. 7). Although we did
not establish the clonal nature of these populations, it seems likely
that at least some of them are MR12/2 clones that can be used to
study intracellular bacteria of different species than those infecting
the A549 cells. The fact that all the THP-1 derivatives failed to
activate MAIT cells (Fig. 7) is a clear indication of the efficiency
of the positive selection approach we undertook, which could
prove a useful and powerful way to establish the MHC restriction
or Ag specificity of T cells without having to generate clonal
target cell derivatives bearing biallelic mutations. Single-cell
cloning is a cumbersome process and can be impossible to im-
plement in the context of primary cells with limited proliferative
capacity. Moreover, it is conceivable that the efficiency of this
approach can be accurately quantified through a deep amplicon
sequencing approach.
Concerning the nature of the A549 genomic mutations, it is
notable that, on one allele of clone 9, we identified a 126-bp de-
letion spanning the junction between MR1 exon 2 and the flanking
upstream intronic region and ending at the sgRNA target sequence
(Fig. 2C). Such large deletions are not commonly observed fol-
lowing nonhomologous end joining genome editing with nuclease
systems (CRISPR/Cas9 or others). The genomic DNA disruptions
observed on the three other alleles were more in line with what is
described in the literature, as we identified a single nucleotide
FIGURE 6. Isolation and characterization of THP-1 clonal derivatives bearing disruptive mutations in the MR1 gene. (A) Flow cytometry analysis of MR1
expression in THP-1 cells transduced with MR1 CRISPR/Cas9 lentiviral particles before and after enrichment of MR1-deficient cells by selection with the
426B1 MAIT cell clone, as indicated in the key to the figure. MFI values were: unstained, 45.5; isotype control, 53.9; WT THP-1, 1033; preselection edited
cells, 820; and postselection edited cells, 161. (B) Staining of 20 different THP-1 clones obtained by limiting dilution from the postselection THP-1 parental
cell line. MFI values of the indicated populations are represented. The data shown are representative of two independent experiments. (C) Molecular char-
acterization of mutations at the MR1 locus target site. CEL-I–digested PCR amplicon homoduplexes of WT THP-1 cells (lane 1), heteroduplexes of WT THP-1
cells DNA hybridized with DNA from bulk-transduced THP-1 preselection (lane 2) and postselection (lane 3), as well as clones 3 (lane 4), 6 (lane 5),
7 (lane 6), 11 (lane 7), and 13 (lane 8). The Surveyor assay was performed with a total of 500 ng PCR amplicon obtained from genomic DNA of unmodified
THP-1 cells or from the different bulk and clonal populations. The gel shown is representative of two independent experiments.
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deletion common to all three other alleles that disrupted the pro-
tein reading frame from amino acid 34 onward (Fig. 2C–E).
Although the MR1 target sequence we used bears little ho-
mology with other classical and nonclassical HLA genes, it was
important to test whether other Ag presentation pathways had been
disrupted as a result of the genome editing process. Albeit not
exhaustive, our control experiments showed that classical HLA
class I expression (Fig. 5A, 5B) as well as presentation of cognate
exogenous peptide to an HLA-B*1801–restricted CD8+ T cell
clone (Fig. 5C, 5D) by both A549 derivatives were equivalent to
the unmodified A549 cells. Moreover, both clones activated an
HLA-E–restricted CD8+ T cell clone with efficiencies similar to
WTA549 (Fig. 5E, 5F). Collectively, these results imply that both
the expression and processing of HLA alleles as well as peptide
presentation are intact in these cells. Additionally, the basic
properties of A549 clones 9 and 11 such as growth rate and
morphology appeared unaffected (not shown); however, this
does not exclude the possibility of other off-target mutations in
unrelated genes. To address this possibility, we performed whole-
genome sequencing on both A549 clones and searched for mu-
tations in genes containing sequences with homology to our MR1
gRNA target. In total we examined 7580 locations with off-target
potential across the genome. We found no mutations in these
except in the RP11-46A10.6 pseudogene (Fig. 3B) locus that
contains DNA regions of high homology with some MR1 introns
and exons (Fig. 3A). Most notably, the 23 nucleotides composing
the MR1 gRNA target sequence and adjacent PAM are 100%
conserved in RP11-46A10.6 (Fig. 3B, 3C). Interestingly, the
RP11-46A10.6 A549 loci contained the same mutation we iden-
tified as being the most common in MR1, that is, a single base
deletion at position 17 of the sgRNA seed region. Even though this
mutation was clearly unintended, it is on-target in the sense that it
occurred at a locus bearing the full intact sgRNA target and PAM
sequences. The potential for such an unintended effect was missed
during the initial assessment of our MR1 gRNA candidates be-
cause we only searched for gRNA target and PAM sequence ho-
mology against coding genomic regions using the BLAST tool.
Both A549 clones bear this pseudogene mutation, most likely in a
homozygous manner, yet we anticipate no functional conse-
quences given the noncoding nature of this locus. The fact that our
sgRNA induced mutation in both MR1 and the RP11-46A10.6
pseudogene, where there is a 100% conservation of sequence,
serves to highlight both the high efficiency and on-target speci-
ficity of CRISPR/Cas9.
The availability of MR1-deficient cells should be useful for
fundamental investigations into the biology of MR1 and MR1-
restricted T cells as well as for the potential development of
therapeutic and diagnostic tools seeking to harness this invariant
nonclassical HLA molecule. First, MR12/2 cells will help with the
unambiguous identification of MR1-restricted T cells because,
unlike Ab blockade, the absence of MR1 completely obliterates
MAIT cell responses to bacterially infected cells (Fig. 4). Second,
in in vitro activation experiments, MR1-deficient APCs should
allow characterizing and quantifying MR1-restricted T cells
within the bulk pathogen-specific T cell response. Third, it is
unclear at present whether bacterial Ags presented by MR1 show a
degree of chemical and structural variability (36) and whether
responding T cells can discriminate between distinct cognate
MR1/Ag complexes via their clonal TCR. MR12/2 cells should be
a useful tool to test the ability of individual putative MR1 ligands
to activate T cells. This would require obtaining chemically pure
compounds used to pulse MR1-sufficient or -deficient APCs to test
the response of T cell clones with distinct TCR usage and assess
MR1 restriction. Fourth, the availability of cell lines in which
endogenous MR1 expression is abrogated could also prove useful
to knock-in mutated or chimeric reporter MR1 proteins and
characterize the cellular biology of MR1, such as its trafficking
and distribution in subcellular compartments. Such an approach
may help shed light on the mechanisms governing the processing
and loading of vitamin B derivatives without interference from
endogenous MR1 molecules. Finally, MR12/2 cells are likely to
prove valuable for the generation and/or validation of biologicals
and compounds targeting MR1.
In summary, we have generated THP-1 and A549 isogenic cells
deficient for MR1 and a CRISPR/Cas9 lentivector that should allow
applying the same process to other cell types. These reagents
should facilitate investigations seeking to further understand the
mechanisms underpinning the unique biology of MR1 and to
harness its therapeutic and diagnostic potential. In the future,
similar genome editing approaches could also be extended to fa-
FIGURE 7. THP-1 single-cell de-
rivatives infected with M. smegmatis
are unable to activate MAIT cells.
The D481A9 and 426B1 MAIT cell
clones were cocultured with the in-
dicated THP-1 derivatives infected
with M. smegmatis or not as de-
scribed in Materials and Methods.
Supernatants were collected follow-
ing overnight incubation. TNF-a pro-
duced by MAIT cell clones D481A9
(A) and D426B1 (B), respectively, was
quantified by ELISA. IFN-g levels
were also measured for both D481 (C)
and D426B1 (D). Assays were carried
out in triplicate wells. Means 6 SEM
are shown on the graph using data
representative of two experiments.
Assays were carried out in tripli-
cate wells.
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cilitate basic and applied research on other invariant MHC-related
proteins such as the CD1 family, HLA-E, or other MHC class Ib
gene products that may serve as ligands for the TCR (37).
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gRNA target sequence 
PCR cloning primers 
gRNA_A_Fwd GAAACGCCCGTTTTAGAGCTAGAAATAGCAAGTTAA 
gRNA_A_Rev GGATCCCATCCGGTGTTTCGTCCTTTCC 
gRNA_B_Fwd CAGCGATTCCGTTTTAGAGCTAGAAATAGCAAGTTAA 
gRNA_B_Rev TGCTTCACCGGTGTTTCGTCCTTTCC 
gRNA_C_Fwd AATTTATTTCGGTGTTTTAGAGCTAGAAATAGCAAGTTAA 
gRNA_C_Rev CAGGGACGGTGTTTCGTCCTTTCC 
gRNA_D_Fwd GCCTGATCACTGTTTTAGAGCTAGAAATAGCAAGTTAA 
gRNA_D_Rev GCGAGGTTCGGTGTTTCGTCCTTTCC 
gRNA_E_Fwd TATGACGGGCGTTTTAGAGCTAGAAATAGCAAGTTAA 
gRNA_E_Rev TGCATACTGCGGTGTTTCGTCCTTTCC 
Primers for genomic MR1 
PCR and SURVEYOR assay 
SURV1_Fwd GCATGTGTTTGTGTGCCTGT 
SURV1_Rev GGTGCAATTCAGCATCCGC 
Primers for MR1 cDNA 
PCR and SURVEYOR assay 
SURV2_Fwd GGTCTTACTGACATCCACTTTGC 
SURV2_Rev CAGTGATCAGGCGCGAG 
MR1 amplicon cloning 
primers  
SURV_Fwd_BsaI gcgcGGTCTCcGCATGTGTTTGTGTGCCTGT 
SURV_Rev_BsaI gcgcGGTCTCcTGCCGGTGCAATTCAGCATCCGC 
Primers used to sequence 
MR1 amplicons 
Seq_Fwd CCAGTTGCTGAAGATCGCGAAGC 
Seq_Rev TGCCACTCGATGTGATGTCCTC 
Colony PCR primers 
flanking gRNA target sites 
pLKO.1-A GACTATCATATGCTTACCGT 
gRNAcolPCR_R CACTTGATGTACTGCCAAGT 
gRNA/pCMV-Cas9 PCR 
amplification in pCDNA.3 
pCDNA.3_Fwd GCACCGGTTGTACAAAAAAGCAGGCTTTA 
pCDNA.3_Rev GCATGCATTCACACCTTCCTCTTCTTCT 
“Empty” pRRL vector PCR 
amplification 
pRRL.0_Fwd GCATGCATAATCAACCTCTGGATTACAAAATTTG 
pRRL.0_Rev ACCGGTGCTAGTCTCGTGATCGATAAAAT 
  
 
Supplementary Table 1. List of primers used in project. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 








 
Supplementary Figure 1. Annotated full DNA sequence of the pRRL.sin.CRISPR/Cas9 
plasmid.. 
